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Abstract 
Resistance to various chemotherapeutic agents can arise via a multitude of 
mechanisms, but one of the common mechanisms of multidrug resistance (MDR) results 
from the action of ATP-dependent multidrug efflux pumps. P-glycoprotein (P-gp) is the 
most extensively studied multidrug efflux pump. It is overexpressed in a variety of cancers 
and associated with the development of MDR. Despite extensive research over almost 40 
years, the molecular mechanism by which P-gp transports drugs and other endogenous 
molecules has not been conclusively resolved.  
Over the years it has been proposed that different molecules have different binding 
sites in P-gp, but no specific binding sites, or any targeted inhibitors that prevent the 
transport of specific substrates, have been identified. In order to understand the molecular 
basis of substrate binding, molecular dynamics (MD) simulations have been performed to 
estimate the potential of mean force (PMF) for the process of substrate binding to P-gp. As 
a proof of concept, this approach was used to identify the binding locations of morphine 
and nicardipine within the transmembrane (TM) pore. It has been found that morphine and 
nicardipine bind at different but overlapping sites within the TM pore. The results indicate 
that their permeation pathways through the TM pore are not well separated. This set of 
PMF calculations was extended to include the canonical competitive and non-competitive 
P-gp substrates and inhibitors, Hoechst 33342, Rhodamine 123, paclitaxel, tariquidar and 
verapamil. The obtained PMF profiles show that all these molecules have an energy 
minimum within the TM pore. The interactions with a specific set of residues can be 
identified for each molecule in its minimum energy location. However, none of the 
molecules have a distinct, well-defined binding site. Instead, the binding locations overlap 
with several residues interacting with multiple P-gp substrates. This suggests that the 
binding locations for both competitive and non-competitive substrates are not well 
separated and cannot be considered as unique. 
Considering the lipophilic and/or amphipathic nature of many P-gp substrates, it has 
been suggested that P-gp effluxes drugs directly from the membrane. In addition, it has 
been observed that the presence of cholesterol increases the drug-stimulated ATPase 
activity of P-gp. However, whether this is due to the direct effect of cholesterol on the 
activity of P-gp, its effect on the local concentration of substrate in the membrane, or on 
the rate of entry of the drug into the cell, is currently unresolved. To understand better, the 
role of cholesterol in drug-membrane interactions, unrestrained and umbrella-sampling 
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simulations examining the spontaneous binding and partitioning of four P-gp substrates 
into a POPC bilayer in the presence or absence of 10% cholesterol has been investigated. 
It was found that the presence of cholesterol lowers the free energy associated with 
entering the middle of the bilayer in a substrate-specific manner, suggesting that P-gp 
substrates may preferentially accumulate in cholesterol-rich regions of the membrane.  
During the investigation of the substrate binding to the mouse P-gp structure (PDBid: 
3G5U), two further structures of mouse P-gp (PDBid: 4KSB and PDBid: 4M1M) became 
available. Both were resolved to 3.8 Å. Comparison of the structures reveals that the 
amino acid assignment in four (TM 3, 4, 5 and 12) of the twelve helices differs across all 
three structures. To identify which of these three mouse P-gp crystal structures best 
represents the conformation of P-gp under physiological conditions, long-timescale MD 
simulations of membrane-embedded P-gp structures were performed. When embedded in 
a cholesterol enriched POPC membrane and simulated under experimental conditions, the 
simulations show that P-gp is a highly flexible protein that is able to sample a multiple 
conformations. In each simulation, the conformation of P-gp diverged from the respective 
crystal structures. Furthermore, in all simulations, the widely separated NBDs moved 
together to form a non-specific contact interface. While the precise conformation of P-gp 
varied between the simulations, the overall structural conformations were broadly similar. 
In fact, cluster analysis revealed that 3G5U, 4M1M and 4KSB P-gp all adopted very similar 
conformations at some point during the simulation. Although the C RMSD of 4M1M P-gp 
exhibited the least structural fluctuations and remained closer to the crystal structures than 
either the 3G5U or 4KSB P-gp, it is still not possible to comment on which of the three 
possible structures could best represent the physiological conformation of P-gp. The 
choice of crystallographic starting structure can potentially have a large impact on the 
outcomes of an MD simulation.  
The simulations presented here provide an insight into the mechanism and 
energetics of substrate binding in P-gp. Furthermore, they demonstrate that the results 
obtained for substrate binding to P-gp are independent of the choice of starting structure. 
These results shed light on the mechanism of substrate binding and uptake, increasing our 
understanding of P-gp mediated multidrug resistance, which is a significant medical 
problem in chemotherapeutic treatment of cancer.  
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Chapter 1: Introduction 
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1 THESIS OUTLINE 
 The overall aim of this thesis is to understand the molecular basis of multidrug resistance 
resulting from the overexpression of P-glycoprotein (P-gp).  
Chapter 1: The introductory chapter of this thesis presents detailed background information 
regarding ATP-binding cassette (ABC) transporters, multidrug resistance (MDR) and the 
importance of P-gp. This chapter also describes the theory and methodology used in this work.  
Chapter 2: In this chapter, the potential of mean force (PMF) of P-gp substrates morphine and 
nicardipine calculated along the long axis of P-gp, passing through the transmembrane (TM) pore is 
presented. The PMFs reveal that both morphine and nicardipine have energy wells within the TM 
pore. Further investigations of the energy wells of morphine and nicardipine have provided insight 
into their binding sites and the interacting residues.  
Chapter 3: In this chapter the binding sites of the major P-gp substrates Hoechst 33342, Rhodamine 
123, paclitaxel and verapamil as well as the inhibitor tariquidar are compared. PMFs of the 
substrates and inhibitor calculated along P-gp are also presented. 
Chapter 4: In chapter 4, the question of how the substrates enter the TM pore is addressed. It has 
been proposed that the substrates enter P-gp from the inner lipid membrane. To test this hypothesis, 
unrestrained molecular dynamics (MD) simulations and PMF calculations were performed to 
investigate the extent to which the substrates partition into the lipid membranes. In addition, the 
effect of cholesterol on the partitioning of P-gp substrates is also presented.   
Chapter 5: In this chapter, the TMDs of the three crystal structures of mouse P-gp are compared. To 
resolve the differences between the alternative models, the crystal structures of mouse P-gp were 
embedded into a lipid membrane and unrestrained MD simulations were performed in each case.  
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Chapter 6: In chapter 6, a summary of the combined results of my research is presented along with a 
brief perspective on the future directions in this area of study. 
  
4 
2 ABC TRANSPORTERS 
 ABC transporters constitute one of the largest and oldest superfamilies of proteins. They are 
present in all living organisms – from Archaea to humans1. ABC transporters are integral membrane 
proteins that utilize the energy from adenosine triphosphate (ATP) hydrolysis for the transport of 
their substrates across cellular membranes, a process critical for many aspects of cell 
physiology. These proteins translocate a wide variety of substrates including sugars, amino acids, 
metal ions, lipids, sterols, as well as a large number of other hydrophobic compounds such as drugs 
and metabolites across extra and intracellular membranes. As these proteins transport large numbers 
of antibiotics and chemotherapeutic drugs, they are also responsible for a condition known as 
multidrug resistance2. Furthermore, mutations within ABC transporters can cause, or contribute to, 
several human genetic disorders such as cystic fibrosis, various neurological diseases, 
cholesterol/bile transport defects, retinal degeneration, and anemia3, 4.  
2.1 Architecture of ABC transporters 
 ABC transporters contain two cytosolic ATP binding regions known as nucleotide binding 
domains (NBDs) and two membrane-spanning transmembrane domains (TMDs). Each TMD 
usually consists of six α-helices, embedded in the membrane bilayer. The TMDs transport the 
substrates across membranes. Although structurally similar across the transporter family, TMDs 
have a large proportion of non-conserved amino acids. This variation in sequence and the 
architecture of the TMDs reflect the chemical diversity of substrates that can be recognized and 
translocated. The sequences of the NBDs on the other hand are highly conserved across various 
species. One TMD and one NBD together form a half ABC transporter. The minimal functional 
domain organization of an ABC transporter consists of two TMDs and two NBDs as either TMD–
NBD–TMD–NBD or NBD–TMD–NBD–TMD where, the topological arrangement of TMDs and 
NBDs varies among different species.  
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 Figure 1 shows crystal structures of 
ABC transporters from different organisms 
such as Staphylococcus aureus5, Salmonella 
typhimurium6, Caenorhabditis elegans7, Mus 
musculus8-10, Cyanidioschyzon merolae11, 
Thermotoga maritima12 and Escherichia coli13 
that were crystallized under different conditions 
and in different states and are homologues to 
the ABC transporter from Homo sapiens14. In 
bacterial exporters, the TMDs and NBDs, 
which together form an active transporter, are a 
combination of fused subunits and in the case 
of bacterial importers the active transporter is 
formed by independent subunits. The E.coli 
BtuCD importer involved in the uptake of 
vitamin B12 is an example of an ABC 
transporter formed by four individual subunits 
whereas, the multidrug exporter Sav1866 from 
S.aureus5 is made up of homodimers of 
Figure 1: The structures of ABC transporters from 
S.auerus (PDB id: 2HYD), S. typhimurium (PDB 
id: 3B60), C.elegans (PDB id: 4F4C), M.musculus 
(PDB id: 4M1M), C.merolae (PDB id: 3WMG), 
H.sapiens (PDB id: 4AYT), T.maritima (PDB id: 
3QF4), E.coli (PDB id: 2QI9) showing that the 
transmembrane domains (TMDs) are structurally 
diverse among various organisms. N- and C-
terminal halves are shown in gold and silver 
respectively. 
.  
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individual half transporters where one TMD and one NBD are fused to form a single subunit. In 
eukaryotes, the TMDs and NBDs are often associated as a single subunit forming a complete ABC 
transporter. The multidrug transporter P-gp is one such example8-10.  
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Figure 2: Sequence alignment of SAV1866, MsbA, P-gp from C.elegans and mouse, CmABCB1, 
ABCB10, TM287/TM288 showing the nucleotide binding domains (NBDs) of these ABC transporters 
are more conserved than the transmembrane domains (TMDs). Hydrophobic and aromatic residues 
(A, I, L, M, F, W, V, C A, H and Y) are colored cyan; basic residues are in red; polar residues are 
colored green; G is orange; P is yellow; and acidic residues are colored magenta. The histograms 
indicate the degree of similarity. The key motifs involved in ATP binding are bounded by a red 
rectangle. 
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2.1.1 Transmembrane Domains (TMDs) 
 As described above, most functional ABC transporters contain 2 TMDs with 12 α-helices 
per active transporter. However, active ABC transporters with α-helices between 6 and 12 are 
known (3 to 6 helices per half transporter). The TMDs determine the specificity for the substrate 
molecules transported by a given ABC transporter. The membrane-spanning helices of TMDs 
extend into the cytosol forming the intracellular loops (ICLs). The TMDs of most half transporters 
have a common arrangement of the helices with TM helix 1 being located on the outer side facing 
the membrane, while the TM helices 2 to 5/6 form the substrate translocation pathway. Figure 1 
shows that the TMDs are structurally diverse among various organisms and they can adopt different 
conformations based on whether they are in apo state or nucleotide bound.  
2.1.2 Nucleotide Binding Domains (NBDs)  
 ABC transporters get their name from the conserved ATP binding domains known as NBDs. 
The NBDs are required for binding and hydrolyzing ATPs. This provides the energy for 
transporting the substrate across the membranes. The sequences of NBDs, whether from 
prokaryotes or eukaryotes and irrespective of the transport properties are highly conserved. Figure 2 
shows the sequence alignment of various ABC transporters from both bacteria and a range of 
eukaryotes including mammals. 
 Each NBD is composed of two subdomains: a catalytic (RecA-like)15 subdomain and α-
helical subdomain. The catalytic subdomain contains the Walker A motif (GxxGxGKS/T) and the 
Walker B motif (ɸɸɸɸDE, where ɸ is any aliphatic residue), the Q-loop and the H-loop as shown in 
Figure 3. The smaller and structurally more diverse α-helical subdomain contains the ABC 
signature motif (LSGGQ)16 as seen in Figure 3. One ATP molecule binds at the dimer interface; 
with each binding site being comprised of the Walker A motif of one NBD domain, and the 
signature motifs in the other NBD. One Mg2+ ion binds to the Walker B motif and is necessary for 
the hydrolysis of ATP. The histidine residue in the H-loop is important for the interaction with the 
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α-helical motif of the other NBD domain17, 18. Jones et al.19, 20 first proposed that the dimerization of 
the two NBDs form a “nucleotide sandwich dimer”, which was later identified in crystallographic 
studies17, 21. The dimerization of NBDs plays a critical role in the catalytic cycle of the ABC 
transporters by coupling with the rearrangements in the TMDs and subsequent transport of the 
substrate across the membrane19. 
2.1.3 ATP binding and hydrolysis  
 Comparing the crystal structures of nucleotide bound MalK, Sav1866 and human ABCB10 
to structures of ABC transporters in a nucleotide free state shown in Figure 1, it can be seen that the 
NBDs have close contacts in a nucleotide bound state whereas, in a nucleotide free state, the NBDs 
are separated. Thus, the two NBDs dimerized while binding and hydrolyzing ATP. Structures of 
isolated NBDs in the ATP-bound state have also been reported which have helped to understand the 
process of ATP binding and hydrolysis. The binding of ATP and other nucleotide analogues such as 
ADP, AMP-PMP, and ADP-vanadate have been studied via biochemical and mutational analysis22-
24. The binding of ATP to the NBDs is stabilized by the following interactions: (i) ring-stacking 
interactions between a conserved aromatic residue preceding the Walker A motif and the adenosine 
ring of ATP24, 25; (ii) hydrogen bonds between the conserved lysine residue in the Walker A motif 
Figure 3: Top-down view of the nucleotide binding domains (NBDs) of the MD equilibrated mouse P-gp 
structure51 showing the conserved regions implicated in ATP binding and hydrolysis. (A) Shows the Walker 
A, Walker B and ATP binding cassette (ABC) signature motifs. (B) Shows the Q-loop, D-loop and H-loop. 
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and the oxygen atoms of the β- and γ-phosphates of ATP; (iii) coordination of the β and γ-
phosphates and residues in the Walker A motif with a Mg2+ ion26; (iv) the γ-phosphate interacts with 
the side chain of serine and backbone amide groups of glycine residues in the signature motif19, 20, 27, 
28. In addition, the histidine residue in the H-loop has been proposed by Jones and George to be 
responsible for the tight coupling of ATP binding and dimerization29. They also proposed that 
during the hydrolysis of ATP, the Q-loop and the Walker B glutamate (conserved) alternatively 
interact with a water molecule29. The conserved glutamate, which is located at the junction of the C-
terminus of the Walker B motif and N-terminus of the D-loop, has been proposed to act as the 
catalytic base in concert with the nucleophilic water during ATP hydrolysis5, 30. MD studies have 
suggested that Mg2+ binds to the conserved glutamate and aspartate residues in the Walker B 
motif31.  
2.2 Classification of ABC transporters 
 ABC transporters are classified into two major groups:  
o Importers -- prokaryotic or bacterial 
o Exporters -- bacterial and eukaryotic 
In prokaryotes, ABC transporters consist of both importers and exporters. The importers mediate 
the uptake of nutrients into the cells. The exporters function as efflux pumps. They mediate the 
transport of specific proteins, peptides, polysaccharides, lipids, sterols, salts, ions, hormones and 
other endogenous substrates across the membrane. Some exporters may function in excreting 
substrates, drugs, toxins and other xenobiotics out of the cells. Eukaryotes do not possess importers1.  
2.2.1 Prokaryotic ABC transporters 
 Bacterial ABC transporters are essential for cell viability, virulence, and pathogenicity32. All 
bacterial importers are found in the periplasm of Gram-negative bacteria or anchored via lipid 
moieties to the cytoplasmic membrane in Gram-positive bacteria32. Among the many ABC 
transporters found in bacteria, two systems have been studied extensively. These are the MalK, 
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maltose importer of E.coli18, and the hemolysin transporter, HlyB exporter from E.coli33. Other than 
functioning in transport, most bacterial ABC proteins are also involved in the regulation of several 
physiological processes and play important roles in biosynthetic pathways, including extracellular 
polysaccharide biosynthesis and cytochrome biogenesis32. 
Bacterial importers 
 The bacterial importers possess a unique feature in that they all rely on a high-affinity 
periplasmic binding protein (BP). BPs are soluble proteins located in the periplasmic space between 
the inner and outer membranes of Gram-negative bacteria32. These BPs interact with incoming 
substrates, bind to them, and present them to import complexes in the inner membranes. Whereas, 
Gram-positive bacteria lack periplasm and they possess a form of BPs that are often lipoproteins 
bound to the external wall of cell membranes. Some Gram-positive bacteria have the BPs fused to 
TMDs of the transporter themselves. Some of the examples for bacterial importers are the 
molybdenum transporter (ModBC-A) from A.fulgidus34, E.coli Vitamin B12 importer (BtuCD)35, 
and E.coli maltose transporter (MalFGK2-E)36.   
Bacterial exporters 
 The bacterial exporters are the largest known group of ABC transporters. They are close 
homologues of eukaryotic transporters. Bacterial exporters can be sub-divided into classes based on 
the type of substrate that is transported. One class of transporters is involved in protein and peptide 
export, the second class in the efflux of non-peptidic molecules such as drugs and the final class 
transports small molecules such as salts and ions. The bacterial exporters that transport drugs play a 
major role in the development of resistance to antibiotics37. Like bacterial importers, many bacterial 
exporters also depend on accessory proteins/factors in order to form a functional complex37. The 
accessory proteins/factors are anchored in inner membranes and span the periplasm. These factors 
have been identified in several Gram-negative systems and are necessary when the secreted product 
is destined for release into the extracellular medium. The accessory factors probably act to connect 
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inner and outer membranes and facilitate the export of products through both membranes of Gram-
negative cells. The accessory proteins are primarily involved with bacterial exporters transporting 
proteins and peptides. An example for such a bacterial exporter system is the secretion of hemolysin 
(HlyA) from E.coli38 where the inner membrane ABC transporter HlyB interacts with an inner 
membrane fusion protein HlyD39 and an outer membrane facilitator TolC. TolC allows hemolysin to 
be transported across the two membranes, bypassing the periplasm40. Other bacterial exporters that 
are involved in the transport of non-protein substrates such as lipophilic drugs, antibiotics, and 
polysaccharides do not have accessory factors. Some examples for bacterial exporters are LmrA 
from L.lactis41 and KpsTM capsular polysaccharide exporter of E.coli42.  
2.2.2 Eukaryotic ABC proteins 
 All eukaryotic transporters have their TMDs and NBDs linked to form a half transporter. 
Eukaryotic ABC transporters (exporters) mediate the efflux of compounds including lipids, sterols, 
ions and peptides from the cytosol to the extracellular space or to the inside of intracellular 
membrane-bound compartments, i.e. endoplasmic reticulum, mitochondria, peroxisomes, or 
vacuoles. Eukaryotic transporters that play important roles in numerous cellular processes are prone 
to gene duplication and mutations causing genetic disorders3, 4. Several of these systems are of 
significant medical importance and have been under intense study since their discovery. For 
example, P-gp, which exports a wide range of hydrophobic compounds including many 
chemotherapeutic drugs from cells leads to multidrug resistance in cancer tissue2. Likewise, patients 
with cystic fibrosis have a defective chloride ion transporter, the cystic fibrosis transmembrane 
regulator (CFTR)43, 44. Other medically important eukaryotic ABC exporters include pfMDR in 
P.falciparum, which exports antimalarial drugs45, STE6 in S.cerevisiae, which exports a-type 
mating factor46 and a group of transporters involved in antigen presentation known as TAP26. 
Human ABC transporters 
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 In humans, 48 ABC transporters, distributed to seven subfamilies, have been identified 
(Table 1)3. Although the number of human ABC transporters is much smaller than found in bacteria, 
many of them are of clinical significance. Even though the majority of the members of the human 
ABC transporter family are active transporters, there are some exceptions in which the energy from 
ATP hydrolysis is utilized to control alternative biological processes. For example, the sulfonylurea 
receptor (SUR) functions as a regulatory subunit modulating the activity of the potassium ATP 
channel47. Other members of the ABC transporter family couple ATP binding and hydrolysis during 
translation48 and DNA repair21, 49. Although the active transporters have dedicated functions 
involving the efflux of specific endogenous substrates, physiologically the same ABC transporters 
often also play an important role in the protection of the host against xenobiotics. The importance of 
this secondary function is reflected in their tissue distribution. In humans several ABC transporters 
are highly expressed in physiological barriers such as the apical membrane of gut enterocytes, the 
endothelial cells of the blood–brain barrier or the maternal facing (apical) membrane of the 
placental syncytiotrophoblast3. In all of these organs, ABC transporters protect sensitive tissues 
such as brain or the growing fetus against potentially toxic compounds.  
 Table 1 shows a comprehensive list of the human ABC transporters from seven subfamilies 
– ABCA to ABCG. The ABCA subfamily of transporters consists of the largest ABC transporters, 
whose primary function is transport of lipids and sterols like cholesterol. The human ABCB family 
is one of the most studied subfamilies and the proteins in this subfamily are responsible for 
developing MDR against a wide range of therapeutics. Of these, ABCB1 (MDR1) gene encodes for 
P-gp, a well-studied protein associated with multidrug resistance. The ABCC subfamily contains 
transporters such as CFTR and SURs that perform functions in ion transport, toxin secretion, and 
signal transduction. ABCD are a family of half transporters expressed exclusively in the peroxisome. 
The ABCD1 is responsible for the X-linked form of adrenoleukodystrophy (ALD). The ABCE and 
ABCF subfamilies encode only the ATP binding domains similar to the NBDs of ABC transporters. 
Because of the absence of TMDs, these proteins are not involved in transport function but rather 
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regulate protein synthesis or expression. ABCG transporters are also half transporters. The members 
of ABCG family, except ABCG2 act as gatekeepers in transporting hydrophobic molecules, lipids, 
cholesterols, etc., out of cells.  
2.3 Mechanism of action of ABC transporters 
 Both the ABC importers and exporters are believed to share a common mechanism of action, 
where the transport of substrate is associated with the TMDs alternatively adopting an inward- or 
outward-facing configuration so that the TM pore is alternately open to one side of the membrane or 
the other. These transmembrane segments are presumed to interact and undergo essential 
conformational changes during substrate binding or during ATP hydrolysis50-54.  
 Experimentally, it has been shown that the conformational changes within the TMDs alter 
the substrate binding affinity of the transporter55. In ABC importers, the translocation of substrate is 
directed from the periplasm into the cytoplasm, and then the outward-facing conformation has 
higher binding affinity for substrate. In contrast, the substrate binding affinity in exporters will be 
greater in the inward-facing conformation56. Figure 4 illustrates the alternative states of the ABC 
transporter. From the crystal structures of ABC exporters, it is clear that the inward-facing 
conformation is observed in both the apo state as in mouse P-gp and C.elegans P-gp7, 8 and the 
nucleotide bound state as in human ABCB1012. In these structures, the substrate extrusion chamber 
is open to the cytoplasm. The outward-facing conformation of ABC transporters is thought to 
correspond to the nucleotide bound state after ATP hydrolysis. However, the structure of the 
bacterial homodimer Sav1866 is the only an example of this outward-facing conformation. The 
structure of Sav1866 is an example of an outward-facing conformation with two ADP-vanadate 
molecules bound between the NBD sandwich dimer5.  
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Table 1: List of Human ABC subfamilies and their functions3 
 
 
Family Members Alias Function 
ABCA 
ABCA1 ABC1 Cholesterol efflux onto HDL 
ABCA2 ABC2 Drug transport 
ABCA3 ABC3 Surfactant secretion? Drug resistance 
ABCA4 ABCR N-Retinylidiene-PE efflux 
ABCA5 ABC13  
ABCA6   
ABCA7 ABCX  
ABCA8   
ABCA9   
ABCA10   
ABCA12   
ABCA13   
ABCB 
ABCB1 MDR1 Multidrug resistance 
ABCB2 TAP1 Peptide transport 
ABCB3 TAP2 Peptide transport 
ABCB4 PGY3 Phosphotidyl Choline & drug transport 
ABCB5 ABC19 Drug transport 
ABCB6 ABC14 Iron transport 
ABCB7 ABC7 Fe/S cluster transport 
ABCB8 ABC22  
ABCB9 ABC23  
ABCB10   
ABCB11 SPGP Bile salt transport, drug transport 
ABCC 
 
ABCC1 MRP1 Drug resistance 
ABCC2 MRP2 Organic anion efflux, drug transport 
ABCC3 MRP3 Drug resistance 
ABCC4 MRP4 Nucleoside transport, drug transport 
ABCC5 MRP5 Nucleoside transport, drug transport 
ABCC6 MRP6  
ABCC7 CFTR Chloride ion channel 
ABCC8 SUR Sulfonylurea receptor 
ABCC9 SUR2 K-ATP channel regulation 
ABCC10 MRP7 Drug transport 
ABCC11 MRP8 Drug transport 
ABCC12 MRP9  
ABCD 
ABCD1 ALD VLCFA (very long chain fatty acid) transport regulation 
ABCD2 ALDL1  
ABCD3 PXMP1  
ABCD4 PMP69  
ABCE ABCE1 OABP Oligoadenylate binding protein 
ABCF 
ABCF1 ABC50  
ABCF2 ABC28  
ABCF3 ABC25  
ABCG 
ABCG1 White Cholesterol transport 
ABCG2 ABCP Toxin efflux, drug resistance 
ABCG4 White2  
ABCG5 White3 Sterol transport 
ABCG8 White4 Sterol transport 
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2.4 Catalytic cycle of ATP hydrolysis 
 The precise molecular mechanism by which ATP hydrolysis is coupled with substrate 
transport is still unknown. Studies on ABC transporters have shown that there is dependence 
between ATP binding at the NBDs and substrate binding in the TMDs56. Crystal structures of the 
ABC transporters5-12, 14 obtained under different crystallization conditions display distinct 
conformational differences within the transporter family. Experimental studies have demonstrated 
that substrate binding increases the rate of ATP hydrolysis but the mechanism by which this occurs 
is not clear56. It is generally accepted, however, that the binding and/or hydrolysis of one or more 
ATP molecules within the NBDs, induces changes within the structure of the TMDs. These changes 
trigger the release of the substrate into the extracellular medium. Dissociation of ADP + Pi 
Figure 4: The proposed transport cycle of an ABC exporter represented by (A) inward-facing, mouse P-
gp, (B) inward-facing and nucleotide bound, human ABCB10 and (C) outward-facing and nucleotide 
bound, SAV1866. N- and C-terminal halves are shown in gold and silver respectively. The nucleotide 
ADP/AMP-PNP are shown in a violet space fill representation in (B) and (C). 
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(inorganic phosphate) then takes place 
followed by the transporter returning to its 
original configuration after the hydrolysis of 
a second ATP molecule.  
 Two models have been proposed to 
explain the coupling of ATP hydrolysis with 
substrate translocation. These are the 
“switch” model of Higgins and Linton57 and 
the “constant contact” model of Jones and 
George58. Both models are represented 
schematically in Figure 5. In the switch 
model, ATP first binds to one of the two 
NBDs but is not hydrolyzed. When the 
second ATP binds to the second site, the NBDs form a closed dimer conformation with two ATP 
molecules at the dimer interface. The dimerization of NBDs induces the conformational change in 
the TMDs such that reducing the affinity of bound substrate thereby transports it across the 
membrane. This is followed by the ATP hydrolysis and the release of ADP and Pi. The release of 
ADP and Pi leads to the dissociation of the dimerized NBDs. 
  In contrast the constant contact model is based on the alternating site model developed by 
Senior et al59. This model features the alternating ATP hydrolysis in each NBD, with one ATP 
binding site opening during ATP hydrolysis, while the second ATP binding site remains dimerized 
and closed. However, in this model, one of the ATP binding sites open sufficiently for ATP release 
without the need for the NBD monomers to separate fully, then as this site closes with a new ATP 
molecule now bound and occluded, the opposite site becomes primed for hydrolysis and the process 
repeats in alternating cycles58. 
Figure 5: Proposed models for ATP hydrolysis in ABC 
transporter. (A) “Switch” model and (B) “Constant 
contact” model. NBDs 1 and 2 are colored in gold and 
silver respectively. 
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3 P-GLYCOPROTEIN 
 P-glycoprotein (P-gp) is also known as 
multidrug resistance protein (MRP1). It belongs 
to the ABCB subfamily of transporters. P-gp is 
an integral membrane protein that transports a 
large number of hydrophobic, positively charged 
molecules and some specific peptides across 
membranes. P-gp is expressed in the tissues of 
the small intestine, liver and kidney and in the 
blood – tissue barriers1. P-gp acts as an active 
efflux pump leading to a lower intracellular 
concentration of transported molecules. It plays 
an important role in the efflux of metabolites and 
xenobiotics into urine, bile, and the intestinal 
lumen. P-gp also protects these organs from toxic 
compounds that gain entry into the circulatory 
system. Because of its ability to transport a broad 
spectrum of molecules, overexpression of P-gp can lead to the development of MDR. In fact, one 
reason P-gp has been studied extensively over the last 30 years is due to its role in MDR in cancer, 
a major reason for the failure of chemotherapy. 
3.1 Structure of P-gp 
 P-gp is a 1280 amino acid integral membrane protein. Like other eukaryotic ABC 
transporters, it is comprised of two TMDs and two NBD formed as a single polypeptide chain. 
Figure 6 shows one of the structures of mouse P-gp (PDBID: 4M1M) crystallized in an inward-
facing, nucleotide free conformation10. The protein shows a pseudo two fold symmetry. A 60 amino 
Figure 6: Structure of mouse P-gp in an inward-
facing, nucleotide free state (PDB id: 4M1M). The 
N-terminal half is coloured in gold and C-terminal 
half is coloured in silver. The N- and C-termini of 
the unresolved linker are labelled (red circle). 
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acid linker region that connects the two halves (NBD1 to TMD2) was not resolved in this crystal 
structure. Each of the TMDs folds into six membrane-spanning α-helices, which extend 70 Å into 
the cytosol as intracellular loops (ICLs). The TM helices from the two TMDs associate to form the 
TM pore through which substrates are believed to pass.  
 
3.1.1 Crystal structures of P-gp 
 Mammalian (mouse) P-gp was first crystallized in 2009 in an apo and inward-facing state. 
The image on the left panel of Figure 7 shows the crystal structure of mouse P-gp as proposed 
originally by Aller et al. (PDBID: 3G5U, resolution 3.8 Å)8. Two additional structures of P-gp 
complexed with cyclic peptide inhibitors, QZ59-SSS and QZ59-RRR bound to the ~6000 Å central 
cavity were also solved by Aller et al. as a part of the same work8. In 2012, Jin et al. reported a 
higher resolution (3.4 Å) crystal structure of C.elegans P-gp7. A detailed comparison between the 
C.elegans P-gp structure and the original mouse P-gp structure revealed differences (registry shifts) 
in three TM helices (3, 4 and 5) suggesting a possible misinterpretation of the mouse data. 
Following this finding, in 2014, Aller and co-workers released a new model of mouse P-gp (PDBID: 
Figure 7: Crystal structures of mouse P-gp in an inward open APO state (A) viewed from the membrane 
and (B) the NBDs viewed from the extracellular side.  
 
Extracellular side 
Intracellular 
side 
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4M1M) based on a reinterpretation of Aller’s original data10. This reanalysis was performed on data 
collected at a single wavelength using single-wavelength anomalous dispersion (SAD) to obtain the 
initial maps. This model of mouse P-gp was also refined to 3.8 Å resolution. The most relevant 
changes between the original and re-refined structures for this work are (1) a one residue registry 
shift of TM3, (2) a four residue registry shift for TM4, (3) a 90° rotation of TM5, (4) a one residue 
registry correction for TM8 and (5) a 45° rotation of a part of TM9. However, a number of changes 
in other parts of the model were also introduced. Li et al have described a detailed list of all the 
proposed corrections.10.  
 In 2013, Ward et al. proposed three alternative crystal structures for the inward-facing 
conformation of mouse P-gp9. Two of these structures were in the apo state (PDBID: 4KSB and 
4KSC) and one structure had a nanobody bound to the C-terminal end of the NBD1 (PDBID: 
4KSD). This nanobody has been shown to inhibit ATP hydrolysis in mouse P-gp, presumably by 
preventing the dimerization of the NBDs9. In the experimental electron density map produced using 
multi-wavelength anomalous dispersion (MAD) by Ward et al., the conformation of the protein was 
even more open to the cytoplasm than the 4M1M structure of Li et al. The models proposed by 
Ward et al. for mouse P-gp incorporated the registry changes to TM helices 3, 4 and 5 based on the 
C.elegans P-gp. However, the structure does not contain a range of other changes proposed in the 
most recent structure of Li et al., in particular the register shift in TM12. In Figure 7, the three 
structures of mouse P-gp (3G5U, 4KSB and 4M1M) from the membrane and the NBDs from the 
extracellular side are presented for comparison. 
 Note the conformation of mouse P-gp in the 4KSB structure is slightly different to that of 
3G5U and 4M1M. The presence of the nanobody results in the NBDs being separated by a distance 
of 6.0 nm in 4KSB compared to 4.5 nm in 3G5U and 4M1M. The distance between the NBDs in 
each case corresponds to the distance between the Cα atoms of Leu549 and Leu1194 located in the 
centers of the NBD1 and NBD2 respectively. The separation of the NBDs also affects the angle 
formed by the two TMDs. In 4KSB the angle between the two TMDs is ~43° whereas in 3G5U and 
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4M1M the angle is ~34°. The angles formed by the TMDs are calculated from the angle formed by 
the plane of the vector passing through the TM helices 1, 2, 3, 6, 10, 11 and the plane of the vector 
passing through the TM helices, 4, 5, 7, 8, 9, and 12. The differences between the NBDs and the 
angles between the TMDs suggest a degree of the structural flexibility in the apo and inward-facing 
state. 
3.2 Tissue distribution of P-glycoprotein 
 Studies in both human and rodents have shown that P-gp is expressed in most tissues60. In 
particular, it is highly expressed at the apical surface of epithelial cells lining the colon, small 
intestine, pancreatic ductules, bile ductules and kidney proximal tubules, and the adrenal gland61. P-
gp is also found in the endothelial cells of blood-brain barrier (BBB)62, blood-testis barrier63 and the 
blood-mammary tissue barrier64. The role of P-gp in the blood-brain and blood-tissue barriers is 
likely to protect these organs from toxic compounds that gain entry into the circulatory system65, 66. 
P-gp is expressed at high levels at the luminal surface of secretory epithelial cells in the pregnant 
endometrium67, as well as the placenta68, where it may provide protection for the foetus69. 
3.3 Physiological role of P-gp 
 As noted above, the tissue localization of P-gp suggests that the protein plays a major role in 
protecting susceptible organs from toxic xenobiotics, in the secretion of metabolites and xenobiotics 
into bile, urine, and the lumen of the gastrointestinal tract, and possibly the transport of hormones 
from the adrenal gland and the uterine epithelium61. In the intestinal epithelium, P-gp plays an 
important role in the extrusion of many drugs from the blood into the intestinal lumen, and in 
preventing drugs in the intestinal lumen from entering the bloodstream65, 66. P-gp is oriented in the 
BBB cells to transport substrates towards the blood, and is thus a major factor in limiting their entry 
to the brain65. Similarly, it appears to play a central role in protecting the fetus and other sensitive 
tissues from the toxicity of a variety of endogenous and exogenous molecules69. P-gp is known to 
affect the distribution of many clinically administered drugs, and makes a major contribution to 
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ADME (absorption, distribution, metabolism, excretion)70. For example, the presence of P-gp in the 
intestinal lumen reduces the absorption and oral availability of many drugs. P-gp knockout mice 
display increased uptake of P-gp substrates from the digestive tract and markedly slower 
elimination from the circulation. Such P-gp knockout mice have proved very useful for identifying 
or confirming clinically important drugs as substrates for the transporter in vivo71, as the differences 
between mouse and human P-gp substrate specificity is small. In addition to xenobiotics, P-gp is 
thought to transport a range of endogenous molecules and metabolites. Possible endogenous 
substrates include phospholipids and glycolipids, platelet activating factors, amyloid β peptides and 
small cytokines such as interleukins. P-gp may also export steroid hormones such as aldosterone 
and progesterone from the adrenal gland and the uterine epithelium. However, little information is 
available on the extent of P-gp mediated transport of these endogenous molecules in vivo. 
3.4 Substrates, modulators and inhibitors of P-gp 
 P-gp substrates are generally aromatic, hydrophobic and positively charged compounds. 
Some of the known P-gp substrates include natural products, anticancer drugs, steroids, fluorescent 
dyes, linear and cyclic peptides and ionophores70, 72, 73. The transport of over 50 drugs has been 
documented and more than 70 additional P-gp modulators or inhibitors have been identified70. The 
promiscuity of P-gp has made it difficult to define precisely the criteria that could be used to 
identify compounds as substrates or not. There is little information available on the extent to which 
endogenous compounds are transported by P-gp in vivo. Table 2 shows an extensive list of P-gp 
substrates illustrating the fact they are both structurally and functionally diverse. 
A subclass of P-gp transport substrates is also modulators. Modulators act by interfering with the 
ability of P-gp to transport other substrates and thus to generate a concentration gradient of these 
molecules across the membrane74, 75. The ability to selectively block the action of P-gp is of high 
clinical importance. For example, modulators have been shown to reverse MDR in intact cells in 
vitro, suggesting selective inhibitors or modulators of P-gp could lead to more efficacious cancer 
chemotherapy, improved drug bioavailability and the ability to regulate the uptake of drugs into the 
  
24 
intestine or their delivery into the brain. Numerous pharmacologic agents have been identified as P-
gp modulators75. Some of these are listed in Table 2. Modulators appear to interact with the same 
pharmacological binding site(s) as substrates, and compete with them for transport74. However, the 
mechanism in which modulators exert their action at the molecular level is still not well understood. 
To date, modulators such as verapamil76, nicardipine and  cyclosporine A77, 78 have not proved to be 
useful clinically in reversing MDR.  
 Molecules that block the function of P-gp are known as inhibitors. Table 2 lists a number of 
known P-gp inhibitors. Inhibitors affect the transport properties of P-gp by preventing ATP binding 
and/or hydrolysis, or by competitive binding with substrates. The mechanism by which most 
inhibitors affect the function of P-gp is still unclear. Drugs such as erythromycin and tamoxifen, act 
as mild inhibitors of P-gp74. In addition, at a high concentration, modulators such as verapamil and 
cyclosporine A also act as inhibitors. However, as they are low potency inhibitors, high 
concentrations are required to achieve therapeutically useful levels of P-gp inhibition70. Second and 
third generation inhibitors such as biricodar and tariquidar not only abrogate multidrug resistance, 
but also inhibit P-gp function in normal tissue. This results in neutropenia, neural toxicity and 
enhanced toxicity of the primary chemotherapeutic agent due to perturbations in drug ADME70. In 
fact, all P-gp inhibitors to date have failed during Phase III clinical trials. They have failed largely 
because they are non-specific, completely blocking the function of P-gp, as opposed to blocking the 
transport of specific substrates.  
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Table 2: List of widely used P-gp substrates, modulators and inhibitors 
 
Substrates Class Type 
vincristine, vinblastine vinca alkaloids anticancer drugs 
doxorubicin, daunorubicin, epirubicin anthracyclines 
etoposide, teniposide epipodophyllotoxins 
paclitaxel taxane 
actinomycin D polypeptide antibiotic 
topotecan cytotoxic quinoline alkaloid 
mithramycin  
mitomycin C  
colchicine alkaloids cytotoxic agents 
terfenadine  antiallergics  
cefazolin,  cefoperazon  antibiotics 
cyclosporin A  immunosuppressant  
nicardipine dihydropyridine,  calcium channel blockers 
verapamil phenylalkylamine 
gramicidin D,  valinomycin  cyclic and linear peptides 
n-acetyl-leucyl-leucyl-norleucine  
indinavir, ritonavir,  saquinavir   HIV protease inhibitors 
aldosterone  steroids 
dexamethason  
hydrocortisone  
morphine  opioid 
Hoechst 33342  dyes 
Rhodamine 123  
calcein-AM  
Modulators   
verapamil phenylalkylamine calcium channel blockers 
nicardipine dihydropyridine 
nifedipine 
morphine  opioid 
indinavir, nelfinavir, ritonavir,  saquinavir   HIV protease inhibitors 
propafenone  antiarrhythmic agent 
ivermectin  antiparasitic  
rifabutin, rifampicin rifamycin derivative antibiotics 
Inhibitors   
verapamil phenylalkylamine First generation 
cyclosporin A  
tamoxifen  
PSC‑833 (valspodar), VX710 (biricodar)  Second generation 
LY335979 (zosuquidar), OC144093 
(ontogen), XR9576 (tariquidar), GF120918 
(elacridar) 
 Third generation 
azithromycin, erythromycin   Antibiotics 
lovastatin, simvastatin  statins Hypolipidemic agent 
quercetin  flavonoid  
quinidine   Antiarrhythmic agent 
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3.5 Substrate binding to P-gp 
 Various studies have attempted to locate a substrate binding site within the TMDs of P-gp, 
in particular, to identify key residues or interactions that would enable P-gp to discriminate between 
different classes of compounds. P-gp has only been crystallized together with cyclic peptide 
inhibitors8, 10 or a nano-body9. Given that no crystal structure of P-gp with a bound substrate is 
available, the majority of the information related to possible binding sites has been inferred from 
mutational studies. These mutational studies have been used to identify residues that affect the 
transport rate and binding affinity of different substrates73, 79, 80. While the residues identified occur 
throughout P-gp, including within the NBDs, the majority of the residues known to affect transport 
rates are clustered in the TM region. In addition, FRET experiments involving Hoechst 33342, 
suggested that the physical location of the binding site for substrates lies in the TM region, towards 
the intracellular leaflet81. In particular, the binding of different substrates has been proposed to be 
associated with TM helices 5, 6, 11 and 12. This suggests that the TM region may be the primary 
substrate recognition or pre-transport binding region73, 80. However, as residues from other TM 
helices have also been shown to affect the ability of P-gp to transport substrates, it has not been 
possible to identify the physical location of a single specific substrate binding site73, 80. In fact, some 
experimental results have been interpreted as suggesting that P-gp contains multiple sites, which 
interact with different classes of substrate. For example, photoaffinity labeling studies have shown 
that verapamil and vincristine compete for binding to P-gp, whereas azidopine and vinblastine bind 
noncompetitively82, 83. Using equilibrium binding studies and competition/modulation studies 
examining the effect of combinations of substrates on ATP hydrolysis, Martin et al. suggested that 
there might be four pharmacologically distinct interaction sites in P-gp55. Others have proposed that 
P-gp has as many as seven distinct substrate interaction sites79. However, the molecular 
composition of any specific site has not been elucidated in detail. In fact, as certain residues appear 
to interact with multiple classes of substrate, it has also been suggested that the TMDs collectively 
form a single non-specific binding pocket80, 84.  
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3.5.1 Computational studies on substrate binding  
 A number of computational approaches have also been used in an attempt to characterize 
potential substrate binding sites in P-gp. These include molecular docking and pharmacophore 
mapping studies85-89. For example, Ferreira et al.85 and also Tarcsay and Keserű86 have performed 
docking studies involving multiple P-gp substrates such as Rhodamine 123, vinblastine, verapamil 
and Hoechst 33342 interacting with P-gp. Ferreira et al. proposed that 45 residues were involved in 
forming the binding site for Hoechst 33342. However, Tarcsay and Keserű proposed only 28 
residues formed the Hoechst site. Critically, only three residues Gln191, Gln343 and Ser340 were 
common to both proposals. Likewise, the Rhodamine sites derived from these two docking studies 
only have four residues in common out of 49 and 31 residues respectively. Based on 
pharmacophore mapping Silva et al.87 also proposed a set of residues corresponding to the 
colchicine binding site. However in this case, there is no overlap at all with those proposed by 
Tarcsay and Keserű86. In contrast, Klepsch et al.88 and Chufan et al.89 based on docking and binding 
studies concluded that the inhibitors propafenone, tariquidar, cyclosporine A, and valinomycin 
could bind at multiple locations within the TM region and that it was not possible to identify unique 
binding sites for these molecules.  
 Molecular dynamics (MD) simulation is another approach that has been used extensively to 
provide insight into the properties of P-gp and other ABC transporters including substrate binding. 
For example, Jara et al.90 docked two inhibitors, a propafenone derivative (GP-240) and XR9576 
(tariquidar) to P-gp and used these complexes to initiate a series of MD simulations. As in the work 
by Klepsch et al.88 and Chufan et al.89, both inhibitors interacted with residues from multiple TM 
helices with considerable overlap: TM helices 4, 5, 6, 7, 8, 9 and 12 in the case of XR9576; and TM 
helices 4, 5, 6, 7 and 12 in the case of GP-240. Note, during these simulations the protein was held 
fixed and only minor changes compared to the initial docked conformations were observed. In 
another study using an homology model of human P-gp, Zhang et al.91 placed paclitaxel or 
doxorubicin at the intracellular entrance to the TMD pore and performed a series of unrestrained 
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MD simulations to determine whether either drug entered into the TM pore. It was found that both 
substrates spontaneously moved into the TM pore region close to the center of the membrane. 
Zhang et al.91 proposed that Phe303 played a major role in the interaction with paclitaxel but did not 
identify a distinct binding site. Other studies have attempted to understand how the binding of 
substrates affects the overall conformation of P-gp. For example, Ma and Biggin92 suggested that 
the binding of daunorubicin within the TM region perturbed the dimerization of the NBDs. 
Simulations have also been used to shed light on how substrates or inhibitors may enter the TM 
region from the membrane or solvent. Using a combination of MD simulations and data from 
double electron-electron resonance (DEER) experiments, Wen et al.93 analyzed the extent to which 
a membrane embedded P-gp could adopt a range of conformations. During these simulations, Wen 
et al. observed a partial protrusion of a lipid tail into the TM pore and proposed that this region 
could form a substrate uptake portal. 
 Despite all of these previous experimental and theoretical studies, the basic question of 
whether there are distinct binding sites for different classes of substrates, or just a single 
overlapping binding region has remained a matter of continuing debate. It is also not clear how 
different substrates enter the TM region. Given the difficulties in working with P-gp in a membrane 
environment under experimental conditions, simulation based approaches would appear to hold the 
most promise in shedding light on these issues. Simulations have been central in resolving a range 
of questions related to transporters such as P-gp at an atomic level. For example, studies carried out 
using isolated NBDs20, 58, 94-96 have given us information on the conformational changes taking 
place as result of ATP hydrolysis. Also, MD simulations of whole ABC transporters including P-gp 
have played a major role in elucidating the conformational changes within the TMDs and also 
conformational transition and flexibility of the transporters31, 90-93, 97-104. Simulations of mouse P-
gp31, 98, have also highlighted the importance of the membrane environment, Mg2+ and the 
protonation state of specific residues in determining the physiologically relevant state of the protein.  
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4 THEORY 
 In order to address the intrinsic problem of P-gp being responsible for multidrug resistance, 
MD simulation techniques coupled with PMF calculations have been used. Such simulations can 
provide information on the dynamic properties of the protein and the drug binding pathway in 
atomic detail, as well as providing a means to the thermodynamic quantities such as PMF and 
binding affinities.  
4.1 Molecular Dynamics 
 Molecular dynamics (MD) simulation techniques can be used to model the motions of a 
system of particles. In the classical limit, this can be achieved by iteratively solving Newton’s 
equations of motion, which can be expressed as: 
𝐅𝑖 = 𝑚𝑖
𝑑2𝑟𝑖
𝑑𝑡2
          (1) 
where ri represents the Cartesian coordinates of an atom i with a mass mi, at a specific time t. Fi is 
the force acting on atom i which can be expressed as: 
𝐅𝑖 = −
𝜕𝑉(𝑟1, 𝑟2, 𝑟3 … 𝑟𝑖 … 𝑟𝑛)
𝜕𝑟𝑖
          (2) 
where V(r1, r2, r3…ri ...rn) is the potential energy of the system as a function of coordinates. Once 
the potential energy of the system is known, along with the coordinates of a starting configuration 
and a set of velocities, the force acting on each atom can be calculated. These can be used to 
propagate the system forward in time in order to generate a new set of coordinates and velocities. 
The utility of the trajectory generated is governed by the accuracy of the potential energy function, 
which describes the interactions between the particles. The size and complexity of biological 
systems together with the time scales that must be reached necessitate the use of empirical potential 
energy functions commonly referred to as force fields. In general, such force fields consist of a set 
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of equations that describe the bonded and non-bonded interactions between atoms. A general form 
the potential energy function can be written as: 
𝑉 =  𝑉𝐶𝑜𝑢𝑙𝑜𝑚𝑏 +  𝑉𝑣𝑑𝑊  +  𝑉𝑏𝑜𝑛𝑑𝑠 +  𝑉𝑎𝑛𝑔𝑙𝑒𝑠 + 𝑉𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙𝑠  +  𝑉𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟          (3) 
In the GROMOS force field 105, 106, the Coulomb and van der Waals potentials are given as: 
𝑉𝐶𝑜𝑢𝑙𝑜𝑚𝑏 = ∑
𝑞𝑖𝑞𝑗
4𝜋𝜀0𝑟𝑖𝑗
          (4)
𝑝𝑎𝑖𝑟𝑠,𝑖𝑗
 
𝑉𝑣𝑑𝑊 = ∑ (
𝐶𝑖𝑗
12
𝑟𝑖𝑗
12
𝑝𝑎𝑖𝑟𝑠,𝑖𝑗
−
𝐶𝑖𝑗
6
𝑟𝑖𝑗
6 )          (5) 
where qi and qj are the charges on the atoms i and j, and rij is the distance between the atoms i and j. 
Cij
12 and Cij
6 are Lennard-Jones parameters dependent on pairs of atom types and ɛ0 is the dielectric 
permittivity in free space (vacuum). The stretching potential energy of the covalent bonds is 
represented by the function: 
𝑉𝑏𝑜𝑛𝑑 = ∑
1
4
𝐾𝑏𝑛(𝑏𝑛
2 − 𝑏0𝑛
2 )2          (6)
𝑁𝑏
𝑛=1
 
where Kbn is the bond stretching force constant, b is the length of the covalent bond length and b0 
the length of covalent bond at equilibrium. The bond angle, dihedral angle and improper dihedral 
potential energies are given by: 
𝑉𝑎𝑛𝑔𝑙𝑒 = ∑
1
2
𝐾𝜃𝑛(𝑐𝑜𝑠𝜃𝑛 − 𝑐𝑜𝑠𝜃0𝑛)
2         (7)
𝑁𝜃
𝑛=1
 
𝑉𝑑𝑖ℎ𝑒𝑑𝑟𝑎𝑙 = ∑ 𝐾𝜑𝑛
𝑁𝜑
𝑛=1
[1 + cos(𝛿𝑛) cos ( 𝑚𝑛𝜑𝑛)]          (8) 
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𝑉𝑖𝑚𝑝𝑟𝑜𝑝𝑒𝑟 = ∑
1
2
𝐾𝜉𝑛(𝜉𝑛 − 𝜉0𝑛)
2
𝑁𝜉
𝑛=1
          (9) 
Here Kθn, Kφn and Kξn are the bond angle, dihedral angle and improper dihedral angle force 
constants respectively. θ, δ and ζ are the bond angle, dihedral angle and improper dihedral angle 
respectively. mn is the multiplicity of the torsional dihedral angle. The subscript 0 indicates the 
equilibrium value of these terms.  
4.2 Free energy calculations 
 The probability of finding a molecular system in one state or another is governed by the 
difference in free energy between those states107. Using statistical mechanics, the difference in free 
energy between two states of a system may also be expressed in terms of an average over an 
ensemble of atomic configurations of the molecular system of interest. Free energy is one of the 
most important state functions in chemistry, as it governs the spontaneity of a process and gives the 
probability of the system adopting a given state in the canonical ensemble. The free energy F of a 
system in the canonical ensemble, i.e., at constant number of particles, volume, and temperature, is 
given by 108, 109: 
𝐹(𝑁, 𝑉, 𝑇) = −
1
𝛽
𝑙𝑛 𝑄         (10) 
where β is the inverse temperature divided by Boltzmann’s constant kB (i.e., β = kB.T-1) and Q is the 
partition function of the system. If the system is at thermodynamic equilibrium, the partition 
function can be expressed as: 
𝑄 =
1
𝑁! ℎ3𝑁
∬ 𝑒−𝛽𝐻(𝑝,𝑟) 𝑑𝑝 𝑑𝑟          (11) 
where N is the number of particles in the system and h is Planck’s constant. The factor N! appears 
only for indistinguishable particles. The integral is performed over all 3N positions r and conjugate 
momenta p, respectively. The Hamiltonian H (p, r) gives the total energy of the system in a given 
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configuration, i.e. a given set of coordinates and momenta. From the definition of the partition 
function Q, it is clear that the calculation of the absolute free energy requires the sampling of the 
complete phase space of the system, which is not possible109. Although the absolute free energy 
cannot be determined, the difference in the free energy between closely related systems can be 
determined. The difference in free energy between two states A and B of a molecular system can be 
expressed as a function of the ratio of the partition functions of the individual states: 
∆𝐹𝐴→𝐵 = 𝐹𝐵 − 𝐹𝐴 = −
1
𝛽
ln
𝑄𝐵
𝑄𝐴
           (12) 
To calculate ΔF, the Hamiltonian is made dependent on the coupling parameter λ. When λ = λA, the 
system corresponds to state A with H (p, r; λA) = HA (p,r) and when λ = λB the system corresponds 
to state B with H (p, r; λB) = HB(p,r). In such cases, the partition function Q is expressed as: 
𝑄 =  
1
𝑁! ℎ3𝑁
∬ 𝑒−𝛽𝐻(𝑝,𝑟,𝜆)𝑑𝑝 𝑑𝑟          (13)  
As the partition function becomes a function of coupling parameter λ, so does the expression for F: 
𝐹(𝑁, 𝑉, 𝑇, 𝜆) = −
1
𝛽
𝑙𝑛 𝑄((𝑁, 𝑉, 𝑇, 𝜆))         (14) 
Currently, there are two standard methods using this coupling parameter approach: the 
thermodynamic integration (TI) method and the free energy perturbation (FEP) method108, 109.  
In the FEP method, free energy difference can be computed as a sum of a series of small steps in λ: 
Δ𝐹𝐴→𝐵 = −
1
𝛽
∑ ln
𝜆𝐵
𝜆=𝜆𝐴
⟨𝑒−𝛽[𝐻(𝜆+Δ𝜆)−𝐻(𝜆)⟩
𝜆
          (15)           
where <…>λ denotes an ensemble average at a given value of λ. In the TI method, the free energy 
difference is calculated as the work done on the system to force the transition from the state A to the 
state B via a reversible path: 
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Δ𝐹𝐴→𝐵 =  ∫ ⟨
𝛿𝐻(𝜆)
𝛿𝜆
⟩
𝑁,𝑉,𝑇,𝜆
𝜆𝐵
𝜆𝐴
𝑑𝜆          (16) 
The value of λ can be changed either in discrete intervals or continuously from state A to state B. To 
examine the convergence and reduce the correlation between the starting conformations, a series of 
simulations with random order of λ value can also be used. Note, the equations presented above 
have been derived for the microcanonical ensemble (NVT) and expressed in terms of the change in 
the Helmholtz free energy ΔF, physical experiments are normally performed in the isothermal 
isobaric ensemble (NPT). The relevant quantity is the change in Gibbs energy or the free enthalpy 
ΔG. The equations corresponding to 14, 15 and 16 are given below.  
𝐺(𝑁, 𝑃, 𝑇, 𝜆) = −
1
𝛽
𝑙𝑛 𝑄((𝑁, 𝑃, 𝑇, 𝜆))         (17) 
Δ𝐺𝐴→𝐵 = −
1
𝛽
∑ ln
𝜆𝐵
𝜆=𝜆𝐴
⟨𝑒−𝛽[𝐻(𝜆+Δ𝜆)−𝐻(𝜆)⟩
𝜆
         (18)  
Δ𝐺𝐴→𝐵 =  ∫ ⟨
𝛿𝐻(𝜆)
𝛿𝜆
⟩
𝑁,𝑃,𝑇,𝜆
𝜆𝐵
𝜆𝐴
𝑑𝜆             (19) 
 The thermodynamic cycle can be used to estimate the difference in the free enthalpy 
associated with the binding of a series of alternative ligands to a receptor (for example, a protein). 
Figure 8 shows a scheme to determine the relative binding strength of two ligands X and Y to a 
receptor. ΔGX and ΔGY are the changes in Gibbs energy associated with the binding of two ligands, 
X and Y, to the receptor, respectively. ΔGXY, bound is the free energy associated with the mutation of 
receptor-bound ligand X into receptor-bound ligand Y and ΔGXY, water is the free energy associated 
with the mutation of ligand X into ligand Y in water. As the change in free energy is zero in a cyclic 
mutation, the difference in free energy associated with the binding of X and Y to the receptor (ΔΔG, 
or ΔGX – ΔGY) within the thermodynamic cycle can be determined from:  
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ΔΔG = Δ𝐺𝑌 − Δ𝐺𝑋 = Δ𝐺𝑋→𝑌,𝑏𝑜𝑢𝑛𝑑 − Δ𝐺𝑋→𝑌,𝑤𝑎𝑡𝑒𝑟          (20) 
 
4.2.1 Potential of Mean Force (PMF) 
 In MD simulations, often one wishes to know how the free energy of a system varies as a 
function of a particular change within the system, such as a change in a spatial coordinate. In this 
case, one can project the free energy onto a hyper-surface in configurational space: 
𝑅(𝑟) = 𝑅(𝑟1, 𝑟2, 𝑟3, … … , 𝑟𝑛)         (21) 
Such a hyper-surface is commonly referred to as a reaction coordinate, R. In configurational space, 
R is a function of positions of atoms in the system. The free energy as a function of R corresponds 
to the probability of finding the system in one state compared to another becomes: 
𝐺(𝑅) = −𝑘𝐵𝑇 ln𝑃(𝑅) + 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡          (22) 
where, P(R) is the probability of finding the system on the reaction coordinate. The function G(R) 
can also be written as the derivative of free energy of the system with respect to the reaction 
coordinate R. This is equal to the ensemble average of the derivative of the potential energy 
projected along the reaction coordinate R that can be expressed as 
Figure 8: Thermodynamic scheme for the estimation of the relative binding free energy of molecules X 
and Y.  
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∆𝐺𝐴→𝐵 = ∫ ⟨
𝜕𝑉
𝜕𝑅
⟩
𝑅
𝑅𝐵
𝑅𝐴
𝜕𝑅 = ∫ ⟨?⃗?⟩𝑅
𝑅𝐵
𝑅𝐴
𝜕𝑅         (23) 
where, V is the potential energy of the system at a given state. ?⃗? is the force required to constrain 
the system to a specific position on the reaction coordinate R. As the function G(R) corresponds to 
the average force along R, it is also known as the potential of mean force (PMF), and can be 
obtained by integrating the mean force along the reaction coordinate R110.  
4.2.2  Umbrella Sampling 
 In principle, the PMF along any given reaction coordinate can be computed from a 
simulation where one can select those configurations that satisfy Rʹ= R(r) for any value of Rʹ for 
the coordinate R. The relative probability P (Rʹ) follows then directly from the relative frequency 
with which the selected configurations occur and the free energy profile can be obtained from 
equation 14. However, in order to compute the correct probability distribution along a specific 
degree of freedom, good statistics must be achieved. In the presence of barriers, this is a formidable 
task, since the barrier regions will be visited rarely. Several techniques have been developed to 
enhance sampling in barrier regions. A general approach that can be used to improve the sampling 
of specific regions of the reaction coordinate is to apply a restraining or umbrella potential111. For 
example, the potential Wr (R(r); R0) can be added to the Hamiltonian H (p, r).  
𝑊𝑟  (𝑅(𝑟); 𝑅0) =
1
2
𝐾𝑟[𝑅(𝑟) − 𝑅0]
2          (24) 
which will harmonically restrain the molecular configurations so that the R coordinates remains 
close to R0. The potential of mean force G(R) of the unrestrained system can be constructed as: 
𝐺(R) = −𝑘𝐵𝑇 ln 𝑃𝑟(Rʹ) − 𝑊𝑟 (R; R0) + 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡          (25) 
where, the Pr (Rʹ) is the restrained probability.  
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5 METHODOLOGY  
5.1 Simulation parameters 
 In general the MD simulations presented in this thesis were performed using GROMACS112 
MD engine (version 3.3.3) in conjunction with the GROMOS 54A7 force field for proteins113. The 
simple point charge (SPC) water model114 was used to describe the solvent water. All simulations 
were performed under periodic boundary conditions in a rectangular box. The dimensions of the 
box were chosen such that the minimum distance to the box wall was at least 1.0 nm. A twin-range 
method was used to evaluate the non-bonded interactions. Interactions within the short-range cut-
off of 0.8 nm were updated every step. Interactions within the long-range cut-off of 1.4 nm were 
updated every 8 fs, together with the pair list. A reaction field correction was applied using a 
relative dielectric constant of r = 78.5 to minimize the effect of truncating the electrostatic 
interactions beyond the 1.4 nm long-range cut-off115. The LINCS algorithm116 was used to constrain 
the lengths of the covalent bonds. The geometry of the water molecules was constrained using the 
SETTLE algorithm117. In order to extend the timescale that could be simulated, explicit hydrogen 
atoms in the protein were replaced with dummy atoms, the positions of which were calculated each 
step based on the positions of the heavy atoms to which they were attached. This eliminates high 
frequency degrees of freedom associated with the bond angle vibrations involving hydrogens, 
allowing a time step of 4 fs to be used to integrate the equations of motion without affecting 
thermodynamic properties of the system significantly118. The simulations were carried out in the 
NPT ensemble at T = 300 K, and P = 1 bar. The temperature and pressure were maintained close to 
the reference values by weakly coupling the system to an external temperature119 and pressure bath 
using a relaxation time constant of 0.1 ps and 0.5 ps, respectively. The pressure coupling was semi-
isotropic. Images were produced using VMD120. Further details on the simulations are provided in 
the respective chapters. 
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5.2 Parameterization of P-gp substrates and inhibitors 
 A large number of empirical force fields have been developed for the biomolecular 
simulations. Some of the commonly used force fields are GROMOS106, 113, 121-125, AMBER126, 127, 
CHARMM128, 129 and OPLS130, 131. These force fields are well parameterized for biomolecules such 
as proteins, DNA and RNA. All these force fields use a similar form for the potential energy 
function but they vary in terms of the parameters used to describe individual molecules. A set of 
internally consistent parameters for a core set of molecules such as amino acids, nucleotides, simple 
sugars, common lipids, and common solvents is available for each of these force fields. However, 
they are not general force fields but have instead been specifically parameterized to reproduce a 
given set of properties of this core set of molecules. 
 Due to the diverse composition of hetero-molecules such as substrates, inhibitors, or drug 
molecules, it is not feasible to directly adopt the force field parameters from one molecule to 
another. Hence, the parameters for each new set of heteromolecules must be parameterized 
individually. A variety of programs and webservers have been developed to facilitate the generation 
of force field descriptions of novel molecules for use in MD simulations. Accurate force fields are 
critical when calculating the free energy of binding and there are several serious limitations in some 
of the servers. To overcome this limitation, an in-house database called Automated Topology 
Builder (ATB) and Repository132 was developed. ATB uses a knowledge-based approach in 
combination with QM calculations to obtain the force field parameters for small molecules. The key 
feature of this builder is that it is designed to maintain the compatibility of heteromolecules with the 
GROMOS force field. The advantage of this builder is that it is predominantly intended to generate 
force field topologies for use in MD simulations and free energy calculations. Figure 9 shows the 
chemical structures of P-gp substrates and inhibitors used in this thesis. The initial coordinates of 
the P-gp substrates and inhibitors were taken from PubChem Substance and Compound database133. 
Before generating specific force field parameters for individual molecules, the protonation states for 
each of the molecules at pH 7.0 was determined by calculating the ionization constant of each 
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titratable group in the compound, using the algorithm implemented in ChemAxon134, 135. At pH 7.0, 
the tertiary amine of most of the molecules was predicted to be protonated, resulting in a +1 charge 
on each molecule. Parameters for the molecules in the protonated state at pH 7.0 were developed 
using the Automated Topology Builder (ATB) and Repository132. The ATB produces refined 
parameters for small molecules such as morphine that contain less than 50 atoms based on the 
GROMOS 54A7 force field113. As others contains more than 50 atoms, the interaction parameters 
were obtained by sub-dividing each of the molecule into a series of overlapping chemical fragments, 
each containing less than 50 atoms. These were then submitted separately to the ATB. The final set 
of parameters used to describe each of the molecules was obtained by combining these fragments. 
The final parameters for each molecule are available for download from the ATB132. A 
comprehensive list of the parameters generated for the P-gp substrates, modulators and inhibitors 
are presented as Appendix A. 
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Figure 9: The chemical structures of P-gp substrates and inhibitors in pH 7 protonated state. 
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Chapter 2: Identification of possible binding sites for 
morphine and nicardipine on the multidrug 
transporter P-glycoprotein using umbrella sampling 
techniques 
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1 ABSTRACT   
The multidrug transporter P-glycoprotein is central to the development of multidrug 
resistance in cancer. While residues essential for transport and binding have been identified, the 
location, composition and specificity of potential drug binding sites is uncertain. Here molecular 
dynamics simulations are used to calculate the free energy profile for the binding of morphine and 
nicardipine to P-glycoprotein. We show that morphine and nicardipine primarily interact with key 
residues implicated in binding and transport from mutational studies, binding at different but 
overlapping sites within the transmembrane pore. Their permeation pathways were distinct, but 
involved overlapping sets of residues. The results indicate that the binding location and permeation 
pathways of morphine and nicardipine are not well separated and cannot be considered as unique. 
This has important implications for our understanding of substrate uptake and transport by P-
glycoprotein. Our results are independent of the choice of starting structure and consistent with a 
range of experimental studies.  
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2 INTRODUCTION 
Multidrug resistance presents a major obstacle to the successful treatment of diseases 
ranging from bacterial infections to cancer. In many cases, multidrug resistance results from the 
overexpression of membrane-embedded efflux proteins. One such efflux protein is P-glycoprotein 
(P-gp), the major human multidrug transporter. The expression of P-gp in cancer cells confers 
resistance to chemotherapeutic agents. P-gp transports over 120 different pharmaceuticals, steroids 
and peptides, and plays a key role in the uptake and excretion of a wide range of therapeutic drugs1. 
Despite extensive research over 38 years, neither the physical location of any binding site, nor the 
nature of the interaction between P-gp and its transport substrates has been fully characterized.  
P-gp is a transmembrane protein that belongs to the ATP-binding cassette (ABC) 
transporter family of proteins. All ABC transporters, including P-gp, use the energy of ATP 
hydrolysis to transport a wide range of molecules out of the cell. As shown in Figure 1, P-gp is 
composed of two transmembrane domains (TMDs), each made up of six transmembrane (TM) 
helices that associate to form a transmembrane (TM) pore; and two cytosolic nucleotide-binding 
domains (NBDs). The TMDs are involved in substrate recognition and efflux, while the binding and 
hydrolysis of ATP at the NBDs is coupled to the transport of substrate across the TMDs. It has long 
been proposed that substrate transport is associated with the TMDs adopting an inward- or an 
outward-facing conformation in which the transmembrane pore is open to the cytosolic side or the 
extracellular side of the membrane, respectively2. The structures of several homologous ABC 
transporters3-11 obtained under different crystallization conditions, such as the presence or absence 
of nucleotides, display a range of inward-facing and outward-facing conformations. It has been 
postulated that these crystallographic conformations represent a spectrum of distinct states in the 
proposed transport cycle. Further experimental studies have demonstrated that the addition of a 
transport substrate to purified P-gp reconstituted in lipid vesicles increases the ATPase activity of P-
gp12, suggesting that the binding of substrate may drive the hydrolysis of ATP.  
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 Various studies have attempted to 
elucidate the physical location of a substrate 
binding site within the TM pore. In particular, 
these studies have sought to identify key 
residues or interactions that would enable P-gp to discriminate between different classes of 
compounds. To date, no crystal structure of P-gp with a bound transport substrate has been solved. 
Instead, P-gp has only been crystallized in complex with cyclic peptide inhibitors4, 11 and nano-
bodies10. Given that no crystal structure of P-gp with bound substrate is available, the majority of 
the information related to possible binding sites has been inferred from mutational studies, which 
have been used to identify residues that affect the transport rate and binding affinity of different 
Figure 1: Equilibrated membrane-embedded P-
glycoprotein (P-gp). (a) The initial configuration of 
membrane-embedded P-gp used in the umbrella 
sampling simulations. The black line represents the 
reaction coordinate (Z-axis) along which the 
substrate is moved. The N-terminal and C-terminal 
halves are shown in gold and silver cartoon 
representation, respectively. The membrane is 
shown in line representation. The substrate 
morphine or nicardipine (CPK spacefill) was placed 
at a distance of 15 nm from the reference group of 
P-gp (purple spacefill). The structure of (b) 
morphine and (c) nicardipine at pH 7.0. The pKa(s) 
of ionizable groups are shown in blue. The rings of 
morphine (a-e) and nicardipine (a-c) are labelled in 
green. 
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substrates13-15. While the residues identified are 
distributed throughout P-gp, including within 
the NBDs, the majority of the residues known 
to affect transport rates are clustered in the TM 
region. In addition, FRET experiments 
involving Hoechst 33342 suggested that the 
physical location of the primary binding site for 
substrates lies in the membrane-embedded 
region of TMDs, within the span of the 
intracellular leaflet16. In particular, the binding 
of different substrates has been proposed to be 
associated with residues within TM helices 4, 5, 
6, 10, 11 and 1217. However, residues from 
other TM helices have also been shown to 
affect the ability of P-gp to transport substrates, 
and thus, it has not been possible to identify the 
physical location of a single specific substrate 
binding site14, 15. Some experimental results 
have been interpreted as suggesting that P-gp 
contains multiple sites, which interact with 
different classes of substrate. For example, photoaffinity labeling studies have shown that verapamil 
binds competitively to vincristine, whereas azidopine and vinblastine bind noncompetitively18, 19. 
Using equilibrium binding studies and competition/modulation studies examining the effect of 
combinations of substrates on ATP hydrolysis, Martin et al. suggested that there might be four 
pharmacologically distinct interaction sites in P-gp20. Others have proposed that P-gp has as many 
as seven distinct substrate interaction sites13. Despite this, the molecular composition of any of the 
proposed sites has not been elucidated in detail. As certain residues appear to interact with multiple 
Figure 2: Spatial distribution of experimentally 
identified residues involved in the binding and/or 
transport of P-gp substrates. (a) The equilibrated 
membrane-embedded P-gp system with residues 
affecting the binding (cyan) or transport (purple) 
of verapamil shown in spacefill representation. 
The N-terminal (gold) and C-terminal (silver) 
halves of P-gp are shown in cartoon 
representation. Phosphate groups of the lipid 
bilayer are shown in licorice representation. A 
truncated view of the membrane-embedded region 
of P-gp showing the residues experimentally 
implicated in (b) vinblastine, (c) colchicine, and 
(d) Rhodamine binding (cyan) and transport 
(purple). The dotted lines in (b), (c) and (d) give 
the span of the lipid membrane. 
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classes of substrate, it has also been suggested that the TMDs collectively form a single non-
specific binding pocket14, 21.  
For example, Figure 2 shows the residues within the TM region of P-gp that affect the 
binding and/or transport of four commonly studied P-gp transport substrates: verapamil17, 22-29, 
vinblastine17, 23-27, 29, 30, colchicine17, 23, 24, 26-28 and Rhodamine 12328-32. Figure 2(a) shows the 
equilibrated structure of membrane-embedded P-gp, highlighting the residues within the TMDs that 
are primarily implicated in the binding (cyan) and transport (purple) of verapamil. In contrast, 
Figures 2(b), (c) and (d) show the corresponding residues within the TMDs associated with the 
binding and/or transport of vinblastine, colchicine, and Rhodamine 123, respectively. These 
residues are listed in Table 1. Based on competitive binding studies, it has been proposed that 
verapamil and vinblastine interact with the same site in P-gp, commonly referred to as the 
vinblastine site13, 33. In a similar manner, colchicine and Hoechst 33342 have also been proposed to 
bind to P-gp at a separate pharmacological site, the H-site or Hoechst site34, 35. Rhodamine 123 and 
related molecules have been proposed to bind to a third pharmacologically distinct site, the R-site or 
Rhodamine site35. While vinblastine, Hoechst 33342, and Rhodamine 123 bind non-competitively 
with one another, it is evident from Figure 2 that in each of these cases, the residues involved in 
binding and transport are not spatially well separated.  
Further examination of all the residues implicated in binding and transport indicate that a 
key subset of residues is involved in the binding or transport of multiple substrates, irrespective of 
whether they are competitive or non-competitive substrates. For example, Table 1 shows that His60, 
Leu64, Phe724 and Gln942 are all implicated in the binding of the non-competitive substrate pair 
colchicine and verapamil23, 26, 27, while two of these residues, Leu64 and Phe724, together with 
Tyr949, are implicated in the binding or transport of a second non-competitive substrate pair, 
Rhodamine and vinblastine24, 26, 30. In addition, Leu335 and Val978 are implicated in binding of 
verapamil, but not colchicine, Rhodamine or vinblastine and are implicated in the transport of all 
four substrates (Table 1). While conformational changes during substrate transport cannot be 
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excluded, the close spatial proximity of these residues suggests that the binding locations are not 
truly independent or distinct.  
 
P-gp 
Substrates 
 Binding Residues Ref  Transport Residues  Ref 
verapamil a  
L335 22 S218 17 
V978 23 L335, A338, I864, G980 22 
G935, F938, T941, Q942, A943 24 A981 23 
I302 25 Q128 29 
F724 26   
H60, G63, L64 27   
A298, L335, G868, F938, Q942  28   
V978, S989 28   
vinblastine b 
A943 24 S218, G868 17 
I302 25 L335, L971, V978 23 
F724 26 T941, Y946, Y949 24 
H60, G63 27 Q128 29 
L64, T195, I302 30   
colchicine c 
Q942 24 S218 17 
F724 26 L335, L971, V978 23 
H60, L64 27   
F766, M982, A983 28   
Rhodamine d  
F724 26 Q769 29 
F332, F766, F979, M982, A983 28 L335 30 
Q986 28 L64, I336, A837, L971, V978 31 
F339 30   
Y949 32   
a Figure 2(a), b Figure 2(b), c Figure 2(c) and d Figure 2(d) 
In recent years, a number of computational approaches have been used in an attempt to 
characterize potential substrate binding sites in P-gp. These include molecular docking and 
pharmacophore mapping studies36-40. In two independent studies, Ferreira et al.36 and Tarcsay and 
Keserű37 examined the interaction of various P-gp substrates such as Rhodamine 123, vinblastine, 
verapamil and Hoechst 33342 with P-gp using molecular docking studies. In one of these studies, 
Table 1: Residues within the transmembrane (TM) region of membrane-embedded P-gp that affect 
the experimental binding and transport of P-gp substrates. 
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45 residues were implicated in the binding of Hoechst 3334236. In the other, only 28 residues were 
proposed to form the Hoechst site37. Critically, only three residues, Gln191, Gln343 and Ser340, 
were common to both studies36, 37. Likewise the Rhodamine 123 binding sites proposed by these 
two docking studies only contain four common residues out of 4936 and 3137 residues respectively. 
Based on pharmacophore mapping, Silva et al.38 also proposed a set of residues corresponding to 
the colchicine binding site. In this case there is no overlap at all with those proposed by Tarcsay and 
Keserű37. In contrast to these studies, both Klepsch et al.39 and Chufan et al.40 used independent 
docking and binding studies to conclude that the inhibitors propafenone, tariquidar, cyclosporine A 
and valinomycin could bind at multiple locations within the TM region, and thus it was not possible 
to identify unique binding sites for these molecules.  
Molecular dynamics (MD) simulation is another computational approach that has been 
used extensively to provide insight into the nature of substrate recognition and binding by P-gp and 
its homologues. For example, Jara et al.41 docked two inhibitors, a propafenone derivative (GP-240) 
and tariquidar (XR9576), into the P-gp TMD region and used these complexes to initiate a series of 
MD simulations. Their results were consistent with the findings of Klepsch et al.39 and Chufan et 
al.40: both inhibitors interacted with residues from multiple TM helices with considerable overlap. 
Here, TM helices 4, 5, 6, 7, 8, 9 and 12 were implicated in the binding of tariquidar; while TM 
helices 4, 5, 6, 7 and 12 were implicated in the binding of GP-240. It is important to note that 
during these simulations, the protein was held fixed and only minor changes in the side chain 
orientations were observed compared to the initial docked conformations. In another study using an 
homology model of human P-gp, Zhang et al.42 placed paclitaxel or doxorubicin at the intracellular 
entrance to the TM pore and performed a series of free MD simulations to determine whether either 
drug entered the TM pore. They found that both substrates spontaneously moved into the TM pore, 
close to the central plane of the membrane. Based on their observations, Zhang et al.42 proposed 
that in human P-gp, Phe303 played a major role in the interaction with paclitaxel; however, they did 
not identify distinct binding sites.  
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Other studies have attempted to understand how the binding of substrates affects the 
overall conformation of P-gp. For example, Ma and Biggin43 suggested that the binding of 
daunorubicin within the TM region perturbed the dimerization of the NBDs. Simulations have also 
been used to shed light on how substrates or inhibitors may enter the TM region from the membrane 
or solvent. Using a combination of MD simulations and data from double electron-electron 
resonance (DEER) spectroscopy, Wen et al.44 analyzed the extent to which a membrane-embedded 
P-gp could adopt a range of conformations. During one of these simulations, Wen et al. observed a 
partial protrusion of a lipid tail into the TM pore through the cleft formed by the membrane-
embedded regions of TM helices 4 and 644. They claim that the protrusion of this lipid tail into P-gp 
supports the proposed role of this cleft as a possible lipid-accessible substrate uptake portal4-11. 
Despite all of these previous experimental and theoretical studies, the basic question of 
whether there are distinct binding sites for different classes of substrates, or one single overlapping 
binding region, has remained a matter of continuing debate. Given the difficulties in working with 
purified and reconstituted P-gp, simulation based approaches would appear to hold the most 
promise in shedding light on these issues. Simulations have played a role in resolving the dynamic 
structural mechanism by which ABC transporters, such as P-gp, function. For example, the MD 
studies carried out using isolated ABC transporter NBDs45-49 have provided information on the 
conformational changes that occur on ATP binding and after the hydrolysis of ATP to ADP. MD 
simulations of P-gp and other full-length ABC transporters have also been used to examine 
conformational changes within the TMDs and their possible role in transporter function41-44, 50-58. In 
addition, simulations of mouse P-gp51, 52, have highlighted the importance of the lipid composition 
of the membrane environment, Mg2+ and the protonation state of specific residues in determining 
the physiologically relevant state of the protein.  
In this study, we have used a combination of MD simulations and umbrella sampling 
techniques to investigate the interactions between membrane-embedded mouse P-gp and two 
substrates, morphine and nicardipine. Specifically, umbrella sampling techniques have been used to 
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calculate the potential of mean force (PMF) associated with the binding of these two P-gp substrates 
along an axis normal to the plane of the membrane projecting through the center of P-gp as shown 
in Figure 1(a). The aim was to identify the specific locations within the translocation pore where the 
substrates form stable interactions with P-gp. MD simulations have also been used to examine 
whether the two substrates would bind spontaneously to the locations identified from the 
corresponding PMFs on a 100 ns timescale. Previous docking and simulation studies of the 
interaction of substrates or inhibitors with P-gp have primarily relied on homology models, which 
by their very nature, are uncertain36, 37, 41, 59; or on crystal structures of the protein outside of a 
membrane environment43, 44, 57, 58, the physiological relevance of which has been questioned. In 
contrast, the current work is based on an extensively equilibrated structure of membrane-embedded 
apo mouse P-gp that has been demonstrated to be consistent with a wide range of experimental 
cross-linking studies51. In fact, this structure predicted changes in the TM helices that were later 
confirmed in revisions to the published crystal structures10, 11. 
The substrates morphine and nicardipine were chosen for this work based on a 
combination of biochemical and computational criteria. Most P-gp substrates contain aromatic or 
cyclic groups and are primarily hydrophobic in nature. As such, they bind to and interact with lipid 
bilayers. However, almost all substrates also contain at least one positively charged group, most 
commonly a tertiary amine that is protonated at neutral pH, and thus have an overall charge of +1 at 
physiological pH. P-gp substrates range in size from large complex molecules such as vinblastine 
(811 a.m.u.), to smaller molecules such as morphine (285 a.m.u.). In this study, we compare 
morphine, a small and compact substrate, with nicardipine (479 a.m.u.) a medium sized, elongated 
substrate. As shown in Figure 1, both are predominantly hydrophobic, but carry a charge of +1 at 
neutral pH. Morphine is a potent natural opiate and the most common analgesic used for the 
treatment of pain associated with cancer. It also plays an important part in the regulation of 
neoplastic tissue60, 61. Morphine is one of the smallest P-gp substrates62 and has a rigid pentacyclic 
structure, making it computationally efficient to simulate. Drug accumulation studies by Callaghan 
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et al. examined the binding of radiolabelled morphine, vinblastine, and verapamil to the membranes 
of cell lines over-expressing or not expressing P-gp. They found that vinblastine and verapamil 
could displace membrane-bound morphine in cell lines expressing P-gp62. These results suggest that 
morphine competes for binding and transport with verapamil and vinblastine. In contrast, the 
calcium channel blocker nicardipine is believed to bind to P-gp in a non-competitive manner to 
morphine. Nicardipine enhances the effects of antineoplastic agents, leading to chemo-sensitivity in 
tumor cells, and has been extensively used experimentally in drug binding/transport studies of P-
gp63, 64. Studies by Martin et al. and Pascaud et al. suggested that nicardipine binds to a site 
different to that of both vinblastine and Hoechst20, 33. 
  In the next section, the methodology used in the simulations and analysis is 
described in detail. The steps taken to ensure the convergence of the PMFs are also presented. The 
implications of the PMFs obtained are discussed in terms of the residues with which the two 
substrates interact, and whether there is a single or multiple binding sites. Finally, a model is 
presented that can be used to reconcile the fact that classes of substrates bind competitively with 
each other but non-competitively with other classes given our current understanding of the binding 
region of P-gp.  
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3 METHODOLOGY 
Two sets of MD simulations were performed. In order to identify the binding sites for 
morphine and nicardipine, the potential of mean force for each of these substrates was calculated 
along an axis projecting through the center of P-gp normal to the plane of the membrane as 
described below. To examine whether morphine and nicardipine would bind spontaneously to the 
sites identified on a nanosecond (ns) timescale, a series of free MD simulations were also performed.  
3.1 Simulation setup 
The starting configuration for all MD simulations performed here was based on an 
equilibrated conformation of P-gp (PDBid: 3G5U) embedded in a 9:1 POPC (2-oleoyl-1-palmitoyl-
sn-glycero-3-phosphocholine) and cholesterol bilayer obtained by O’Mara and Mark51 (Figure 1A). 
The coordinates of this system were downloaded from the Automated Topology Builder (ATB) and 
Repository65. The protonation states of all residues corresponded to the values described by O’Mara 
and Mark51. In addition to the 60-residue linker region, the first 32 residues and final five residues 
of P-gp were not resolved crystallographically. To avoid the introduction of inappropriate charges, 
the N- and C-termini were acetylated and aminated, respectively. All MD simulations were 
performed using GROMACS66 version 3.3.3 in conjunction with the GROMOS 54A7 forcefield for 
proteins67. The simple point charge (SPC) water model68 was used to describe the solvent water. 
The parameters for POPC were taken from Poger et al69. The parameters for cholesterol and 
simulation conditions were the same as those used by O’Mara and Mark51. An electrolyte 
concentration of 150 mM NaCl and 1.5 mM MgCl2 was added to the system to mimic the 
experimental conditions.  All simulations were performed under periodic boundary conditions in a 
rectangular box. The dimensions of the box were chosen such that the minimum distance of the 
protein to the box wall was at least 1.0 nm. A twin-range method was used to evaluate the non-
bonded interactions. Interactions within the short-range cut-off of 0.8 nm were updated every step. 
Interactions within the long-range cut-off of 1.4 nm were updated every 8 fs, together with the pair 
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list. A reaction field correction was applied using a relative dielectric constant of r = 78.5, to 
minimize the effect of truncating the electrostatic interactions beyond the 1.4 nm long-range cut-
off70. A value of r = 78.5 was used, as this is the experimental relative dielectric constant for water 
at ~300 K. Note, while a range of other values have been used with SPC water to attempt to match 
the reaction field to different calculated values for the dielectric constant of SPC water, the 
properties of water have been shown to be insensitive to small changes in the relative dielectric 
constant beyond the 1.4 nm cutoff71. The LINCS algorithm72 was used to constrain the lengths of 
the covalent bonds. The geometry of the water molecules was constrained using the SETTLE 
algorithm73. In order to extend the timescale that could be simulated, explicit hydrogen atoms in the 
protein were replaced with dummy atoms, the positions of which were calculated at each step based 
on the positions of the heavy atoms to which they were attached. This eliminates high frequency 
degrees of freedom associated with the bond angle vibrations involving hydrogens. These degrees 
of freedom are largely uncoupled from the rest of the protein and their elimination allows a time 
step of 4 fs to be used to integrate the equations of motion without affecting thermodynamic 
properties of the system significantly, as discussed by Feenstra et al74. The simulations were carried 
out in the NPT ensemble at T = 300 K, and P = 1 bar. The temperature and pressure were 
maintained close to the reference values by weakly coupling the system to an external temperature75 
and pressure bath using a relaxation time constant of 0.1 ps and 0.5 ps, respectively. The pressure 
coupling was semi-isotropic. Data was collected for analysis every 25 ps during the potential of 
mean force calculations and every 50 ps during the unbiased MD simulations. Images were 
produced using VMD76. 
3.2 P-gp Substrates 
The initial coordinates of the P-gp substrates morphine and nicardipine were taken from 
PubChem Substance and Compound database77. The protonation state of morphine and nicardipine 
at pH 7.0 was determined by calculating the ionization constant of each titratable group in the 
compound, using the algorithm implemented in ChemAxon78, 79. At pH 7.0, the tertiary amine of 
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morphine and that of nicardipine were predicted to be protonated, resulting in a +1 charge on each 
molecule. The pKa’s of the tertiary amine groups, and the cyclic groups of morphine (a-e) and 
nicardipine (a-c) are shown in Figure 1. Parameters for morphine and nicardipine in the protonated 
state at pH 7.0 were developed using the Automated Topology Builder (ATB) and Repository65. 
The ATB generates parameters for small molecules based on the GROMOS 54A7 force field67. The 
parameters produced by the ATB have been demonstrated to perform well in the SAMPL4 blind 
computational challenge in which the calculated hydration free enthalpies of drug-like molecules 
are compared to experimental results80. The ATB can generate fully refined parameters for 
molecules that contain less than 50 atoms. As nicardipine contains 86 atoms the interaction 
parameters were obtained by sub-dividing nicardipine into a series of overlapping chemical entities 
each containing less than 50 atoms. These were then submitted separately to the ATB. The final set 
of parameters used to describe nicardipine was obtained by combining these fragments. The final 
parameters obtained are available for download from the ATB (MOLID: 5089 and MOLID: 2009)65. 
Note, these parameters maintain the conformation of both morphine and nicardipine within < 0.1 
nm, (all-atom RMSD) from the conformation optimized at the B3LYP/6-31G* level of theory in 
implicit solvent65. 
3.3 Potential of Mean Force calculations 
The potential of mean force (PMF) of morphine or nicardipine along the central axis of P-
gp was calculated using the umbrella sampling method81. To initiate the simulations, a group of 
eight residues (Ala79, Ser80, Val81, Gly82, Asn83, Val84, Ser85, and Lys86) from the extracellular 
region of TM1 was chosen as a reference group. A single molecule of the substrate was placed at a 
distance of 15.0 nm on the cytosolic side from the reference group of P-gp, along the chosen 
reaction coordinate defined as the axis passing through the reference group and normal to the 
membrane. The initial position of the substrate relative to P-gp, and the direction of the reaction 
coordinate are shown in Figure 1A. A harmonic restraint with a force constant of 500 kJ·mol-1·nm-2 
was applied to the center of mass (COM) of the substrate and it moved along the reaction 
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coordinate from its starting position towards the reference group at a rate of 15 nm/ns. This 
simulation was used to generate a set of 15 reference configurations separated by 1.0 nm intervals 
along the reaction coordinate. These were then used as starting configurations for umbrella 
sampling calculations at intermediate distances spaced every 0.25 nm along the reaction coordinate 
giving 60 windows in total. In each umbrella sampling simulation, the center of mass of the 
substrate was harmonically restrained using a force constant of 500 kJ·mol-1·nm-2 in the Z-direction 
to allow it to sample a specific region (window) along the reaction coordinate. To reduce the effect 
of any directional bias induced during the generation of the reference configurations on the final 
PMF, the starting configuration for each of the intermediate distances were selected randomly from 
the two adjacent reference configurations. The motion of the substrate was not restrained in 
the XY plane.
 
Reaction 
Coordinate Z 
(nm) 
Morphine simulation time (ns) Nicardipine simulation time (ns) 
Total time Equilibration time Total time Equilibration time 
-15.00 15 5 19 9 
-14.75 18 8 17 7 
-14.50 17 7 18 8 
-14.25 17 7 20 10 
-14.00 18 8 19 9 
-13.75 17 7 19 9 
-13.50 18 8 18 8 
-13.25 17 7 18 8 
-13.00 19 9 17 7 
-12.75 20 10 18 8 
-12.50 18 8 19 9 
-12.25 19 9 19 9 
-12.00 21 11 23 13 
-11.75 22 12 24 14 
-11.50 21 11 22 12 
-11.25 21 11 22 12 
-11.00 24 14 22 12 
-10.75 23 13 24 14 
-10.50 23 13 24 14 
-10.25 25 15 23 13 
-10.00 28 18 22 12 
Table 2: Summary of the simulation time taken for each window to meet the convergence criteria. 
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-9.75 26 16 23 13 
-9.50 27 17 22 12 
-9.25 28 18 24 14 
-9.00 27 17 25 15 
-8.75 29 19 25 15 
-8.50 28 18 24 14 
-8.25 28 18 23 13 
-8.00 27 17 24 14 
-7.75 25 15 22 12 
-7.50 26 16 22 12 
-7.25 26 16 21 11 
-7.00 26 16 21 11 
-6.75 27 17 20 10 
-6.50 26 16 23 13 
-6.25 25 15 22 12 
-6.00 28 18 23 13 
-5.75 27 17 24 14 
-5.50 27 17 24 14 
-5.25 25 15 22 12 
-5.00 26 16 23 13 
-4.75 26 16 22 12 
-4.50 25 15 20 10 
-4.25 25 15 22 12 
-4.00 23 13 21 11 
-3.75 27 17 22 12 
-3.50 25 15 22 12 
-3.25 24 14 21 11 
-3.00 26 16 23 13 
-2.75 25 15 26 16 
-2.50 27 17 25 15 
-2.25 24 14 26 16 
-2.00 25 15 25 15 
-1.75 26 16 26 16 
-1.50 27 17 25 15 
-1.25 26 16 23 13 
-1.00 26 16 25 15 
-0.75 27 17 26 16 
-0.50 27 17 26 16 
-0.25 26 16 25 15 
     
 The PMF was obtained by integrating the derivative of the free energy with respect to the 
distance along the reaction coordinate as described by Kaestner and Thiel82, 83. The system was 
simulated at each distance corresponding to a specific umbrella sampling window along the reaction 
coordinate until the derivative of the free energy had converged. The derivative of free energy was 
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considered to have converged when the difference between the average of the derivative calculated 
for a series of 1 ns sliding windows taken every 0.5 ns did not vary by more than 5 kJ/mol over a 
period of 5 ns (10 windows). The time for each window to meet the convergence criteria is given in 
Table 2. Once the system was considered to have converged, the simulation was extended for a 
further 10 ns. The average derivative over these final 10 ns was used in the calculation of the PMF. 
The accumulated error from the derivative of the free energy was also calculated over the final 10 
ns.   
3.4 Simulations of spontaneous binding 
To examine if morphine or nicardipine would bind spontaneously to the binding locations 
identified on a nanosecond timescale, 8 molecules of the substrate were placed randomly in the 
water layer surrounding P-gp. As both morphine and nicardipine carry a +1 charge, 8 Cl- counter 
ions were added to neutralize the system. The membrane-embedded P-gp system was already 
equilibrated prior to the addition of eight substrate molecules. Nevertheless, 1000 steps of steepest 
descent energy minimization was performed to relax the solvent around the substrate. A 50 ps 
simulation was then performed in which the backbone of the protein was position restrained using a 
harmonic potential with a force constant of 500 kJ·mol-1·nm-2. Starting from this configuration, 
three independent simulations without restraints were then performed by assigning new velocities in 
each case. Each simulation was 80 ns in length. 
3.5 The effect of starting structure on substrate binding  
In order to determine whether the interactions of morphine and nicardipine with the TMDs 
of P-gp observed in the simulations were biased by the choice of the P-gp starting structure, a series 
of MD simulations based on a revised mouse P-gp structure (PDBid: 4M1M)11 were also performed. 
The 4M1M P-gp structure was extensively equilibrated in a POPC and cholesterol membrane 
(POPC: cholesterol, 9:1) as described in the methods under similar conditions to those used by 
O’Mara and Mark used to equilibrate 3G5U51. The two substrates, morphine and nicardipine were 
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placed within the TM pore of the equilibrated 4M1M structure at Z = -2.5 nm for morphine and Z = 
-2.3 nm for nicardipine, corresponding to their respective free energy minimum shown in Figure 3. 
Though the 4M1M P-gp structure was equilibrated before the addition of the substrates, 1000 steps 
of steepest descent energy minimization was performed in each case to relax the solvent around the 
substrate. In each case, a free MD simulation of 40 ns was performed.  
3.6 Analysis 
Calculation of the spatial density function (SDF) 
In order to calculate the spatial distribution of the substrates during the MD simulations, 
each frame of the trajectory was aligned onto a given reference frame (starting structure) by 
performing a least squares rotational and translational fit to the P-gp protein backbone. A cubic grid 
with a spacing of 0.1 nm was then superimposed onto the reference system. The spatial density 
function for the substrates was then generated by counting the number of times the center of mass 
of a given substrate was found within a specific element of the grid using the g_spatial program84. 
The resulting grid was visualized in VMD as an isosurface showing 65% probability of finding 
either morphine or nicardipine. 
Root mean squared deviation (RMSD) 
As a measure of the difference between configurations extracted from the trajectories or 
clusters, the RMSD was calculated using the method of Maiorov and Crippin85 after first 
performing a rotational and translational fit of each frame of the trajectory to a reference structure 
or domain.  
Cluster Analysis 
To determine the relative populations of the conformations of nicardipine, the trajectories 
were clustered using the method of Daura et al86, 87. In this work, two conformations were 
  
66 
considered to fall within the same cluster if the backbone RMSD between the conformations was < 
0.15 nm. 
Protein and substrate contacts 
All the protein residues for which the average distance between the centers of at least one 
atom lay within a 0.3 nm radius of the center of any atom of the given substrate were considered to 
be in direct contact with the substrate. In all cases the averaging was performed over the last 10 ns 
of the relevant simulation.  
Inter-residue distances 
To compare the distances between specific pairs of amino acids, or between morphine and 
Gln942, the distance between the centers of the representative atoms specified for each group was 
calculated.  Note, the distances used were averaged over the last 10 ns of the relevant simulation.  
Calculating electrostatic potential 
 The Adaptive Poisson-Boltzmann Solver (APBS) was to calculate the electrostatic potential 
of membrane embedded mouse P-gp structures88-90. APBS uses a Poisson-Boltzmann equation to 
describe the distribution of the electric potential in solution in the direction normal to a charged 
surface. This distribution is important to determine the electrostatic potential at surfaces. A 
modified The resulting electrostatic potential surface was visualized usingVMD76,  using the APBS 
plugin. The electrostatic potential surface was contoured at +1 (blue) and -1 (red) kT/e, assuming a 
dielectric of 78.5 and 150 mM NaCl.  
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4 RESULTS AND DISCUSSION 
The potential of mean force (PMF) of 
the two P-gp substrates, morphine and 
nicardipine were calculated at discrete 
positions in P-gp along the reaction coordinate 
(Z) shown in Figure 1. This reaction 
coordinate passes between the NBDs and the 
cytosolic parts of P-gp and into the TM pore. 
Note, a PMF gives the relative free energy 
with respect to a given reference location 
along a chosen reaction coordinate (pathway). 
While the difference in free energy between 
any two states is independent of the pathway 
chosen, the shape of the PMF is dependent on 
the reaction coordinate.  In principle, a wide 
range of alternative reaction coordinates could 
have been chosen91. In this work it is assumed the substrate enters P-gp from the cytoplasm. It has 
also been proposed that substrate uptake may involve two steps, with substrates first partitioning 
into the lipid bilayer before binding to P-gp2. Based on the available crystal structures two putative 
substrate uptake portals have been proposed. However, as there is little direct experimental data to 
support any one proposed pathway over another, the simplest possible reaction coordinate was used 
in this study. Note, the starting location for the PMF has been chosen as the substrate in aqueous 
solution (Z = -15 nm). Thus the difference in free energy between this reference location and the 
minimum along the reaction coordinate provides an estimate of the free energy of binding to the 
protein. Figure 3 shows the PMF along the central axis of P-gp for morphine and nicardipine 
overlaid onto the structure of P-gp.  
Figure 3: The potential of mean force (PMF) of 
morphine (pink) and nicardipine (blue) in P-gp 
as a function of the reaction coordinate (Z). A 
plot of the PMFs of morphine and nicardipine 
are superimposed on the membrane-embedded P-
gp structure (cartoon). The distances along the 
reaction coordinate are calculated with respect to 
the center of mass of the reference group (purple 
spacefill). The error bars reflect the accumulated 
error of the PMF. 
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4.1 Potential of Mean force (PMF) of Morphine 
The PMF of morphine (pink line in Figure 3) progressively decreases as the substrate is 
moved along the region spanning the NBDs and cytosolic extensions of the TMDs, between Z = -
11.0 nm and Z = -4.0 nm. The PMF culminates in a single energy well within the membrane-
embedded span of the TM pore (between Z = -4.0 nm and Z = -2.0 nm) located at Z = -2.5 nm. This 
energy well has a depth of -56 ± 4 kJ/mol relative to the free energy of morphine in bulk solution.  
4.1.1 The interaction of morphine with P-gp 
As shown in Figure 1, morphine has a rigid pentacyclic structure and thus, has limited 
conformational flexibility. The orientation of morphine is not sterically constrained by the protein, 
and in principle, it could rotate within the TM pore. However during the simulations morphine 
primarily adopted a single orientation with respect to the TM helices once it had entered the TM 
pore, in which the protonated piperidine ring (Figure 1(b), ring c) faced towards the water interface. 
When placed in the energy well shown in Figure 3, morphine binds between TM helices 1, 2, 9, 11 
and 12, close to the center of the lipid bilayer as shown in Figures 4(a) and (b). In this conformation, 
morphine forms direct contacts with 10 residues: Leu64, Met68 (TM1), Tyr113, (TM2), Asn838, 
Leu839, (TM9), Met945, Tyr946, Ser948, Tyr949 (TM11), Val978 (TM12). Note, a residue was 
Figure 4: A representative snapshot showing the interaction of morphine with P-gp at its minimum 
energy well. (a) Front and (b) top views of P-gp (cartoon) showing the position of morphine relative to 
TM helices 1 (brown), 2 (blue), 9 (yellow), 11 (cyan), and 12 (magenta). (c) A close-up view of bound 
morphine (pink spacefill) showing water molecules (green spacefill) that hydrogen bond with 
morphine. Gln942, which has a water-mediated interaction with morphine, is shown in a stick 
representation. Note: for clarity, TM helices 4 and 5 are not shown in (a) and (c). 
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considered to be in direct contact with the substrate if the average distance, over the last 10 ns of the 
relevant trajectory, between the center of at least one atom lay within a 0.3 nm radius of the center 
of any atom of the substrate. A more detailed figure showing the positions of these residues relative 
to morphine is provided as Figure 5. These residues form stable interactions with morphine that 
persist throughout the simulation. The protonated piperidine ring (ring c) of morphine forms a 
hydrogen bond with an adjacent water molecule, which in turn forms a hydrogen bond with the 
hydroxyl group of Gln942 from TM11, as shown in Figure 4(c). While the specific water molecule 
involved varies, this hydrogen bonding pattern persists throughout the simulation. Further details of 
the water occupancy and distance distribution between the morphine piperidine ring and the side-
chain carbonyl Gln942 is given in Figure 6.  
Several of the residues identified have 
previously been proposed from experimental 
studies to be involved in the binding or 
transport of different substrates. For example, 
Gln942 in TM11 has been proposed to be 
involved in the binding of verapamil24, while 
verapamil itself has been proposed to bind in a 
similar location to vinblastine. Photo-labeled 
drug accumulation studies using morphine and 
verapamil have demonstrated that verapamil 
competes for binding and transport with 
morphine62. Studies have also shown that the 
mutation of residues Leu64 and Tyr949 alters 
the binding affinity of verapamil23, 26, 27. These 
two residues are amongst those that form direct 
contacts with morphine when it resides at the energy minimum identified from the PMF. In the 
Figure 5: The interaction of morphine with 
3G5U P-gp at Z = -2.5 nm. Close-up showing 
residues that form direct contacts with 
morphine (spacefill) in the energy well located 
within the transmembrane pore. The protein 
backbone is shown in cartoon representation 
and individual residues are shown in liquorice 
representation. TM helices 1, 2, 9, 11 and 12 
are colored brown, blue, yellow, cyan, and 
magenta, respectively. 
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simulations, Leu64 interacted directly with morphine (ring b) and Tyr949 coordinates the 
allylic hydroxyl of morphine (ring d). Furthermore, these simulations highlighted the role of Tyr113 
in the coordination of the phenolic hydroxyl of the morphine (ring a). Several hydrophobic residues 
have also been shown to influence the binding and transport of vinblastine and verapamil under 
experimental conditions. Of these, Val978 forms a direct contact with morphine, which persists 
while morphine is within the energy well (Z = -2.5nm). 
 
Amino 
Acid 
TM 
helix 
Reaction 
coordinate 
Experimental binding/transport interactions 
Gln343 6 
Z = - 4.5 nma 
-- 
Pro346 6 -- 
Gln349 6 -- 
Phe351 6 -- 
Asn353 6 -- 
Gln128 3 
Z = -3.5 nmb 
verapamil29, vinblastine29 
Gly868 9 verapamil28, vinblastine17 
Thr941 11 verapamil24, vinblastine24 
Ala943 11 verapamil24 
Phe979 12 Rhodamine28 
Ala983 12 colchicine28, Rhodamine28 
Leu64 1 
Z = -2.5 nmc 
verapamil27, vinblastine30 
Met68 1 -- 
Tyr113 2 -- 
Asn838 9 -- 
Leu839 9 -- 
Gln942 11 verapamil24, colchicine24 
Met945 11 -- 
Tyr946 11 vinblastine24 
Ser948 11 -- 
Tyr949 11 vinblastine24, Rhodamine32 
Val978 12 verapamil23, 28, vinblastine23, colchicine23, 
Rhodamine31 
a intracellular lipid-water interface, b intermediate region between the lipid-water interface and the energy well 
of morphine, c energy well within the TM pore as shown in Figure 3. 
Table 3: Residues that interact with morphine at specific locations along the reaction coordinate in the 
umbrella sampling simulations. 
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Table 3 lists the residues that interact with morphine at specific locations along the reaction 
coordinate of the PMF. Several of the residues identified in Figure 5 as interacting with morphine at 
Z = -2.5 nm have also been proposed to interact with vinblastine. However, the binding of morphine 
to P-gp also involves residues implicated in the binding of colchicine, which is non-competitive 
with verapamil. This suggests that the site at which morphine interacts with P-gp in MD simulations 
is not physically distinct from that of colchicine, verapamil, or vinblastine. Again whether a residue 
was considered to interact with a substrate was based on the distance averaged over 10 ns of the 
relevant trajectory, not a single snapshot, and thus incorporates local fluctuations.  
 
 
  
Figure 6: The interaction between morphine, water and Gln942. (a) The distance between the 
hydrogen from the piperidine amine bridge of morphine and the side chain carbonyl of Gln942. (b) A 
representative snapshot of the morphine, water and Gln942 complex from the equilibrated MD 
simulations of morphine at its minimum energy binding site. The hydrogen bonding network between 
the piperidine amine bridge hydrogen, the water molecule and the carbonyl side chain of Gln942 is 
shown as dashed lines. The distance between the center of mass of each atom pair is given below the 
H-bond. Morphine (pink) and Gln942 (cyan) are shown in a stick representation. The hydrogen-
bonded water is shown in space-fill representation. Neighboring water molecules are shown in CPK 
representation. (c) Water occupancy from (b) as a function of simulation time. 
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4.2 Potential of Mean force (PMF) of Nicardipine 
The PMF of nicardipine (blue line in Figure 3) remains relatively flat while nicardipine is 
moved along the NBDs, between Z = -15 nm and Z = -9 nm. The PMF then gradually decreases 
along the reaction coordinate forming two energy wells, one located at in the intracellular lipid-
water interface (Z = -4.5 nm) that has a relative depth of -37 ± 4 kJ/mol, and a second deeper energy 
well within the TM pore (Z = -2.3 nm) with a relative free energy of -43 ± 5 kJ/mol. The two 
energy wells are separated by an energy barrier of ~17 kJ/mol at Z = -3.5 nm. As the energy well in 
the TM pore has a lower free energy, nicardipine is expected to bind preferentially within the TM 
pore at a location slightly past the center of the lipid membrane and within the span of the 
extracellular leaflet.  
4.2.1 The interaction of nicardipine with P-gp 
Figure 6 shows representative snapshots from the simulations of nicardipine at the two 
energy wells corresponding to Z = -4.5 nm and Z = -2.3 nm, as well as the intervening barrier at Z = 
-3.5 nm. The first energy well at Z = -4.5 nm is located at the intracellular lipid-water interface. 
Nicardipine is a highly flexible molecule and can adopt a variety of alternative conformations, 
which potentially allows it to form a large number of alternative interactions with P-gp in the 
simulations. To identify the preferred conformation adopted by nicardipine in this energy well, 
cluster analysis was performed. Once equilibrated at this location, nicardipine spent the majority of 
the time in a single conformation (60%, cut-off 0.15 nm) with the top three most populated clusters 
accounting for 94% of the conformations sampled. Figure 7(a) shows the central conformation of 
nicardipine from the dominant cluster. Here, nicardipine adopted an elongated spiral conformation, 
interacting predominantly with the TM helices 4, 5 and 6 (Figures 7(a) and (b)). Two residues, 
Lys230 and Asp237 (TM4), interacted with the protonated amino benzyl group (Figure 1(c), ring a) 
and the nitrophenyl ring (ring b) of nicardipine, respectively. At this low affinity site, nicardipine 
also formed direct contacts with residues Ala229, Ser233, Thr236 (TM4), Met295, Gly296, Ala297 
(TM5), Gln343, Ser345 and Pro346 (TM6). 
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 A snapshot showing these contacts in detail is shown in Figure 8(a).  These residues line the 
entrance to the TM pore from the inner lipid leaflet. To date, all inward-facing crystallographic 
conformations of P-gp and its homologues show a large separation between the cytosolic extensions 
of TM helices 4 and 6; and also between TM helices 10 and 12, on the opposite side of the TMDs4-
11. The separation of the helices extends into the membrane-embedded regions of the TMDs, 
forming two lipid-accessible clefts, proposed by Aller et al. to be substrate uptake portals for 
hydrophobic P-gp substrates that partition into the cell membrane4. Of the residues identified above, 
Ala229 and Ser345 were reported to be associated with the protrusion of the tail of a lipid into the 
TM pore in a previous set of MD simulations44. This suggests that hydrophobic molecules such as 
Figure 7: The interaction of nicardipine with P-gp in its two energy wells and at the intervening 
barrier. (a) Front and (b) top views of the predominant conformation and orientation of nicardipine 
(cyan spacefill) from cluster analysis, at the first energy well (Z = -4.5 nm) located near the 
intracellular lipid-water interface, coordinated by TM helices 4 (orange), 5 (olive green) and 6 
(purple). (c) Front and (d) top views of nicardipine at the top of the barrier (Z = -3.5 nm), coordinated 
by TM helices 3 (green), 5 (olive green), 6 (purple) and 12 (magenta). (e) Front and (f) top views of the 
dominant conformation of nicardipine from cluster analysis, at the second (lowest) energy well (Z = -
2.3 nm) located within the TM pore, coordinated by TM helices 1 (brown), 5 (olive green), 6 (purple), 7 
(beige) and 12 (magenta). 
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lipids and nicardipine may be able to enter into the TM pore from the membrane, consistent with 
the proposed “hydrophobic vacuum cleaner” model2. 
 
 The two energy wells identified in 
the PMF of nicardipine are separated by an 
energy barrier of 17 ± 4 kJ/mol at Z = -3.5 nm. 
As such, this barrier represents a rate-limiting 
step for the diffusion of nicardipine to its 
minimum energy well in the transmembrane 
pore. Note that this barrier is low enough for 
nicardipine to cross on a nanosecond timescale 
and the top of the barrier is still -19 kJ/mol 
below that of the bulk solution. At the top of 
the barrier, at Z = -3.5 nm (Figures 7(c) and 
(d)), nicardipine was found to adopt a single 
conformation in which the molecule was 
folded so that the amino benzyl group lies parallel to the pyridine ring (ring c) in an apparent π-π 
stacking arrangement. In this conformation, nicardipine formed direct contacts with Met188, 
Figure 8: The interaction of nicardipine with 
3G5U P-gp at Z = -4.5, -3.5 and -2.3 nm. Close-
up showing residues that form direct contacts 
with nicardipine (spacefill) in (a) the energy well 
located at the lipid-water interface (Z = -4.5 nm), 
(b) at the barrier (Z = -3.5 nm) and (c) in the 
energy well located within the transmembrane 
pore (Z = -2.3 nm). The protein backbone is 
shown in cartoon representation and individual 
residues are shown in liquorice representation. 
TM 3, 4, 5, 6, 7 and 12 are colored green, 
orange, olive green, purple, beige and magenta, 
respectively. 
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Gln191 (TM3), Phe299 (TM5), Ser340 (TM6), and Val984 (TM12). Again, a more detailed image 
is provided as Figure 8(b)). Of these residues, Val984 has been shown experimentally to affect the 
transport efficiency of P-gp92, 93. 
The second and deepest energy well of nicardipine (Figure 3) is located within the TM 
pore at Z = -2.3 nm, just beyond the center of the lipid membrane and within the span of the 
extracellular leaflet. This well, which is expected to be the primary binding site, has a free energy of 
-43 ± 5 kJ/mol relative to that of nicardipine in bulk solution. This compares well to the measured 
binding affinity of P-gp for nicardipine of approximately -30 kJ/mol (Kd = 4.89 ± 0.34 μM)20. Note, 
the value from the PMF has not been corrected for concentration effects, as this would require 
assumptions regarding the volume accessible to the substrate when bound. The corrections for 
concentration effects are not expected to be large compared to the uncertainty in the calculations 
and in the experimental data due to differences in the experimental and simulation conditions. 
Again, cluster analysis was used to identify if nicardipine predominately adopted a single 
conformation. Five different conformational clusters were identified. Of these the dominant cluster 
accounted for 67% of total population. In the dominant cluster nicardipine adopted the elongated 
conformation shown in Figure 7(e) with the protonated tertiary amine projecting towards the 
cytosolic water interface, while the pyridine ring (ring c) and the nitrophenyl ring (ring b) of 
nicardipine were buried deep within the TM pore. The projection of the charged group towards the 
water is similar to that observed for morphine. As seen in Figure 7(f), nicardipine binds between 
TM helices 1, 5, 6, 7 and 12 and forms direct contacts with residues Met68 (TM1), Tyr303 (TM5), 
Phe332, Leu335, Ile336, Phe339, Ser340 (TM6), Ser725, Phe728 (TM7), Ile977, Val978, Phe979, 
Met982 and Ala983 (TM12) (Figure 8(c)). Note, although nicardipine predominately adopted an 
elongated conformation, other conformations were observed, suggesting nicardipine retains a 
degree of flexibility within the TM pore.  
Table 4 lists residues that interact with nicardipine at selected locations along the reaction 
coordinate of the PMF. Of the 14 residues that interact with nicardipine at Z = -2.3 nm (Figure 8(c)), 
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corresponding to the deepest energy well, 9 have previously been implicated in the transport and/or 
binding of verapamil, vinblastine, colchicine, or Rhodamine 123 (Figure 2)17, 22-32. In particular, 
Leu335 has been shown to play an important role in the transport of all four of these substrates22, 23, 
28, 30, while Phe332, Leu335, Phe339, Val978, Phe979, Met982 and Ala983 have been specifically 
implicated in the binding of Rhodamine 12328-32.  
 
Amino Acid TM 
helix 
Reaction 
coordinate 
Experimental binding/transport interactions 
Ala229 4 
Z = -4.5 nma 
-- 
Lys230 4 -- 
Ser233 4 -- 
Thr236 4 -- 
Asp237 4 -- 
Met295 5 -- 
Gly296 5 -- 
Ala297 5 -- 
Gln343 6 -- 
Ser345 6 -- 
Pro346 6 -- 
Met188 3 
Z = -3.5 nmb 
-- 
Gln191 3 -- 
Phe299 5 -- 
Ser340 6 -- 
Val984 12 -- 
Met68 1 
Z = -2.3 nmc 
-- 
Tyr303 5 -- 
Phe332 6 Rhodamine28 
Leu335 6 verapamil22, 28, vinblastine23, colchicine23, 
Rhodamine30 
Ile336 6 -- 
Phe339 6 Rhodamine30 
Ser340 6 -- 
Ser725 7 -- 
Phe728 7 -- 
Ile977 12 -- 
Val978 12 verapamil23, 28, vinblastine23, colchicine23, 
Rhodamine31 
Phe979 12 Rhodamine28 
Met982 12 colchicine28, Rhodamine28 
Ala983 12 colchicine28, Rhodamine28 
a first energy well at the intracellular lipid-water interface, b energy barrier, c second and deeper energy well within 
the TM pore as shown in Figure 3.  
This suggests that nicardipine could bind to P-gp in a similar manner to Rhodamine 123. 
However, nicardipine was also found to interact with Val978 in the simulations. This residue affects 
Table 4: Residues that interact with nicardipine at specific locations along the reaction coordinate in the 
umbrella sampling simulations. 
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the binding and/or transport of the non-competitive substrates verapamil and colchicine23, 26, 27. 
Based on the range of interacting residues and the conformational flexibility of nicardipine 
observed in simulations, it appears that the interaction between nicardipine and P-gp cannot be 
described in terms of being a distinct binding site.  
4.3 Substrate permeation pathways 
Figures 4(b) and 7(f) show top views of morphine and nicardipine at their respective 
lowest energy wells within the TM pore. While morphine and nicardipine both bind within the same 
general region of P-gp, they interact with residues from different sets of TM helices. In order to 
understand how the two substrates reach these locations within P-gp, the configurations from the 
umbrella sampling simulations have been analyzed to construct the lowest energy permeation 
pathway for each substrate along the chosen reaction coordinate within the confines of the TMD 
pore. Note, this does not exclude other mechanisms by which each substrate may enter the TMD 
pore.  
Figures 9(a) and (b) show the path taken by morphine as it moves from the cytosolic 
entrance to the TM pore (Z = -4.5 nm, blue surface) to its energy well within the TM pore (Z = -2.5 
nm, red surface). At the cytosolic entrance of the TM pore, morphine formed contacts with residues 
from TM6, as detailed in Table 3. As morphine entered the TM pore, it interacts with residues from 
TM3 and TM6 near the cytosolic membrane-water interface before diffusing laterally across the 
protein, at the level of the cytosolic entrance to the TM pore. Morphine then interacts with TM3 and 
TM12 and maintains these interactions as it moved deeper into the TM pore to reach its minimum 
energy well. During this process, it also formed contacts with residues from TM helices 9 and 11.  
The permeation pathway identified for morphine contains many residues implicated 
experimentally in the binding and transport of P-gp substrates. As noted above, morphine initially 
formed direct contacts with residues from TM6, part of the proposed substrate uptake portals4. 
Morphine also interacts with residues from TM12 that have been proposed to be involved in 
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substrate recognition14, 15. In addition to these interactions, morphine formed direct contacts with a 
range of residues along its permeation pathway that are experimentally implicated in the binding or 
transport of verapamil and/or vinblastine. These include Gln128 (TM3), Gly868 (TM9), Thr941, 
and Ala943 (TM11) (Table 3). Taken together, this suggests that the pathway identified for 
morphine may represent a common pathway for other P-gp drug substrates, such as verapamil and 
vinblastine.  
 
Figures 9(c) and (d) show the permeation pathway of nicardipine as it moves from the 
cytosolic entrance of the TM pore to its deepest energy well within the TM pore. As nicardipine 
moves into the cytosolic entrance of the TM pore (corresponding to the first energy well of 
Figure 9: Substrate-specific permeation pathways through the P-gp TM pore. (a) Front and (b) side 
views of the permeation pathway of morphine from the intracellular lipid-water interface (blue) to its 
energy well (Z = -2.5 nm) within the P-gp TM pore (red). (c) Front and (d) side views of the permeation 
pathway of nicardipine from the energy well near the intracellular lipid-water interface (Z = -4.5 nm, 
blue), to the energy well within the TM pore (Z = -2.3 nm, red). The motion of morphine and 
nicardipine along their respective pathways are shown using overlapping space filling representations. 
In (b) and (d) TM helices 7, 8, 9 and 12 are not shown for clarity. 
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nicardipine, Z=-4.5 nm), it interacts with residues from TM helices 4, 5, and 6 (Figure 9(c) and (d), 
blue surface). As nicardipine moves deeper into the pore, it crosses an energy barrier of 17 kJ/mol 
(Z=-3.5 nm) and forms contacts with TM helices 6 and 12. After crossing this energy barrier, 
nicardipine diffuses freely, sampling the entire cross-sectional area of the TM pore. Here 
nicardipine forms transient contacts with TM helices 1, 3, 5, 6, 7, 9, 11, and 12 (Figures 9(c) and (d), 
white surface) before reaching the energy well at Z= -2.3 nm (Figures 9(c) and (d), red surface) 
described above. A list of the contact residues for nicardipine along its permeation pathway is also 
given in Table 4. Notably, Phe190 (TM3) has been implicated in substrate transport28. While 
Phe190 did not make direct contacts with nicardipine in these simulations, nicardipine did make 
direct contacts with two neighboring residues of Phe190, Met188 and Gln191 (TM3). As stated 
above, nicardipine also made contacts with a number of other residues previously implicated in the 
transport and/or binding of the P-gp substrates verapamil, colchicine and Rhodamine 123. This 
suggests that other classes of P-gp substrates, such as verapamil, colchicine, and Rhodamine 123, 
share the permeation pathway identified for nicardipine.  
Figure 9 shows that in the simulations morphine and nicardipine take different but 
overlapping pathways. Based on the residues in close contact with morphine and nicardipine, we 
propose that the morphine permeation pathway is likely to be shared by verapamil and vinblastine, 
while the nicardipine permeation pathway is likely to be shared by verapamil, colchicine and 
Rhodamine 123. Note, based on the residues identified, the pathway used by verapamil would 
appear to overlap with both that of morphine and nicardipine. In fact, TM helices 1 and 12 are 
common to both pathways, indicating that the permeation pathways are not truly distinct. It should 
be noted that analysis of the permeation pathway has been performed on simulations based on the 
membrane-embedded, equilibrated 3G5U P-gp structure. Since the current work commenced, a 
revised structure of mouse P-gp (PDBid: 4M1M)11 based on the same diffraction data has been 
released. There are small differences between TM12 in the original 3G5U and revised 4M1M 
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structures (discussed below), which may result in minor differences between the permeation 
pathways through each structural model.  
4.4 Comparison of the binding of substrate to alternate P-gp structures (3G5U and 
4M1M) 
All of the simulations described above were initially based on the structure of P-gp 
corresponding to the PDBid: 3G5U4. Although the 3G5U P-gp structure was incorporated into a 
membrane environment and equilibrated extensively by O’Mara and Mark51 it is still possible that 
Figure 10: Comparison of the binding sites of morphine (pink spacefill) and nicardipine (cyan 
spacefill) in membrane-embedded 4M1M and 3G5U P-gp (cartoon representation). (a) Top and (b) 
front views of morphine bound to equilibrated 4M1M P-gp. Morphine forms close contacts with TM 
helices 1 (brown), 6 (purple), 11 (cyan), and 12 (magenta). (b) An expanded view of (a) showing 
residues that interact directly with morphine. (c) Residues interacting with morphine in 3G5U p-gp 
structure at the minimum energy well (Z = -2.5 nm). (d) Top and (e) front views of nicardipine bound 
to equilibrated 4M1M P-gp. Nicardipine forms close contacts with TM helices 5 (olive green), 6 
(purple), 7 (beige), and 12 (magenta). (e) An expanded view of (d) showing residues that make direct 
contact with nicardipine. (f) Residues interacting with nicardipine bound to 3G5U P-gp at the lowest 
energy well (Z = -2.3 nm). The dashed lines in (a) and (d) represent the viewing plane. The arrows 
represent the direction the plane is viewed in (b) and (c); and in (e) and (f) respectively. The residues 
labeled in red correspond those observed in both the 4M1M and 3G5U simulations. 
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the simulations presented here have been biased by the choice of starting structure. To investigate 
this possibility, a series of MD simulations were performed using the revised structure, 4M1M P-
gp11. The 4M1M P-gp structure was extensively equilibrated in a cholesterol-enriched POPC 
membrane prior to its use in these simulations. These simulations showed that 4M1M P-gp adopted 
a conformation consistent to that observed in the equilibrated 3G5U P-gp. A more detailed 
comparison of the structures of 3G5U and 4M1M from MD simulations are discussed later in 
Chapter 5. Namely, the NBDs moved inwards to form a contact interface, while the TMDs 
maintained a conformation similar to that of the equilibrated 3G5U P-gp. As previously reported in 
simulations of 3G5U P-gp, some kinking of the TMDs was observed in the vicinity of the 
endogenous proline residues44, 51, 52. Two simulations were performed in which either a molecule of 
morphine or a molecule of nicardipine, was placed within the TM pore at the position 
corresponding to the location of their respective free energy minimum obtained from the PMF 
(Figure 3). The systems were simulated for 40 ns in which morphine or nicardipine was allowed to 
interact freely with the equilibrated 4M1M P-gp structure. In these simulations, the overall location 
of morphine and nicardipine in the TM pore was consistent with that obtained using 3G5U P-gp. 
There were, however, subtle changes in the orientation of both morphine and nicardipine, which 
lead to some differences in the contact residues within the TM pore between the two P-gp starting 
conformations. 
A comparison of the binding locations and contact residues for morphine and nicardipine 
in the 4M1M P-gp simulations is shown in Figure 10. Also shown in Figure 10 are the contact 
residues for morphine and nicardipine in 3G5U P-gp for comparison. From Figure 10(a) it can be 
seen that morphine bound to TM helices 1, 6, 11 and 12 of 4M1M P-gp, forming direct contacts 
with Leu64 (TM1), Gln942, Met945, and Tyr946 (TM11) (Figure 10(b), red). This is consistent 
with the previous simulations using 3G5U P-gp (Figure 10(c), red). In addition, morphine also 
formed direct contacts with His60 (TM1), Phe339, Glu343 (TM6), and Met982 (TM12) in the 
4M1M P-gp simulations. Of these, His60 has been experimentally implicated in the binding of 
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verapamil, vinblastine, and colchicine27. It should be noted however, that Tyr949, which was 
identified as a contact residue in the 3G5U P-gp simulations (Figure 10(c)), and is implicated in the 
binding of verapamil24, did not contact morphine in the 4M1M P-gp simulations. Similar changes 
were noted for nicardipine. Nicardipine formed direct contacts with residues from TM helices 5, 6, 
7 and 12 of 4M1M P-gp (Figure 10(d)). Ile302, Tyr303 (TM5), Phe339, Ser340 (TM6), Ser725, 
Phe728 (TM7), Phe979 (TM12) formed direct contacts with nicardipine in both the 4M1M and 
3G5U P-gp simulations (indicated in red in Figures 10(e) and (f), respectively). In addition to these 
residues, nicardipine formed direct contacts with Phe299 (TM5), Gln343, Ser345 (TM6), Gln986 
and Ser989 (TM12) in 4M1M P-gp simulations (Figure 10(e)). As far as we are aware none of these 
residues have been implicated in the binding or transport of P-gp substrates. In addition to those 
indicated in red, which were common to both the 4M1M P-gp and the 3G5U P-gp simulations, in 
the 3G5U P-gp simulation nicardipine also formed direct contacts with Met68, Phe332, Leu335, 
Ile336, Ile977, Met982 and Ala983. Apart from Met68, each of these residues has been shown to 
affect the binding or transport of one or more substrates. 
When considering the results obtained using 3G5U P-gp and 4M1M P-gp, it is important to 
note that in their work, O’Mara and Mark found a number of discrepancies between distances 
inferred from experimental cross-linking distances and the proposed P-gp crystal structure (PDBid: 
3G5U)51. In particular, O’Mara and Mark demonstrated that after equilibration, the structures 
sampled in the simulations could better explain cross-linking data involving TM helices 4 and 6 
than the proposed 3G5U crystal structure51. An expansion of this cross-linking dataset, 
incorporating the 4M1M P-gp crystal structure, is provided as Table 5. For 50 of the 52 residue 
pairs, the variation in the distance between paired Cα atoms between the two crystal structures was 
≤0.3 nm. Of the remaining 2 residue pairs the corresponding distance between the two crystal 
structures varied by 0.5 nm for the residue pairs 314 (TM5) / 749 (TM8), and by 0.6 nm for residues 
pairs 302 (TM5) / 980 (TM12). Discrepancies between the experimental cross-linking data and 
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distances obtained from the crystal structures were noted in the same 20 residue pairs in both 3G5U 
and 4M1M.  
 
Cross-linked residues 
(Mouse P-gp numbering) 
Distance between Cα’s (nm) Temp (K) Ref 
3G5
U 
4M1M MD Simulations 
of 3G5U 
Calc. from 
MTS 
spacer TM 
helices 
1 2 A A Average  
(5 * 60 ns)51 
2 & 11 113 951 1.1 1.2 1.1 ± 0.1 1.2 – 2.0 a 310 94 
2 & 11 113 952 1.3 1.4 
1.2 ± 0.1 
1.2 – 2.0 a 310 94 
2 & 11 113 953 1.1 1.2 
1.1 ± 0.1 
1.2 – 2.0 a 310 94 
2 & 11 114 951 0.8 0.9 
1.0 ± 0.1 
1.2 – 2.0 a 310 94 
2 & 11 114 952 1.0 1.1 1.3 ± 0.1 1.2 – 2.0 a 310 94 
2 & 11 114 953 1.0 1.0 1.2 ± 0.2 1.2 – 2.0 a 310 94 
2 & 11 115 951 1.1 0.9 1.3 ± 0.1 1.2 – 2.0 a 310 94 
2 & 11 115 952 1.4 1.2 1.6 ± 0.1 1.2 – 2.0 a 310 94 
2 & 11 115 953 1.4 1.2 1.5 ± 0.2 1.2 – 2.0 a 310 94 
2 & 11 129 931 0.7 0.7 0.6 ± 0.1 1.2 – 2.0 a 310 95 
2 & 11 129 935 0.5 0.5 0.7 ± 0.2 1.2 – 2.0 a 277, 295, 310 95 
2 & 11 133 931 0.5 0.6 0.7 ± 0.2 1.2 – 2.0 a 277, 295, 310 95 
2 & 11 133 935 0.9 0.9 1.2 ± 0.2 1.2 – 2.0 a 310 95 
3 & 9 171 816 2.7 2.8 3.9 ± 0.4 1.3 d 273 96 
4 & 10 218 864 3.0 3.2 3.3 ± 0.3 1.4 – 2.6 b 310 97, 98 
4 & 10 218 868 3.0 3.0 3.5 ± 0.2 1.4 – 2.6 b 310 97, 98 
4 & 12 223 989 2.3 2.3 2.5 ± 0.2 0.9 c 310 99 
4 & 12 227 989 2.1 2.2 2.2 ± 0.2 0.9 c 294, 310 99 
4 & 12 228 989 2.0 1.9 2.2 ± 0.2 0.9 c 294, 310 99 
4 & 12 229 989 1.7 1.7 1.7 ± 0.2 0.9 c 277, 294, 310 99 
4 & 12 231 989 2.0 2.1 2.0 ± 0.2 0.9 c 277, 294, 310 99 
4 & 12 232 989 1.8 1.8 1.7 ± 0.3 0.9 c 277, 294, 310 99 
4 & 12 291 989 1.6 1.5 1.2 ± 0.2 0.9 c 294, 310 99 
4 & 12 295 989 1.3 1.3 1.2 ± 0.3 0.9 c 277, 294, 310 99 
5 & 8 302 864 2.9 2.6 3.0 ± 0.2 1.7 – 2.6 b 310 97, 98 
5 & 8 302 868 2.8 2.6 2.9 ± 0.3 1.7 – 2.6 b 310 97, 98 
Table 5: Comparison of the 3G5U and 4M1M murine P-gp crystal structures to the experimental 
cross-linking data collected in the absence of nucleotides. 
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5 & 8 313 749 1.3 1.1 1.6 ± 0.2 1.2 – 2.0 a 310 94 
5 & 8 313 750 1.3 1.4 1.5 ± 0.1 1.2 – 2.0 a 310 94 
5 & 8 313 751 1.0 1.2 1.2 ± 0.1 1.2 – 2.0 a 310 94 
5 & 8 314 749 1.3 0.8 1.6 ± 0.1 1.2 – 2.0 a 310 94 
5 & 8 314 750 1.2 1.1 1.5 ± 0.2 1.2 – 2.0 a 310 94 
5 & 8 314 751 0.9 1.0 1.2 ± 0.1 1.2 – 2.0 a 310 94 
5 & 8 315 749 1.1 0.8 1.4 ± 0.2 1.2 – 2.0 a 310 94 
5 & 8 315 750 1.0 1.2 1.3 ± 0.2 1.2 – 2.0 a 310 94 
5 & 8 315 751 0.9 1.2 1.1 ± 0.2 1.2 – 2.0 a 310 94 
5 & 11 302 941 3.1 3.3 3.0 ± 0.3 1.7 – 2.6 b 310 97, 98 
5 & 12 302 978 1.9 1.9 2.0 ± 0.2 1.7 – 2.6 b 310 97, 98 
5 & 12 302 980 2.3 1.7 1.9 ± 0.5 1.7 – 2.6 b 310 97, 98 
6 & 10 328 852 2.4 2.5 2.7 ± 0.3 1.2 – 2.0 a 277 98 
6 & 10 335 864 2.3 2.3 2.6 ± 0.2 1.7 – 2.6 b 310 97, 98 
6 & 10 335 868 2.3 2.3 2.6 ± 0.3 1.7 – 2.6 b 310 97, 98 
6 & 10 346 870 2.3 2.3 3.1 ± 0.2 0.9 c 294, 310 99 
6 & 10 346 871 2.0 1.9 2.7 ± 0.3 0.9 c 310 99 
6 & 10 346 872 1.8 1.8 2.7 ± 0.3 0.9 c 294, 310 99 
6 & 11 335 938 2.4 2.4 2.6 ± 0.3 2.6 b 310 97, 98 
6 & 11 335 941 2.3 2.3 2.5 ± 0.2 2.3 – 2.6 b 310 97, 98 
6 & 11 346 935 2.1 2.1 3.0 ± 0.2 0.9 c 294, 310 99 
6 & 12 335 978 1.5 1.8 1.6 ± 0.3 2.0 – 2.6 b 310 97, 98 
6 & 12 335 981 1.6 1.9 1.7 ± 0.5 2.3 – 2.6 b 310 97, 98 
6 & 12 346 989 1.5 1.6 2.3 ± 0.3 0.9 c 310 100 
6 & 12 339 982 1.5 1.5 1.4 ± 0.4 0.9 c 310 100 
6 & 12 342 985 1.5 1.7 1.9 ± 0.4 0.9 c 310 100 
NOTE: The distance between C atoms has been estimated as follows: 2 x (length of cysteine side chain + distance to 
spacer) + length of spacer. 
a Precise reducing agent not provided. Reducing agents used in this study were N,N’-o-phenylenedimaleimide, N,N’-p-
phenylenedimaleimide and 1,6-bismaleimidohexane. The spacer span lengths range from ~0.3 to ~1.0 nm.  
b Cross-linking was attempted with each of the following spacers: M2M (approximate cross-linking span: 0.52 nm),  
M3M (~0.65 nm), M4M (~0.78 nm), M5M (~0.91 nm), M6M (~1.04 nm), M8M (~1.30 nm), M11M (~1.69 nm), M14M 
(~2.08 nm) and M17M (~2.47 nm). The distance range given is calculated from the span of the largest and smallest 
spacer cross-linked. 
c Reducing agent is copper phenanthroline. Distance between the S atoms is ~0.37 nm. 
d  Spacer used was M1M, which has a span of ~0.4 nm. 
This suggests that neither the 3G5U or 4M1M crystal structures satisfy the available cross-
linking data better than the other; and neither satisfies the data as well as the ensemble of structures 
obtained in the simulations starting from either structure. Previous simulation studies have also 
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demonstrated that the TM helices in P-gp are highly flexible44, 51-53, 57. This flexibility was also 
observed in our simulations of 4M1M P-gp and may be associated with the presence of prolines 
within the TMDs, in particular, Pro65 (TM1), Pro219 (TM4) Pro346 (TM6), Pro705 (TM7), Pro722 
(TM7), Pro862 (TM10) and Pro992 (TM12)101, 102. Overall, the results demonstrate that the work 
presented here is not heavily influenced by the use of the membrane equilibrated 3G5U P-gp 
structure as the starting conformation. Specifically, after equilibration in a membrane environment 
the residues that line the pore and interact with the two substrates are similar using either 3G5U or 
4M1M as the starting structure.  However, it should be noted that the P-gp TMDs are flexible and 
that on the time scales used in this work not all of the functionally important contacts may have 
been sampled.  
4.5 Spontaneous binding of morphine and nicardipine 
 
Figure 11: Stereo view of the spatial distribution of morphine and nicardipine around P-gp. 
Probability isosurfaces for both morphine (pink) and nicardipine (blue) averaged over 3 independent 
80 ns simulations. The surfaces correspond to regions where the probability of finding a given 
substrate is > 65%. The spatial distribution is superimposed over the reference structure of protein 
shown in cartoon representation. 
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To examine the spontaneous binding of morphine and nicardipine to P-gp, two series of 
simulations were performed, in which either eight molecules of morphine or of nicardipine were 
placed randomly in solution surrounding the membrane-embedded P-gp and simulated three times 
for 80 ns. Both morphine and nicardipine were observed to interact spontaneously with different 
regions of P-gp. Figure 11 shows a stereo view of the spatial distribution of morphine and 
nicardipine around P-gp obtained from the simulations. The spatial distribution for the substrates 
was calculated by averaging the probability of finding either morphine or nicardipine at a specific 
location after combining the three independent 80 ns simulations. The isosurfaces in Figure 11 are 
contoured at a probability of 65% of finding the substrate at that location during the simulation. The 
spatial distribution is superimposed onto the starting structure, the equilibrated membrane-
embedded 3G5U P-gp. The pink surface and blue surface in Figure 11 correspond to the spatial 
distribution of morphine and nicardipine, respectively, during the 80 ns of the simulation.  
In the case of morphine 12 out of the 24 molecules (50%) bound to the lower lipid leaflet 
of the membrane. Once bound, these molecules remained in contact with the membrane for the 
remainder of the time simulated. Six morphine molecules (25%) interacted with the TMDs close to 
the membrane interface, primarily with TM helices 6 and 7. The final 6 morphine molecules 
interacted with negatively charged residues within the NBDs.  
In contrast, nicardipine interacted primarily with NBD1 and the cytosolic regions of the 
TMDs (Figure 11).  Specifically, 11 of the 24 molecules (45%) interacted with the cytosolic side of 
the NBD1, 6 molecules (25%) interacted with the intracellular extension of TM11 and 4 molecules 
(17%) close to the lipid-water interface in the vicinity of TM helices 2, 3 and 10. The remaining 3 
nicardipine molecules formed transient (apparently non-specific) interactions with NBD2 and other 
cytosolic regions of TMDs. The locations identified in Figure 11 at which morphine and nicardipine 
preferentially interacted with P-gp are associated with regions of negative charge. Approximately 
20% of all residues in P-gp are charged at pH 7. The distribution of these residues in 3G5U and 
4M1M is shown in Figure 12. Here, the charged residues are distributed throughout the hydrophilic 
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regions of P-gp. This distribution of the positively and negatively charged residues within the 
protein results in the generation of an electric field surrounding P-gp, which could in principle guide 
the hydrophobic substrates towards the TM pore.  
 
Figure 13(a) and (b) shows a cross-section of the electrostatic potential surface through the TM 
pore of 3G5U and 4M1M P-gp, parallel to the XZ plane. The electrostatic potential is contoured at 
+1 and -1 kT/e, assuming a dielectric of 78.5 and 150 mM NaCl. While it should be noted that the 
exact features of the electrostatic potential are influenced by the precise conformation of the protein 
at any point in time, it can be seen from Figure 13(c) that both 3G5U and 4M1M adopt a very 
similar conformation, and that the cross-section of the electrostatic potential of both 3G5U and 
4M1M P-gp contain similar features. There are clear and corresponding regions of net negative 
potential (red) through the TM pore, in the area surrounding the proposed TM4 and 6 substrate 
uptake portal, between the cytosolic extensions of the TMDs and also localized regions of net 
Figure 12: (a) An overlay of the equilibrated, membrane-embedded conformations of 3G5U (silver) 
and 4M1M (blue). The distribution of all negatively charged residues, aspartate (pink), and glutamate 
(red) and all positively charged residues, lysine (cyan) and arginine (blue) within (b) 3G5U and (c) 
4M1M P-gp. The protein backbone is in cartoon representation. The N-terminal and C-terminal halves 
of P-gp are colored gold and silver, respectively in (b) and (c). The dashed lines give the span of the 
membrane.  
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negative potential in the NBDs. This would be expected to electrostatically steer P-gp substrates, of 
which almost all are positively charged, towards the TM pore. 
 
Figure 13: Cross-section of the electrostatic potential of P-gp. A cross-section through the 
electrostatic potential surface of the MD equilibrated conformations of (a) 3G5U and (b) 4M1M P-gp, 
taken through the TM pore parallel to the XZ plane. The electrostatic potential, contoured at +1 and -
1 kT/e, was calculated at pH 7.0 using 150 mM NaCl and a relative dielectric permittivity of 78.5. 
Negative potential is red, positive is blue. The protein is shown in silver. (c) An overlay of the 
equilibrated, membrane-embedded structure of 3G5U (silver) and 4M1M (blue) P-gp used in (a) and 
(b). The dotted lines show the span of the lipid bilayer. 
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5  CONCLUSION 
Despite over 30 years of research, the basic question of how drugs bind to and interact with 
P-glycoprotein is still debated. Experimental approaches have isolated a number of residues that 
affect substrate binding and transport, but this has not lead to the detailed characterization of the 
specific substrate binding sites. Theoretical approaches such as rigid-body pharmacophore docking 
studies have also yielded inconsistent results. To understand the mechanism of drug uptake and 
binding in a dynamic protein like P-gp more sophisticated approaches are required. Here molecular 
dynamics simulations have been used to examine the spontaneous binding of the substrates 
morphine and nicardipine to P-gp; and calculate their PMF as they move from the aqueous solution 
along the central axis of P-gp and into the TM pore. These simulations showed that the minimum 
energy well for both morphine and nicardipine was located within the TM pore, at different but 
overlapping locations. When residing in their minimum energy locations, both substrates formed 
direct contacts with residues implicated experimentally in drug binding or transport. However, both 
morphine and nicardipine adopted a range of different orientations (or conformations) within their 
respective minimum energy wells. As a consequence it is not possible to allocate specific binding 
sites to either substrate. Equilibrated, membrane-embedded simulations of the revised 4M1M P-gp 
structure demonstrate that a core set of residues interacted with either morphine or nicardipine in 
their minimum energy wells, indicating the results obtained are not heavily influenced by the choice 
of starting structure.  
The substrate permeation pathway through the TM pore identified from these simulations 
shows that morphine and nicardipine follow different, but overlapping uptake pathways, with TM 
helices 1 and 12 common to both pathways. Analysis of the residues forming direct contacts with 
morphine and nicardipine along their respective permeation pathways suggests that the uptake 
pathways for the canonical P-gp substrates, verapamil, vinblastine, colchicine and Rhodamine 123 
may overlap considerably with those identified for morphine and nicardipine. This work 
demonstrates that neither the drug binding sites, nor permeation pathways for morphine and 
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nicardipine are clearly defined in P-gp. This has important consequences for our understanding of 
P-gp as a multidrug efflux pump, and of the therapeutic strategies used to design selective inhibitors 
of drug efflux by P-gp.  For example, this work suggests the development of inhibitors that only 
block the transport of specific substrates may not be possible. 
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Chapter 3: Comparing the binding locations and 
interactions of competitive and non-competitive 
substrates in the multidrug resistance protein, P-
glycoprotein 
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1 ABSTRACT 
The ABC transporter P-glycoprotein (P-gp) transports numerous structurally unrelated 
compounds, including many drugs, out of the cell. Despite being studied for almost four decades, 
the precise location at which transport substrates bind and the mechanism by which the compounds 
enter P-gp has not been conclusively resolved. In this study, molecular dynamics (MD) simulations 
have been used to identify the locations of the binding free energy minima for 7 compounds, 
Hoechst 33342, Rhodamine 123, paclitaxel, tariquidar, verapamil, morphine and nicardipine to P-gp. 
Based on the potential of mean force (PMF) calculations, all of these compounds were found to 
have energy minima within the P-gp transmembrane (TM) pore, although some compounds 
contained an additional energy minimum outside the TM pore. In particular, Hoechst 33342, 
Rhodamine 123, paclitaxel and nicardipine each had two such energy wells. The energy wells in the 
case of the non-competitive substrate pairs Hoechst 33342/Rhodamine 123 and 
paclitaxel/nicardipine were found to have binding locations that were different but overlapping. The 
energy wells of the competitive substrate pairs: tariquidar/Hoechst 33432 and verapamil/morphine 
were found to correspond to the same location within the TM pore, but the substrates did not make 
direct contacts with identical sets of residues. These compounds were found to interact primarily 
with a specific set of experimentally identified residues implicated in binding and transport. The 
results indicate that the binding locations for both competitive and non-competitive substrates are 
not well separated and cannot be considered as unique. This has important implications for our 
understanding of substrate uptake and transport by P-gp. The results obtained from these PMF 
calculations are independent of the choice of starting structure and are consistent with a range of 
experimental studies.  
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2  INTRODUCTION 
The integral membrane protein, P-glycoprotein (P-gp) reduces the cellular accumulation of 
numerous molecules and cytotoxic agents, including those used in cancer chemotherapy1, 2. This 
confers multidrug resistance upon cells in which P-gp is highly expressed. One of the defining 
characteristics of P-gp as a multidrug transporter is its broad substrate specificity, allowing it to 
transport a wide variety of structurally unrelated compounds. As outlined in Chapter 1, a number of 
attempts have been made to understand the ability of P-gp to recognize chemically and structurally 
diverse substrates through biochemical investigations and structural studies. Despite these studies, 
the molecular basis of the substrate promiscuity of P-gp remains poorly understood and is a matter 
of intense debate. Identifying the location of potential substrate binding sites in P-gp has been the 
goal of many computational investigations. Chapter 2 focused on the binding of morphine and 
nicardipine to P-gp to identify the minimum energy binding sites and to characterize their physical 
location within the transmembrane (TM) pore. This chapter focuses on determining the minimum 
energy binding locations of Hoechst 33342, Rhodamine 123, paclitaxel, tariquidar and verapamil 
within the P-gp TM pore. This chapter also presents a hypothesis for the binding of competitive and 
non-competitive P-gp substrates.  
As discussed in Chapter 2, mutational studies have been used to identify sets of residues 
dispersed throughout the transmembrane domains (TMDs) and nucleotide binding domains (NBDs) 
of P-gp that affect the rate of transport and the binding affinity of different P-gp substrates3-5. These 
and other experimental studies6-8, have led some to suggest that P-gp contains multiple sites, which 
interact with different classes of substrates in both a competitive and non-competitive manner. For 
example, based on fluorescence spectroscopy and kinetic studies of substrate transport, Shapiro et 
al.6, 7 proposed that Hoechst 33342, quercetrin and colchicine bind competitively to P-gp at a site 
referred to as the H site or Hoechst site, whereas Rhodamine 123 and anthracyclines such as 
daunorubicin and doxorubicin bind competitively to a site referred to as the R site7. In addition, 
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Shapiro et al. proposed that P-gp has a regulatory site that binds prazosin and progesterone6. 
Competitive binding studies by others have led to the proposal that verapamil, vinblastine and 
morphine may all interact with the same site in P-gp, referred to as the vinblastine site3, 9, 10. Based 
on radioligand binding and equilibrium binding studies involving vinblastine, paclitaxel, 
nicardipine, verapamil, Rhodamine 123, benzamidine, tariquidar, elacridar and XR9051, Martin et 
al. proposed that vinblastine binds to a site unique to that of tariquidar, elacridar, XR9051, 
nicardipine, paclitaxel, Rhodamine 123 and Hoechst 333428. In the same study, Martin et al. also 
identified that Hoechst 33342, tariquidar and elacridar competed for binding to P-gp, suggesting 
that the three compounds could bind to the same site, namely the H site. A detailed list describing 
the competitive and non-competitive interactions of a range of P-gp substrates, inhibitors and 
modulators is given in Table 1. In each case, these sites were defined in terms of a pharmacological 
response and can be considered to be pharmacological sites. They do not necessarily correspond to 
distinct physical locations on the protein. As shown in Figure 2 of Chapter 2, mapping the residues 
implicated in substrate binding and transport to the crystal structures of mouse P-gp11, 12 does not 
yield clear, well-defined binding locations for any known P-gp substrate. 
Despite the large number of experimental studies, the mechanism by which P-gp binds and 
transports substrates remains poorly understood. Considering the experimental difficulties in 
working with complex systems like P-gp, computational approaches such as molecular dynamics 
(MD) simulation offer one of the few avenues to understand poly-substrate specificity in detail. In 
this study, a combination of MD simulations and umbrella sampling techniques were used to 
investigate the interactions between membrane-embedded mouse P-gp and a set of experimentally 
well-studied substrates, namely Hoechst 33342, Rhodamine 123, paclitaxel, the inhibitor tariquidar, 
and the modulator verapamil (Figure 1), which are known to bind competitively and non-
competitively with each other.  
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Table 1. List of non-competitive and competitive P-gp substrates, inhibitors and modulators 
 
 Morphine Nicardipine 
Hoechst 
33342 
Rhodamine 
123 
Paclitaxel Colchicine Vinblastine Verapamil Tariquidar Elacridar Daunorubicin Doxorubicin 
Morphine ---            
Nicardipine NC
a
 ---           
Hoechst 
33342 
NC
b
 NC8 ---          
Rhodamine 
123 
No data No data NC6, 7 ---         
Paclitaxel No data NC8 NC8 No data ---        
Colchicine NC
b
 NC
c
 C6, 7 NC6, 7 No data ---       
Vinblastine C10 NC9 NC8 No data NC8 NC
e
 ---      
Verapamil C10 NC9 NC
d
 No data No data NC
e
 C10 ---     
Tariquidar No data NC8 C8 NC
d
 NC8 C
c
 NC8 NC
b
 ---    
Elacridar No data NC8 C8 NC
d
 NC8 C
c
 NC8 NC
b
 C8 ---   
Daunorubicin No data No data NC6, 7 C6, 7 No data NC6, 7 No data No data NC
c
 NC
c
 ---  
Doxorubicin No data No data NC6, 7 C6, 7 No data NC6, 7 No data No data NC
c
 NC
c
 C6, 7 --- 
NC – non-competitive, C – competitive; a- inferred from references 9, 10; b- inferred from references 8, 10; c- inferred from references 6-8; d- inferred from reference 8; e- inferred from 
references 6-8, 10.   
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Hoechst 33342 (Figure 1A) is a 
bisbenzamide DNA binding fluorescent 
stain, which accumulates in murine 
tumors13 and is transported by P-gp14. 
Rhodamine 123 (Figure 1B) is a P-gp 
substrate15 and flurone dye that belongs to 
Rhodamine family of dyes. Fluorescence 
spectroscopic studies on the kinetics of 
two canonical P-gp substrates Hoechst 
33342 and Rhodamine 123 in isolated P-
gp rich membrane vesicles suggested that 
Hoechst 33342 and Rhodamine 123 bind 
non-competitively to two distinct sites in 
P-gp6, 7. Paclitaxel shown in Figure 1C, is 
one of the largest P-gp substrates (854 
a.m.u.) It is the most common anticancer 
drug and has been used to treat a number 
of types of cancer including ovarian, 
breast, lung, and pancreatic cancers. 
Specifically, paclitaxel is a cytoskeletal 
drug that targets tubulin and blocks 
mitosis16, 17. Tariquidar (Figure 1D), is an 
anthranilic acid derivative, and is one of 
the most potent inhibitors of P-gp. In the 
clinical trials, it has been shown to be the most promising to improve chemotherapy and increase 
brain penetration of drugs18. Tariquidar has been proposed to inhibit the basal ATPase activity 
associated with P-gp. This modulating effect can be derived from the inhibition of binding, 
Figure 1: The chemical structures of (A) Hoechst 33342, 
(B) Rhodamine 123, (C) paclitaxel (D) tariquidar and (E) 
verapamil. The ionizable groups for all these molecules 
at neutral pH are shown in blue. 
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hydrolysis of ATP, binding of substrates or both18. Verapamil (Figure 1E) is also a P-gp substrate 
commonly used in P-gp drug transport studies.  Verapamil acts as a P-gp substrate when 
administered in isolation. However, in the presence of a second substrate, verapamil modulates the 
activity of P-gp, effectively inhibiting transport of the second substrate19. All five compounds 
examined in this chapter are predominantly hydrophobic, but carry a charge of +1 at neutral pH, 
except for paclitaxel, which is neutral at pH 7.0. 
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3 MATERIALS AND METHODS  
To identify and compare the binding locations of Hoechst 33342, Rhodamine 123, 
paclitaxel, tariquidar and verapamil, the PMF for each of these compounds was calculated along an 
axis (Z-axis) passing through the center of the TM pore of P-gp, normal to the plane of the 
membrane. Since this work commenced, a corrected structure of the original mouse P-gp was 
published as discussed in Chapters 1 and 2. To examine whether the binding of the substrates was 
biased by the choice of starting structure, unrestrained MD simulations of Hoechst 33342 and 
Rhodamine 123 in the revised mouse P-gp structure (4M1M) were also performed.   
3.1 Simulation setup and parameters 
All the PMF calculations performed in this chapter were based on the equilibrated 
membrane embedded mouse P-gp (3G5U structure). The details regarding the methodology 
employed for simulation set up, the PMF calculations and the convergence of PMFs are given in 
Chapter 2.  In the case of the unrestrained MD simulations of Hoechst 33342 and Rhodamine 123, 
an extensively equilibrated membrane embedded 4M1M P-gp structure was used as outlined in the 
methods section of Chapter 2. Either Hoechst 33342 or Rhodamine 123 was placed within its 
respective energy well located within the TM pore. All the simulation conditions and analysis used 
have been described in detail in the methods section of Chapter 2. The parameters for the substrates 
used in this chapter are generated as described in chapter 2 and are available for download from the 
ATB20 (MOLID: 7281, MOLID: 6182, MOLID: 7282, MOLID: 7284, and MOLID: 7283) and are 
also provided in Appendix A. 
3.2 Calculation of the PMF through the TM pore 
Paclitaxel, tariquidar and verapamil are large, flexible molecules that spontaneously 
undergo conformational transitions on a nanosecond timescale. Due to the extended computational 
time required to sample their conformational space at each umbrella sampling window, the 
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convergence criteria was not able to be met for these three compounds close to the NBDs, even 
after 40 ns of simulation at each of the 61 umbrella sampling windows (Z = -15 nm to Z = 0 nm). 
This limited our ability to calculate the full PMF in these cases. As the primary aim of this 
investigation was to determine the location of the energy wells for the substrates within the TM 
pore, the PMFs for paclitaxel, tariquidar and verapamil were calculated only from the cytosolic side 
of the intracellular lipid-water interface (Z = -5.5 nm) to the reference group at Z = 0 nm. As these 
PMFs were calculated from Z = -5.5 nm, the relative free energy of paclitaxel, tariquidar and 
verapamil along the reaction coordinate (Z) are presented with respect to the free energy of each 
compound at Z = -5.5 nm. The methodology used for the simulation setup, PMF calculation and 
convergence are the same as used in Chapter 2. The equilibration time for each window to meet the 
convergence criteria is given in Table 2. 
Table 2: Summary of the simulation time taken for each window to meet the convergence criteria 
Reaction 
Coordinate 
Z (nm) 
Hoechst 
33342 
simulation 
time (ns) 
Rhodamine 
123 
simulation 
time (ns) 
Paclitaxel 
simulation 
time (ns) 
Tariquidar 
simulation 
time (ns) 
Verapamil 
simulation 
time (ns) 
Total 
time 
Equil 
time 
Total 
time 
Equil 
time 
Total 
time 
Equil 
time 
Total 
time 
Equil 
time 
Total 
time 
Equil 
time 
-15.00 30 20 30 20 --- --- --- --- --- --- 
-14.75 30 20 30 20 --- --- --- --- --- --- 
-14.50 30 20 30 20 --- --- --- --- --- --- 
-14.25 30 20 30 20 --- --- --- --- --- --- 
-14.00 30 20 30 20 --- --- --- --- --- --- 
-13.75 30 20 30 20 --- --- --- --- --- --- 
-13.50 30 20 30 20 --- --- --- --- --- --- 
-13.25 30 20 30 20 --- --- --- --- --- --- 
-13.00 30 20 30 20 --- --- --- --- --- --- 
-12.75 44 34 47 37 --- --- --- --- --- --- 
-12.50 46 36 48 38 --- --- --- --- --- --- 
-12.25 43 33 40 30 --- --- --- --- --- --- 
-12.00 44 34 41 31 --- --- --- --- --- --- 
-11.75 43 33 47 37 --- --- --- --- --- --- 
-11.50 43 33 43 33 --- --- --- --- --- --- 
-11.25 44 34 46 36 --- --- --- --- --- --- 
-11.00 50 40 42 32 --- --- --- --- --- --- 
-10.75 52 42 49 39 --- --- --- --- --- --- 
-10.50 53 43 50 40 --- --- --- --- --- --- 
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-10.25 49 39 50 40 --- --- --- --- --- --- 
-10.00 51 41 53 43 --- --- --- --- --- --- 
-9.75 49 39 50 40 --- --- --- --- --- --- 
-9.50 56 46 48 48 --- --- --- --- --- --- 
-9.25 52 42 52 42 --- --- --- --- --- --- 
-9.00 60 50 50 40 --- --- --- --- --- --- 
-8.75 57 47 43 33 --- --- --- --- --- --- 
-8.50 48 38 45 35 --- --- --- --- --- --- 
-8.25 45 35 42 32 --- --- --- --- --- --- 
-8.00 47 37 50 40 --- --- --- --- --- --- 
-7.75 55 45 51 41 --- --- --- --- --- --- 
-7.50 54 54 50 40 --- --- --- --- --- --- 
-7.25 55 45 50 40 --- --- --- --- --- --- 
-7.00 55 45 53 43 --- --- --- --- --- --- 
-6.75 57 47 50 40 --- --- --- --- --- --- 
-6.50 60 50 54 44 --- --- --- --- --- --- 
-6.25 56 46 51 41 --- --- --- --- --- --- 
-6.00 54 44 57 47 --- --- --- --- --- --- 
-5.75 55 45 51 41 --- --- --- --- --- --- 
-5.50 54 44 52 42 61 51 55 45 58 48 
-5.25 53 43 59 49 65 55 55 45 52 42 
-5.00 53 43 60 50 61 51 60 50 56 46 
-4.75 55 45 59 49 60 50 53 43 50 40 
-4.50 56 46 55 45 61 51 54 44 51 41 
-4.25 56 46 54 44 60 50 56 46 50 40 
-4.00 56 46 54 44 63 53 59 49 59 49 
-3.75 55 45 54 44 65 55 55 45 50 40 
-3.50 61 51 56 46 69 49 59 49 55 45 
-3.25 58 48 57 47 61 51 61 51 51 51 
-3.00 57 47 55 45 59 49 59 49 57 47 
-2.75 58 48 52 42 62 52 56 46 52 42 
-2.50 57 47 55 45 63 53 63 53 60 50 
-2.25 60 50 58 48 65 55 55 45 56 46 
-2.00 61 51 52 42 62 52 53 43 53 43 
-1.75 59 49 50 40 60 50 60 50 60 50 
-1.50 54 44 50 40 56 46 59 49 59 49 
-1.25 57 47 49 39 62 52 55 45 55 45 
-1.00 55 45 49 39 53 43 56 46 56 46 
-0.75 57 47 51 41 64 54 59 49 54 54 
-0.50 60 50 53 43 58 48 50 40 53 43 
-0.25 60 50 54 44 55 45 50 40 51 41 
 
3.3 Protein and substrate contacts  
All the protein residues for which the centers of at least one atom lay within 0.35 nm of the 
center of any atom of the substrate at any time during the last 10 ns of the relevant simulation were 
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considered to make a direct contact with the substrate. The fraction of the time over the 10 ns of 
simulation that this contact was observed was determined and presented as a percentage.  
3.4 Helix angle 
The angles between selected pairs of TM helices (3/4, 5/6, 9/10 and 11/12) are calculated 
as follows. First, the vector along the helix dipole of each of the pairs of helices was calculated 
using the atom range given in Table 3. Next, the angle between the two vectors was calculated at 
the start and end of the 10 ns simulation. 
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4 RESULTS  
4.1 The full potential of mean force (PMF) of Hoechst 33342 and Rhodamine 123 
The PMFs of Hoechst 33342 and Rhodamine 123 were calculated along the reaction 
coordinate that passes between the NBDs and the cytosolic parts of P-gp and into the TM pore from 
Z = -15 nm to Z = 0 nm. The PMFs of both substrates were found to have two energy wells: one in 
the cytosolic region of P-gp and the other within the TM pore as shown in Figure 2. 
 
4.1.1 PMF and binding of Hoechst 33342  
The PMF of Hoechst 33342 (black line, Figure 2) begins to decrease progressively as it 
reaches the NBDs at Z = -12 nm. The PMF of Hoechst 33342 has an energy well at the interface 
between NBD1 and the cytosolic extensions of TMD1 at Z = -7.5 nm. This energy well has a depth 
of -37 ± 2 kJ/mol relative to the free energy of Hoechst 33342 in bulk solution. Once the energy 
well is passed, the PMF increases and forms an energy barrier at the cytosolic lipid-water interface 
Figure 2: The potential of mean force (PMF) of the P-glycoprotein (P-gp) substrates Hoechst 33342 
(black) and Rhodamine 123 (green) calculated along the longitudinal axis of P-gp which was used as 
the reaction coordinate (Z). 
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(Z = -4.5 nm). The height of the energy barrier from the base of the energy well at NBD1 is 24 ± 4 
kJ/mol, which is ~12 kJ/mol lower than the free energy of Hoechst 33342 in bulk solution. As the 
barrier is crossed, Hoechst 33342 encounters a second energy well within the TM pore at Z = -2.7 
nm with a relative free energy of -25 ± 5 kJ/mol with respect to the bulk solution. 
 
At its first and deeper energy well (Z = -7.5nm), Hoechst 33342 bound to the interface 
between the NBD1 and the cytosolic extensions of TMD1 as shown in Figure 3A. Cluster analysis 
of the conformations of Hoechst 33342, using an all-atom RMSD cutoff of 0.15 nm, shows that in 
Figure 3: Representative snapshots of the interaction of Hoechst 33342 (black) with P-gp in its two 
energy wells. (A) The binding location of Hoechst 33342 (spacefill) between the TMD1-NBD1 
interface at its first energy well located at Z = -7.5 nm. (B) Close-up view of (A) showing the residues 
that make direct contacts with Hoechst 33342 (stick representation). (C) The binding location of 
Hoechst 33342 relative to the TM helices 1 (light blue), 6 (red), 9 (green), 10 (pink), 11 (violet) and 12 
(yellow) at the energy well located within the TM pore (Z = -2.7 nm). (D) Close-up view of (C) showing 
the residues that make direct contacts with Hoechst 33342. Individual protein residues making 
contacts with Hoechst 33342 are shown in a CPK representation. Note for clarity TM helices 7 and 8 
are not shown in (C) and (D). 
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this energy well Hoechst 33342 adopts a range of primarily elongated conformations. The residues 
that make direct contacts with Hoechst 33342 are shown in Figure 3B. Residues were considered to 
make direct contacts when any atom of the residue was within 0.35 nm of Hoechst 33342, over the 
final 10 ns of simulation for the umbrella sampling window corresponding to the mid-point of the 
energy well. The number of times a protein residue makes direct contact was then counted over the 
10 ns simulation and is given in terms of a percentage. Hoechst 33342 interacts with Glu472 and 
Glu898 for 91% of the final 10 ns of the simulation. It also made contacts with Gln471, Val474 and 
Gln899 for ~65% of the time and residues Asn168, Thr169 and Thr894 for ~35% of the time. 
Hoechst 33342 also made transient interactions with Pro473, Asn805 and Glu1115 for ~25% of the 
time. 
The second energy well of Hoechst 33342 is located within the TM pore (Z = -2.7 nm). In 
this energy well, Hoechst 33342 adopted a single elongated conformation with an orientation 
parallel to the plane of the lipid membrane. The binding of Hoechst 33342 to P-gp was stabilized 
via direct contacts with a number of residues from TM helices 1, 6, 9, 10, 11 and 12, as shown in 
Figures 3C and D. In particular, Asn838 from TM9 was in direct contact with Hoechst 33342 for 99% 
of the time, Gly868, Met945 and Ile977 for 80% of the time and Leu64, Ser340, Leu839 and 
Val978 was in direct contact with Hoechst 33342 for 70% of the time. Additionally Hoechst 33342 
formed transient contacts with Phe339 (TM6), Val869, Met872 (TM10) and Gly980 (TM12). 
4.1.2 PMF and binding of Rhodamine 123 
The PMF of Rhodamine 123 (green line, Figure 2) drops suddenly on approaching P-gp, 
with an energy well formed along the cytosolic ends of the NBDs that is ~ -40 kJ/mol deep and ~2.5 
nm wide (between Z = -10.5 nm and Z = -7.5 nm). The lowest point located at Z = -10.0 nm is -45 ± 
3 kJ/mol relative to the bulk solvent. Once the substrate passes the NBDs, the PMF increases until it 
enters the TM pore and forms a second energy well at Z = -2.3 nm. The depth of this second energy 
well is -16 ± 3 kJ/mol relative to the bulk solvent. The two energy wells are separated by a barrier 
peaking at Z = -3.5 nm, which is located close to the entrance to the TM pore. 
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In the first energy well of Rhodamine 123 at Z = -10.0 nm, Rhodamine 123 is sandwiched 
between the cytosolic ends of the two NBDs as shown in Figure 4A. The orientation and interaction 
between Rhodamine 123 and the NBDs of P-gp is shown in Figure 4B. Rhodamine 123 formed a 
direct contact (within 0.35 nm) with 12 residues over the final 10ns of the simulation. Six of these 
residues, namely Met623 (NBD1), Gln1234, Tyr1263, Met1266, Ser1268 and Gln1270 (NBD2), 
were in direct contact for more than 90% of the final 10 ns of the simulation. The remaining 6 
Figure 4: Representative snapshots of the interaction of Rhodamine 123 (green) with P-gp in its two 
energy wells. (A) The binding location of Rhodamine 123 (spacefill) between the C-terminal ends of 
the NBD1 and NBD2 at Z = -10.0 nm. (B) Close-up view of (A) showing the residues that make direct 
contacts with Rhodamine 123 (stick representation). (C) The binding location of Rhodamine 123 
coordinated by TM helices 1 (light blue), 3 (black), 6 (red), 1 (violet) and 12 (yellow) at the energy well 
located within the TM pore (Z = -2.3 nm). (D) Close-up view of (C) showing the residues that make 
direct contacts with Rhodamine 123. Individual protein residues making contacts with Rhodamine 123 
are shown in a CPK representation. Note for clarity TM helices 4 and 5 are not shown in (C) and (D). 
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residues (Met612, Phe619, Val622 (NBD1), Ile1233, Phe1264, and Val1269 (NBD2)) persisted for 
65-75% of the time. 
Like Hoechst 33342, the PMF for Rhodamine 123 also contained a second energy well 
within the TM pore. This energy well is located approximately 0.5nm deeper inside the TM pore 
than the energy well of Hoechst 33342 within the TM pore. Cluster analysis showed that in this 
second energy well, Rhodamine 123 predominantly adopted a single conformation (~92% of the 
simulation time). Here Rhodamine 123 bound between TM helices 1, 3, 6, 11 and 12, as shown in 
Figure 4C. The contact residues during the final 10 ns of the equilibrated simulation are given in 
Figure 4D. In the predominant conformation, Rhodamine 123 interacted with residues Met68 from 
TM1 and Ile977 from TM12 for 98% of the simulation. It also made contacts with Leu64 (TM1), 
Met945 and Tyr949 (TM11) for 65% of the simulation and with other residues Phe71, Phe190, 
Ile336, Phe339, Ser340, Gln942, Val978 and Phe979 for ~55% of the simulation. In addition, 
Rhodamine 123 also formed transient contacts with Met67, Asn838, Thr841 and Tyr949. 
4.2 The partial potential of mean force (PMF) of paclitaxel, tariquidar and verapamil 
Some previous studies14, 21, 22 proposed that substrates enter the TM pore of P-gp from the 
membrane. Other studies23-25 suggest that P-gp can bind substrate in the cytoplasmic regions of the 
protein. However, the majority of the mutagenesis data suggests that the residues implicated in 
substrate binding are located within the membrane-spanning region of the transmembrane domains 
(TMDs), particularly TM helices 4, 5, 6, 10, 11 and 1226. Due to the computational time required to 
equilibrate and sample the conformational space at each umbrella sampling window for large 
molecules such as paclitaxel, tariquidar and verapamil, the PMFs for these substrates were only 
calculated from the intracellular lipid-water interface at Z = -5.5 nm to Z = 0 nm. While this does 
not allow us to determine the total free energy of binding, it does allow us to identify and 
characterize the binding locations of these compounds within the TM pore. 
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4.2.1 PMF and binding of paclitaxel 
 
Figure 5: The PMF and interaction of paclitaxel with P-gp in its two energy wells and at the 
intervening barrier. (A) PMF of paclitaxel (red) in P-gp as a function of the reaction coordinate (Z). 
(B) and (C) shows the binding location and the interacting residues of paclitaxel at its first energy well 
(Z = -4.5 nm) relative to the TM helices 4 (magenta), 5 (dark blue), 9 (green) and 12 (yellow). (D) 
Front view of the barrier location of paclitaxel within the TM helices 9 (green), 10 (pink) and 12 
(yellow). (E) and (F) shows the binding location and the interacting residues of paclitaxel at its energy 
well within the TM pore (Z = -2.7 nm) relative to the TM helices 1 (light blue), 2 (orange), 3 (black), 6 
(red), 11 (violet) and 12 (yellow). Note TM4 and TM5 are not shown for clarity in (E) and (F). 
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The PMF of paclitaxel was calculated from the cytosolic side of the lipid-water interface 
(Z = -5.5 nm) to the reference group at Z = 0 nm. In the initial umbrella sampling window (Z = -5.5 
nm), paclitaxel was found to bind to the cytosolic extensions of TM4 and 5. At this window (Z = -
5.5 nm), the free energy of the system was assigned a value of 0 kJ/mol. The PMF of paclitaxel, 
shown in Figure 5A, has a downhill energy gradient with respect to its starting location, forming 
two energy wells, one at Z = -4.4 nm and a second at Z = -2.7 nm separated by a small energy 
barrier at Z = -3.5 nm. The first energy well for paclitaxel is located at the lipid-water interface (Z = 
-4.4 nm) with a relative free energy of -15 ± 2 kJ/mol with respect to the value at Z = -5.5 nm. In 
this energy well, paclitaxel is bound by TM helices 4, 5, 9 and 12, as shown in Figure 5B. Paclitaxel 
adopted a single conformation interacting with residues Asn816, Ala819, Gln820 and Lys822 from 
TM9. Paclitaxel also formed direct contacts with Thr236, Asp237, Leu240, His241, Lys245 (TM4), 
Ile289, Asn292 (TM5) and Ser989 (TM12) for 85-90% of the time, as shown in Figure 5C.  
The two energy wells in the PMF of paclitaxel are separated by an energy barrier of ~18 
kJ/mol in the TM pore, within the span of the intracellular leaflet of the lipid bilayer (Z = -3.5 nm). 
At the barrier, the conformation of paclitaxel alternated between three conformational clusters, the 
most predominant of which was adopted for nearly 55% of the final 10 ns of the simulation. At the 
barrier paclitaxel bound between TM helices 9, 10 and 12, as shown in Figure 5D, but did not form 
persistent interactions with any specific residues.  
 Once the energy barrier was crossed, paclitaxel experienced a second shallow energy well of 
-5 ± 3 kJ/mol, located within the TM pore close to the center of the lipid bilayer (Z = -2.7 nm). This 
energy well is physically located between TM helices 1, 2, 3, 6, 11 and 12, and cluster analysis 
revealed that paclitaxel adopted two distinct conformations at this location. One conformation was 
adopted for 91% of the time (Figure 5E). The residues that form direct contacts with paclitaxel in 
this conformation are given in Figure 5F. Of the 19 residues contacting paclitaxel, interactions with 
Met67 (TM1), Gln128, Val129, Trp132 (TM2), Val175, Phe190 (TM3), Ile336 and Phe339 (TM6) 
were present for 60% of the time. Leu64 (TM1), Val124 (TM2), Lys177 (TM3), Phe934, Phe938, 
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Gln942 (TM11), Ile977, Val978, Phe979, Gly980, and Met982 (TM12) formed contacts with 
paclitaxel for approximately 33% of the time. 
4.2.2 PMF and binding of tariquidar 
 
In the initial umbrella sampling window (Z = -5.5 nm), tariquidar bound to the cytosolic 
extensions of TM helices 4 and 9. Again, the free energy was assigned a value of zero at this point. 
The PMF of tariquidar, shown in Figure 6A, remains essentially flat from the cytosolic side of the 
Figure 6: Snapshots of binding of tariquidar to P-gp. (A) PMF of tariquidar (cyan) in P-gp with 
respect to the reaction coordinate (Z) calculated from the cytosolic side of the intracellular lipid-water 
interface (Z = -5.5 nm). (B) and (C) The binding location and the interacting residues of tariquidar 
(cyan) at its first energy well (Z = -4.5 nm) relative to TM helices 1 (light blue), 3 (brown), 6 (red), 9 
(green) and 12 (yellow). (D) The final conformation of P-gp with tariquidar bound is shown in black, 
while a selection of 52 conformations taken throughout the last 10 ns of simulation is shown in pink 
cartoon overlays.  
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lipid-water interface (Z = -5.5 nm) to the entrance of the TM pore (Z = -3.7 nm). At the entrance of 
the TM pore, the PMF of tariquidar contains a small energy minimum with a depth of -8 ± 5 kJ/mol. 
In this location, cluster analysis revealed that tariquidar adopts four conformations, the most 
persistent of which lasted for ~61% of the final 10 ns of the simulation. In the major cluster, 
tariquidar adopted a v-shaped conformation where tariquidar is folded onto itself and positioned 
horizontally across the entrance of the TM pore between TM helices 1, 3, 6, 9 and 12, as shown in 
Figure 6B.  
 
TM helices Residues used 
to calculate 
helix dipole 
Angle of the initial 
conformation (degrees) 
Angle of the final 
conformation (degrees) 
TM 3 171 to 206 
35.3˚ 32.5˚ 
TM4 209 to 251 
TM 5 281 to 319 
38.7˚ 28.1˚ 
TM6 323 to 354 
TM9 811 to 848 
31.5˚ 28.8˚ 
TM10 856 to 891 
TM11 921 to 957 
42.5˚ 32.6˚ 
TM12 974 to 1006 
 The residues that tariquidar made direct contacts with in this conformation are given in 
Figure 6C. Notably, interactions with Gln834 (TM9) persisted for 80% of the simulation; and 
interactions with His60 (TM1), Phe189 (TM3), Ala352, Asn353 (TM6), Asn838 (TM9), Ser988 
and Asp993 (TM12) persisted for 60-70% of the final 10 ns of simulation. Tariquidar also made 
transient contacts (< 30%) with Ile186, Met188, Asn347, Arg355 and Lys996. The binding of 
tariquidar across the entrance of the TM pore induced structural changes in the conformation of the 
TMDs, bringing them together and reducing the accessible volume of the TM pore. Figure 6D 
shows a snapshot of the structural changes induced by tariquidar when bound to the TMDs. Figure 
6D shows a snapshot of the structural changes induced in P-gp by the binding of tariquidar to the 
Table 3. Angles formed by the TM helices in during an initial and a final conformation of P-gp while 
tariquidar is located in its energy well. 
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TMDs. In brief, tariquidar binds at the cytosolic entrance to the TM pore, occluded the TM pore and 
triggering a narrowing of the distance between the TMDs. To quantify this, Table 3 gives the angles 
between the TM helix pairs 3/4, 5/6, 9/10 and 11/12 at the start and end of the 10 ns simulation. The 
angles formed by the pseudo symmetric pairs TM3/4 and TM9/10 is ~3˚ lesser than that observed in 
the starting conformation. In contrast, the angle formed by the pseudo-symmetric pairs TM5/6 and 
TM11/12 decreased by approximately 10˚ with respect to the starting conformation. 
4.2.3 PMF and binding of verapamil 
 
The PMF of verapamil within the TM pore of P-gp has an energy profile similar to that of 
tariquidar as shown in Figure 7A. In the initial umbrella sampling window (Z = -5.5 nm), verapamil 
bound to the cytosolic extensions of TM 4 and 9, the same two helices that interacted with 
tariquidar. Again, the free energy was assigned a value of zero at Z = -5.5 nm. The PMF remains 
relatively flat as verapamil traverses the cytosolic lipid-water interface, then forms a small energy 
well in the TM pore, within the span of the intracellular lipid leaflet and close to the center of the 
bilayer (Z = -3.1 nm). The depth of this energy well is -5 ± 2 kJ/mol. Within the energy well, 
verapamil adopted an elongated spiral conformation for 80% of the simulation, as identified by 
cluster analysis. Here verapamil bound to TM helices 1, 3, 5, 6, 7, 9 and 12 (Figure 7B) and formed 
Figure 7: (A) The PMF of verapamil (blue line) along the long axis of P-gp i.e. the reaction 
coordinate. (B) A snapshot of the binding location of verapamil (dark blue) at Z = -3.1 nm relative 
to the TM helices 1 (light blue), 3 (silver), 5 (dark blue), 6 (red), 7 (grey), 8 (purple), 9 (green) and 
12 (yellow). (C) Close-up view of (B) showing the individual residues making direct contacts with 
verapamil at its binding location within the TM pore. Note TM3 and TM4 are not shown for clarity 
in (C). 
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direct contacts with 20 residues, which are shown in Figure 7C. Verapamil formed contacts with 
residues Ile302 (TM5), Phe339 (TM6) and Val984 (TM12) for the duration of the simulation, and 
with Phe724, Ser725, Phe728 (TM7), Ala981, Met982 and Ala983 (TM12) for ~75% of the 
simulation. Verapamil also formed some transient contacts for < 35% of the time with residues 
Leu64, Leu300, Ile336, Phe332, Ser340, Leu758, Asn838, Val978, Phe979, Gly980 and Gln986. 
Verapamil has two dimethoxyphenyl groups, one attached to the protonated tertiary amine, and the 
other attached to the pentanitirle group. In the predominant conformation of verapamil within the 
energy well, the dimethoxyphenyl group of the protonated tertiary amine remained in contact with 
residues from TM helices 5, 6, 7 and 12 throughout the simulation, while the second 
dimethoxyphenyl group remained flexible, allowing the substrate to sample the cross-sectional 
space of the TM pore. 
4.3 The effect of starting structure on substrate binding  
All results presented thus far are based on the original P-gp structure (PDBid 3G5U)11. To 
investigate any possible bias induced by the choice of starting structure, a series of unrestrained MD 
simulations based on a revised mouse P-gp structure (PDBid: 4M1M)12 were performed. The 
methodology implemented was the same as described in the methods of Chapter 2, for the binding 
of morphine and nicardipine to the 4M1M P-gp structure. Unrestrained MD simulations of Hoechst 
33342 and Rhodamine 123 were performed using an equilibrated membrane embedded 4M1M P-gp 
structure. In each case, the substrate was placed within the TM pore in their respective energy wells 
identified from PMF calculations and simulated for 10 ns to examine if similar interactions were 
made to those found using the 3G5U structure.  
In the unrestrained MD simulations of 4M1M P-gp with the Hoechst 33342, the substrate 
was placed at Z = -2.7 nm, which corresponded to the energy well within the TM pore. Cluster 
analysis revealed that Hoechst 33342 again adopted an elongated conformation. There were some 
changes in the orientation of Hoechst 33342 in the energy well with respect to that observed in the 
3G5U simulations and in the set of residues with which it interacted. A comparison of the binding 
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locations and contact residues for Hoechst 33342 in 3G5U and 4M1M P-gp simulations is shown in 
Figure 8. From Figures 8A and B it can be seen that the overall binding location of Hoechst 33342 
is similar in both the 3G5U and 4M1M P-gp structures along the reaction coordinate. A comparison 
of the residues interacting with Hoechst 33342 in the 3G5U and 4M1M P-gp simulations are given 
in Figures 8C and D respectively. Of the 13 residues that made contacts with Hoechst 33342 in the 
3G5U simulations (Figure 8C), 5 residues, namely Leu64, Met945, Tyr949, Ile977 and Val978 
were identified as also making direct contacts in the 4M1M simulations. In the 3G5U and 4M1M 
simulations, interactions with Met945, Ile977 and Val978 persisted for more than half the 
simulation.  
 
Figure 8: Comparison of the binding sites of Hoechst 33342 (black) in the 3G5U and 4M1M P-gp 
structures. (A) The binding location of Hoechst 33342 in 3G5U P-gp identified from the PMF 
calculations. (B) The binding location of Hoechst 33342 in 4M1M P-gp identified from the 
unrestrained simulations. The individual residues that form direct contact with Hoechst 33342 in (C) 
3G5U P-gp structure and (D) 4M1M P-gp structure are shown. The contacting residues that are 
common for both (C) 3G5U and (D) 4M1M are labelled red. Other residues that are specific to 3G5U 
and 4M1M are labelled black. 
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Rhodamine 123 was placed in a position within the 4M1M TM pore corresponding to the 
location of its energy well (Z = -2.3 nm). Rhodamine 123 is a rigid, planar molecule. While the 
preferred location of Rhodamine 123 in the simulations of 4M1M is similar to that of 3G5U 
(Figures 9A and B), the orientation of Rhodamine 123 in the TM pores of 4M1M was different to 
that obtained in the 3G5U simulation (Figures 9C and D). However, the residues making direct 
contacts are almost identical in both cases. A list of contacting residues in both the 3G5U and 
4M1M simulations for comparison are given in Figures 9C and D. The residues, Leu64 (TM1), 
Gln942, Met945, Tyr946 (TM11), Ile977, Val978 and Phe979 (TM12) were identified to form 
contacts with Rhodamine 123 in both 3G5U and 4M1M simulations. Of these, Leu64, Val978 and 
Phe979 were experimentally implicated in the binding and/or transport of Rhodamine 12327-29. 
Overall this shows that the binding locations of these two substrates do not differ significantly 
between the 3G5U and 4M1M.  
Figure 9: Comparison of the binding locations of Rhodamine 123 (green) in 3G5U and 4M1M P-gp 
structures. (A) and (B) The binding locations of Rhodamine 123 in the 3G5U and 4M1M P-gp 
structures. (C) Represents a snapshot of the individual residues interacting with Rhodamine 123 in 
3G5U P-gp. (D) Residues making direct contacts with Rhodamine 123 in the unrestrained simulations 
with 4M1M P-gp.  The contacting residues that are common for both 3G5U and 4M1M are labelled 
red. Other residues that are specific to 3G5U or 4M1M are labelled black. 
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5 DISCUSSION  
5.1 Non-competitive binding pairs 
5.1.1 The binding of Hoechst 33342 and Rhodamine 123  
Hoechst 33342 and Rhodamine 123 have been shown experimentally to bind non-
competitively and on this basis have been proposed to associate with different pharmacological sites. 
The PMF of Hoechst 33342 along the central axis of P-gp has two energy wells, a deeper well in the 
vicinity of the TMD1-NBD1 interface and a second energy well within the TM pore, as shown in 
Figure 2. Of the 12 residues that made contacts with Hoechst 33342 in the TMD1-NBD1 energy 
well, eight (Gln471, Glu472, Val474, Thr894, Glu898, Gln899 and Arg901) were also identified as 
putative substrate binding residues by a previous docking study of Pajeva et al24. The energy well 
within the TM pore (Z= -2.7 nm) lies ~1.5 nm from the intracellular lipid-water interface. Previous 
FRET studies proposed that the primary binding location for Hoechst 33342 lay within the TM pore, 
~1.4 nm from the intracellular lipid-water interface30. This is in close agreement with the energy 
well from the MD simulation. Of the 13 residues that form direct contacts with Hoechst 33342 in 
the TM energy well, Leu64, Phe339, GLy868 and Val978 have also been implicated experimentally 
in the binding of verapamil, vinblastine, colchicine and Rhodamine 12326-29, 31, 32. Ser340 has also 
been implicated in the binding of Hoechst 3334233, 34 in two separate docking studies. 
The PMF of Rhodamine 123 also showed two energy wells within P-gp. The deeper 
energy well is located at Z = -10.0 nm, where Rhodamine 123 is sandwiched between the C-
terminal ends of NBD1 and NBD2. The second energy well for Rhodamine 123 is located within 
the TM pore at Z = -2.3 nm. Of the 17 residues that interact with Rhodamine 123 in the TM energy 
well, Leu64, Ile336, Phe339, Tyr949, Val978 and Phe979 have been implicated biochemically in 
the binding of Rhodamine 12327-29, 31, 35, 36. To the best of our knowledge, no biophysical studies 
identifying a specific binding location for Rhodamine 123, equivalent to that described for Hoechst 
33342, have been published to date.  
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As noted above, Hoechst 33342 and Rhodamine 123 have been shown to bind non-
competitively under certain assay conditions6, 7, suggesting they may bind to distinct sites. Based on 
the PMFs of Hoechst 33342 and Rhodamine 123 (Figure 2), it was identified that both these 
substrates have their primary energy well in the cytosolic NBD regions of P-gp. The physical 
location of these primary energy wells are ~2.5 nm apart and correspond to distinct locations as 
expected. However, the energy wells of Hoechst 33342 and Rhodamine 123 within the TM pore 
show considerable overlap. Of the 21 residues that formed direct contacts with Hoechst 33342 and 
Rhodamine 123 in their TM pore energy wells (Figures 3D and 4D), Leu64, Phe339, Ser340, 
Asn838, Met945, Ile977 and Val978 interacted with both substrates. The energy wells of Hoechst 
33342 and Rhodamine 123 in the TM pore correspond to a lower affinity, transport-competent site 
for each substrate. This suggests that though Hoechst 33342 and Rhodamine 123 bind non-
competitively to P-gp at distinct binding locations, they could compete for transport with each other 
Figure 10: A proposed non-competitive binding mechanism of Hoechst 33342 (black) and Rhodamine 
123 (green) obtained from the umbrella sampling simulations. (A) Both Hoechst 33342 and 
Rhodamine 123 could possibly bind to their respective energy wells (Z= -7.5 nm and Z= -10.0 nm 
respectively) located in the cytosolic NBD regions of P-gp. (B) and (C) represents the alternative 
binding patterns where one substrate binds to the NBD region (Rhodamine 123 in case of (B) and 
Hoechst 33342 in case of (C)) and the other binds to the binding location within the TM pore (Hoechst 
33342 in case of (B) at Z= -2.7 nm and Rhodamine 123 in case of (C) at Z= -2.3 nm). (D) Shows that 
both Hoechst 33342 and Rhodamine 123 could potentially bind to the TM pore to their respective 
energy wells at Z= -2.7 nm and Z= -2.3 nm respectively. N- and C- terminal halves of P-gp are colored 
in gold and silver respectively.  
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as they have an overlapping binding location within the TM pore. Figure 10 shows four alternative 
binding scenarios for Hoechst 33342 and Rhodamine 123.  Firstly, Hoechst 33342 and Rhodamine 
123 could both interact with NBDs as shown in Figure 10A at a separate site. Secondly, one 
molecule of Hoechst 33342 could bind to the TM pore, while one molecule of Rhodamine 123 
binds to the NBD regions, or vice versa, as shown in Figures 10B and C. Finally, both Hoechst 
33342 and Rhodamine 123 could potentially bind simultaneously within the TM pore (Figure 10D) 
although not precisely at the minima indicated in the PMFs. Studies by Lugo et al.37 and Martinez 
et al.38 have shown that the TM pore of P-gp is large enough to accommodate multiple 
substrates/molecules and thus it is plausible for both Hoechst 33342 and Rhodamine 123 to occupy 
the TM pore. 
5.1.2 The binding of paclitaxel and nicardipine 
Like Hoechst 33342 and Rhodamine 123, paclitaxel and nicardipine experimentally bind 
non-competitively. The PMF of paclitaxel (Figure 5A) has its primary energy well located close to 
the intracellular lipid-water interface (Z = -4.4 nm) while the second is located within the TM pore 
at Z = -2.7 nm. The PMF of nicardipine (shown in Chapter 2, Figure 2) also has two energy wells at 
Z = -4.5 nm and Z = -2.3 nm. The primary energy wells of paclitaxel and nicardipine are located at 
Z = -4.4 nm and Z = -2.3 nm respectively. The overall location of the energy wells of both 
paclitaxel and nicardipine are very distinct and well separated by ~2.1 nm. This is in agreement 
with the binding assays that paclitaxel and nicardipine bind non-competitively. However, the energy 
wells within the TM pore for paclitaxel and nicardipine are separated only by ~0.4 nm and a 
number of residues (Ile336, Phe339 (TM6), Ile977, Val978 and Met982 (TM12)) form direct 
contact with both paclitaxel and nicardipine.  Though paclitaxel and nicardipine bind non-
competitively to P-gp8, a comparison of their PMFs suggests that they may be competitive for 
transport. A proposed scheme for paclitaxel and nicardipine binding is shown in Figure 11A and B.   
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5.2 Competitive binding pairs 
Equilibrium binding and substrate accumulation studies have proposed that specific 
substrates could bind competitively and non-
competitively to P-gp6-10, 39, 40. Two such 
competitive binding pairs, tariquidar/Hoechst 
33342 and verapamil/morphine, are discussed 
below. A scheme showing the proposed 
mechanism of competitive binding of these 
substrates is shown in Figure 11C-F. 
5.2.1 Tariquidar and Hoechst 33342 
Previous computational studies by 
Klepsch et al.41 and Chufan et al.42 have 
identified that TM helices 1, 4, 5, 6, 7, 8, 9 
and 12 were implicated in the binding of the 
P-gp inhibitor tariquidar. The PMF of 
tariquidar through the TM pore identified that 
the energy well is located near the entrance to 
the TM pore at Z = -3.7 nm, where tariquidar 
bound to TM helices 1, 3, 6, 9 and 12. The 
simulations of tariquidar in its energy well 
showed that tariquidar adopted a V-shaped 
conformation within the TM pore. Here, 
tariquidar bound across the entrance of the 
TM pore inducing a narrowing of the TM pore, 
reducing its volume. Equilibrium binding 
Figure 11: A scheme representing the binding of 
non-competitive and competitive substrate pairs to 
P-gp. (A) and (B) represent the non-competitive 
binding modes for paclitaxel (PXL, red) and 
nicardipine (NCP, blue). (C) and (D) represent a 
competitive binding mechanism of tariquidar  
(TQR, cyan) and Hoechst 33342 (HST, black). (E) 
and (F) shows possible binding modes for the 
competitive substrate pair verapamil (VPL, blue) 
and morphine (MOI, pink). 
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studies of tariquidar and Hoechst 33342 by Martin et al. suggested that these substrates bind 
competitively. Here we propose that the binding of tariquidar in its energy well physically occludes 
the TM pore inducing a conformation change that narrows the proposed substrate uptake portals, 
preventing the entry of Hoechst 33342. A proposed scheme showing how tariquidar could compete 
with Hoechst 33342 is given in Figures 11C and D. 
 
5.2.2 Verapamil and morphine  
Photo-labeled drug accumulation 
studies using morphine and verapamil have 
demonstrated that verapamil competes for 
binding and transport by P-gp with morphine, 
reducing the transport rate of morphine10. The 
PMF of verapamil through the P-gp TM pore 
contains a small energy well at Z = -3.1 nm 
while the PMF of morphine has an energy well 
at Z = -2.5 nm. Verapamil is the most 
comprehensively characterized P-gp substrate 
and many residues have been implicated in its 
transport and binding, as listed in Table 2 of 
Chapter 2. At its energy minimum, verapamil 
formed direct contacts with 18 residues 9 of 
which (Leu64 (TM1), Ile302 (TM5), Phe339 (TM6), Phe724, Ser725 (TM7), Asn838 (TM9), 
Val978, Gly980 and Ala981 (TM12)) have been experimentally implicated in its binding27, 28, 32, 45-47.  
At their energy minima, both verapamil and morphine formed direct contacts with Leu64 (TM1), 
Asn838 (TM9), and Val978 (TM12), which persisted for nearly 60% of the converged simulation. 
Figure 12 shows a spatial distribution of the residues that formed direct contacts with verapamil 
Figure 12: Spatial distribution of the residues that 
formed direct contacts with verapamil (cyan, space-
filling) and morphine (gray, space-filling) in their 
respective binding locations. The residues those are 
common for both verapamil and morphine are 
shown in red. The membrane-spanning region of 
P-gp is shown in a cartoon representation. 
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(cyan) and morphine (grey) at their respective minimum energy wells. The distribution of the 
residues that are common to both verapamil and morphine (Figure 12, red) suggests that although 
the binding locations are spatially separated, they are not truly distinct. A proposed scheme showing 
the competitive binding of verapamil and morphine to P-gp is shown in Figure 11E. It was proposed 
that when verapamil enters its shallow binding well in the P-gp TM domains, it interacts with 
Leu64, Asn838 and Val978, preventing the binding of morphine. Verapamil and morphine thus act 
as competitive substrates for P-gp (Figure 11F). 
  
128 
6 CONCLUSIONS 
The ability of P-gp to recognize a wide variety of substrates is remarkable and has been the 
subject of intense research for almost 40 years. Numerous biochemical, docking and 
pharmacophore mapping studies examining substrate transport by P-gp have identified numerous 
residues implicated in substrate binding and transport3-5. Based on this, the existence of a number of 
pharmacologically distinct substrate binding sites has been proposed8. However, none of these 
studies have been able to provide a detailed characterization of any physical substrate binding site. 
To understand the interactions that govern competitive and non-competitive substrate binding to P-
gp and to determine the minimum energy binding location of substrates, molecular dynamics 
simulations were employed to calculate the PMF of three P-gp substrates, a P-gp inhibitor and a P-
gp modulator. Taken together with the PMFs for morphine and nicardipine, discussed in Chapter 2, 
a scheme for competitive and non-competitive substrate binding interactions in P-gp has been 
proposed. The PMFs of the non-competitive substrate pairs, Hoechst 33342/ Rhodamine 123 and 
paclitaxel/ nicardipine were all found to have two energy wells. In particular, the TM pore energy 
well of Hoechst 33342 and Rhodamine 123 overlap with residues implicated in the proposed 
pharmacological H and R sites, respectively. Based on this observation, it is proposed that non-
competitive substrates bind to P-gp in alternative energy wells, as illustrated in Figure 10, 11 and 12. 
The P-gp inhibitor tariquidar and the modulator verapamil both have relatively flat PMFs with a 
single, energy well in the TM pore. Tariquidar binds across the cytosolic entrance to the TM pore, 
occluding the pore and blocking entry of substrates to the TM pore. This may explain how 
tariquidar competes with Hoechst 33342 for binding to P-gp. Alternatively both tariquidar and 
Hoechst 33342 could bind to the same site within the NBDs. Verapamil competes with morphine 
for binding and transport by P-gp. Based on analysis of the contact residues and location of the 
single minimum energy well for both verapamil and morphine (Chapter 2), it is proposed that the 
binding site of verapamil and morphine is not spatially separated or distinct.  In the case of 
competitive substrate binding pairs discussed, one of the two substrates has a single energy well and 
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it competes with the second substrate for that energy well within the TM pore region. However, to 
expand on this, simulations with competitive substrate pairs in P-gp simultaneously would be 
necessary. It is also evident that each substrate could have multiple binding sites. The unrestrained 
MD simulations of the membrane-embedded 4M1M P-gp structure demonstrate that the same core 
set of residues interacted with Hoechst 33342 and Rhodamine 123 in their predicted energy wells, 
indicating that the results obtained are not heavily influenced by the choice of starting structure.   
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Chapter 4: Understanding the accumulation of P-
glycoprotein substrates within cells: The effect of 
cholesterol on membrane partitioning. 
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1 ABSTRACT  
The apparent activity of the multidrug transporter P-glycoprotein (P-gp) is enhanced by the 
presence of cholesterol. However, the degree to which this observation is due to the direct effect of 
cholesterol on the activity of P-gp, its effect on the local concentration of substrate in the membrane 
or on the rate of entry of the drug into the cell, is unknown. In this study, molecular dynamics 
simulation techniques coupled with potential of mean force calculations have been used to 
investigate the role of cholesterol in the movement of four representative P-gp substrates: 
doxorubicin, paclitaxel, morphine and nicardipine, across a POPC bilayer in the presence or 
absence of 10% cholesterol. The simulations suggest that the presence of cholesterol lowers the free 
energy associated with entering the middle of the bilayer. In the case of morphine this eliminates 
the barrier to cross the membrane. In the case of the other three substrates it is expected to increase 
membrane solubility. The effect was small in the case of paclitaxel but for doxorubicin and 
nicardipine the presence of cholesterol is expected to increase the local concentration of the 
substrate significantly. These findings together with previous experimental studies on doxorubicin 
suggest that the enhanced pumping activity of P-gp in the presence of cholesterol may be related to 
the preferential accumulation of P-gp substrates in cholesterol-rich regions of the membrane as 
opposed to the direct effect of cholesterol on the activity of P-gp itself. They also suggest that the 
effect of cholesterol on the efficiency of P-gp may be highly substrate dependent. 
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2  INTRODUCTION 
Pharmaceutical intervention is the primary treatment option for conditions ranging from 
bacterial and fungal infections to cancer1-4. One of the risks of intensive chemotherapy is the 
development of resistance, in which different classes of drugs can be rendered ineffective, often 
simultaneously5. Multidrug resistant (MDR) cells exhibit higher membrane cholesterol 
concentrations than drug sensitive cells6 and increased activity of ABC multidrug efflux proteins. 
These ABC efflux proteins prevent the accumulation of drugs inside cells by actively pumping them 
out across the cell plasma membrane. P-glycoprotein (P-gp) is the predominant ABC multidrug 
transporter in humans. It is located in caveolae7 and specialized lipid rafts8, 9, unique micro domains 
of biological membranes enriched in sphingolipids and cholesterol10. While the precise mechanism 
of action of P-gp is unknown, experimental studies have shown that the rate of drug efflux is 
enhanced by the presence of cholesterol9, 11-14. Furthermore, depletion of the membrane cholesterol 
concentration in MDR cells expressing P-gp increases the intracellular accumulation of the anti-
cancer drug doxorubicin6, 15, 16 and the P-gp substrate Rhodamine1236. One possible explanation for 
this is that in the absence of cholesterol, the drug efflux efficiency of P-gp is impaired. However, 
whether these effects are due purely to cholesterol modulating the efflux efficiency of P-gp, the 
effect of cholesterol on the concentration of substrate in the membrane, or the ability of doxorubicin 
and other P-gp substrates to passively partition across the membrane is unclear17, 18.  
Previous work has suggested that the principal mechanism by which drugs such as 
doxorubicin enter cells is passive diffusion19. Thus the composition of the phospholipid bilayer 
plays an important role20. For example, liposomes have been shown to retain up to 55% more 
doxorubicin if 45% cholesterol is present in an egg phosphatidylcholine (EPC) membrane, 
compared to a pure EPC membrane17. Despite this, the effect of membrane composition on the 
partitioning behavior of most P-gp substrates has not been examined in detail. There has also been 
much speculation regarding the mechanism by which multidrug transporters uptake potential 
substrates. Drug molecules that have partitioned into the inner leaflet of the membrane may be 
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directly taken up by a proximal multidrug transporter, such as P-gp, and be immediately exported 
out of the cell13, 14, 21. Many P-gp substrates, including paclitaxel, doxorubicin and vinblastine, have 
intracellular targets, thus these molecules may fully partition into the cell, where they are trafficked 
from the cytosol to a multidrug transporter for cellular efflux. Most P-gp substrates are amphipathic 
molecules that have substantial hydrophobic regions and contain one or more aromatic or cyclic 
groups. However, they also commonly contain one or more tertiary amines, and most P-gp 
substrates possess at least a +1 charge at neutral pH. This positive charge may enhance the 
interaction of the substrate with the phosphate groups of the membrane lipids. Most P-gp substrates 
are thought to partition across the lipid membrane relatively easily. However, in some cases the 
positive charge may also pose an energetic barrier to cross the membrane. This barrier may slow the 
rate substrates enter the inner leaflet of the membrane, thus increasing the probability that they are 
exported by P-gp.  
In this study, a combination of molecular dynamics (MD) simulation techniques and 
potential of mean force (PMF) calculations are used to investigate the effect of cholesterol on the 
partitioning of four P-gp substrates across a POPC (1-palmitoyl-2-oleoylphosphatidylcholine) lipid 
bilayer. The four substrates were: the chemotherapeutic anti-cancer drugs doxorubicin (543 a.m.u.) 
and paclitaxel (854 a.m.u.), the opiate morphine (285 a.m.u.) and the calcium channel blocker 
nicardipine (479 a.m.u.). Chemical structures of the drugs are given in Figure 1A-D. Our results 
suggest that incorporating cholesterol into the POPC bilayer lowered the relative free energy for 
each of the substrates to enter the membrane. However, the magnitude of this effect varied 
significantly between the four substrates.  
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3 METHODOLOGY 
3.1 System setup  
MD simulations and PMF calculations 
have been used to study the effect of cholesterol 
on the spontaneous binding and partitioning of 
doxorubicin, morphine, nicardipine and 
paclitaxel to a POPC bilayer. The parameters for 
all four substrates were determined using 
ChemAxon22, 23 and the Automated Topology 
Builder and Repository (ATB)24, 25. Two 
alternative model membrane systems were used: 
a pure POPC lipid bilayer composed of 184 
lipids (92 lipids per leaflet) and a POPC: 
cholesterol (9:1) bilayer consisting of 164 POPC 
lipids (82 lipids per leaflet) and 17 cholesterol 
molecules. Starting configurations for the pre-
equilibrated lipid bilayers were obtained from the 
ATB24, 25. Each bilayer was solvated in water 
containing an equivalent of 150 mM NaCl to 
mimic in vivo salt concentrations. Detailed 
information regarding the systems simulated is 
provided in Table 1. Images were produced using 
VMD26. 
Figure 1: The chemical structures of four 
representative P-glycoprotein (P-gp) substrates 
(A) doxorubicin, (B) paclitaxel, (C) nicardipine 
and (D) morphine at neutral pH. The pKa(s) of 
ionizable groups are shown in pink. (E) The 
initial configuration of POPC + 10 % 
cholesterol membrane used in the umbrella 
sampling simulations. The black line represents 
the reaction coordinate (Z-axis) along which the 
substrate is moved. The substrate (pink 
spacefill) was placed at a distance of 6 nm from 
the center of the bilayer (z = 0 nm).  
  
138 
3.2 Simulation parameters  
All simulations parameters were the same as described in Chapter 2 unless specified. Data 
was collected for analysis every 25 ps during the potential of mean force calculations and every 50 
ps during the unbiased MD simulations. 
 
Unrestrained MD Simulations 
Bilayer type (number of lipids) Substrates, number Replicates 
Replicate length 
(ns) 
POPC (184) 
DOX, 8 3 300 
POPC+CLR  (164+17) 
POPC (184) 
PXL, 8 3 300 
POPC+CLR  (164+17) 
POPC (186) 
MOI, 25 3 300 
POPC+CLR  (164+17) 
POPC (186) 
NCP, 25 3 300 
POPC+CLR  (164+17) 
PMF Calculations 
Bilayer type (number of lipids) Substrates, number Windows 
Replicate length 
(ns/window) 
POPC (184) 
DOX, 1 49 20 
POPC+CLR  (164+17) 
POPC (184) 
PXL, 1 49 20 
POPC+CLR  (164+17) 
POPC (186) 
MOI, 1 49 20 
POPC+CLR  (164+17) 
POPC (186) 
NCP, 1 49 20 
POPC+CLR  (164+17) 
POPC – 1-palmitoyl-2-oleoylphosphatidylcholine, CLR – Cholesterol, DOX – doxorubicin, PXL – paclitaxel, 
MOI – morphine, NCP – nicardipine 
3.2.1 Lipid and substrate Parameters  
The parameters for POPC were taken from Poger et al25. The parameters for cholesterol 
and simulation conditions were the same as those used by O’Mara and Mark27. The chemical 
structures of the four P-gp substrates (doxorubicin, paclitaxel, morphine and nicardipine) shown in 
Table 1: Summary of the membrane systems simulated. 
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Figure 1A-D (respectively) were obtained from the PubChem Substance database and the PubChem 
Compound database28. The protonation states of the four substrates were determined by calculating 
the ionization constant of each titratable group using ChemAxon22, 23. At neutral pH, doxorubicin, 
morphine and nicardipine are predicted to be protonated. The charged tertiary amine groups in these 
substrates are shown in Figure 1A-C (pink). Paclitaxel is predicted to be neutral at pH 7, as shown 
in Figure 1D. Parameters for all four substrates were developed using the ATB24. The ATB can be 
used to generate fully refined parameters for molecules containing less than 50 atoms, based on the 
GROMOS 54A7 forcefield29. Because nicardipine, doxorubicin and paclitaxel contain more than 50 
atoms, each molecule was sub-divided into a series of overlapping fragments, which were submitted 
to the ATB separately. The final parameters for doxorubicin, paclitaxel, morphine and nicardipine 
are available for download from the ATB (Molecule IDs: 10446, 7282, 5089 and 2009 
respectively)24.  
3.3 Unrestrained MD simulations  
A series of unrestrained simulations were performed to study the spontaneous binding of 
each drug to the two alternative model membranes. Substrate molecules were randomly placed in 
the simulation box, above and below either the POPC or POPC: cholesterol (9:1) bilayer. Eight 
drug molecules were added in the case of doxorubicin and paclitaxel and 25 molecules were added 
in the case of morphine and nicardipine. Water molecules that overlapped with the drug molecules 
in the simulation box were removed and additional Cl− ions were added as required to neutralize 
each system. Following this, each system was energy minimized for 1000 steps using a steepest 
descent algorithm. To further relax the solvent, a 50 ps simulation at 300 K was performed. This 
relaxed configuration was then used as the starting structure for a series of three independent 
unrestrained simulations for each of the 8 membrane-substrate systems. The systems were 
simulated for 300 ns and frames were stored every 50 ps for analysis.  
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3.4 Potential of Mean Force (PMF) calculations  
The PMF to move each P-gp substrate across the bilayer was calculated using umbrella 
sampling techniques30. The starting structure for each system was a solvated POPC or POPC: 
cholesterol (9:1) bilayer with the z-axis normal to the plane of the bilayer. A series of harmonic 
potentials were used to fix a given substrate at different positions along the central axis (i.e. normal 
to the plane of the membrane), allowing it to freely move in the x-y plane. A single drug molecule 
was placed along the z-axis 6 nm from the center of the bilayer (z = 0 nm). Overlapping water 
molecules were removed and additional Cl− ions were added to neutralize the system. Each system 
was then energy minimized as described above. Thirteen initial starting configurations for the 
umbrella sampling simulations were generated at 1 nm intervals by pulling each drug along the 
reaction coordinate from z = ±6 nm towards z = 0 nm (see Figure 1E) at a rate of 6 nm/ns. Each of 
these 13 configurations was used to set up four systems for umbrella sampling spaced at 0.25 nm 
intervals, resulting in a total of 49 windows from z = -6 nm to z = 6 nm. In an attempt to avoid any 
directional bias from the pulling simulations, the starting configurations for the umbrella sampling 
simulations at each position were obtained by randomly selecting a configuration from the adjacent 
reference configurations generated. A harmonic potential with a force constant of 500 kJ mol-1 nm-
2 was applied to the center of mass (COM) of the substrate in both the pulling and umbrella 
sampling simulations. Note the incorporation of substrate into one leaflet can induce curvature and 
distortion of the bilayer. To minimize the effect of this on the resulting PMF, the following protocol 
was used to calculate the distance of the substrate with respect to the center of mass of the 
membrane at each umbrella. A cylinder of radius 3 nm was superimposed over the bilayer and 
aligned with the long axis normal to the plane of the bilayer. The axis of the cylinder was aligned 
with center of mass of the substrate. All POPC molecules for which the center of mass lay within 
this cylindrical section were used to calculate the center of mass of the bilayer (z = 0 nm) in the 
immediate vicinity of the substrate. In addition to the induction of curvature, the incorporation of 
substrate in the bilayer can also induce the lateral displacement of POPC and cholesterol, resulting 
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in an asymmetry in the number of lipids in each leaflet of the bilayer within the cylindrical section. 
To account for the effect of this asymmetry, the center of mass of the bilayer was calculated using a 
weighted average. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 Each window was simulated until the derivative of the free energy was considered to have 
converged, after which the simulation was extended for a further 20 ns. The calculations were 
considered to have convergence when the difference between the average of the derivative, 
calculated for a series of 1 ns sliding windows taken every 0.5 ns, did not vary by more than 5 
kJ/mol over a period of 5 ns (10 windows). For three of the substrates, this was sufficient to obtain a 
nearly symmetric PMF. However, this was not true in the case of paclitaxel. For this reason, the 
Substrate Window position (nm) 
Equilibration time (ns) 
Pure POPC POPC + 10 % cholesterol 
Doxorubicin 
-6.00 to -4.25 
-4.00 to -2.50 
-2.25 to 2.25 
2.50 to 4.00 
4.25 to 6.00 
20 
45 
60 
45 
20 
20 
30 
40 
30 
20 
Paclitaxel 
-6.00 to -4.25 
-4.00 to -2.50 
-2.25 to 2.25 
2.50 to 4.00 
4.25 to 6.00 
20 
55 
65 
55 
20 
20 
70 
70 
70 
20 
Morphine 
-6.00 to -4.25 
-4.00 to -2.50 
-2.25 to 2.25 
2.50 to 4.00 
4.25 to 6.00 
20 
30 
40 
30 
20 
20 
40 
50 
40 
20 
Nicardipine 
-6.00 to -4.25 
-4.00 to -2.50 
-2.25 to 2.25 
2.50 to 4.00 
4.25 to 6.00 
20 
40 
55 
40 
20 
20 
45 
60 
45 
20 
Table 2: Simulation timeframe required for each substrate to attain equilibrium for each window. 
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simulations of paclitaxel were extended until the difference between the average of the derivative 
(calculated for a series of 1 ns sliding windows taken every 0.5 ns), did not vary by more than 5 
kJ/mol over a period of 20 ns (40 windows). The final, equilibrated 20 ns of each simulation was 
used to calculate the PMF by integrating the derivative of the free energy with respect to the 
reaction coordinate as described by Kästner and Thiel31, 32. The standard error of the PMF at each 
distance was calculated using the average derivative of the free energy over the final 20 ns. Note, 
the calculated error in the free energy is cumulative over the reaction coordinate. Both the pulling 
and umbrella sampling simulations were performed with the same parameters as used in the 
unrestrained MD simulations. The simulation time required to attain equilibration at each distance 
for all the substrates is given in Table 2. 
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4 RESULTS AND DISCUSSION 
4.1 Spontaneous binding to the lipid bilayers  
All four drugs bound spontaneously to both bilayers. In fact, although initially placed at 
least 3 nm away from the bilayer, doxorubicin, paclitaxel, morphine and nicardipine bound to the 
lipid head groups within 60 ns. Once bound, the vast majority remained bound to the membrane 
surface for the remaining 240 ns of the simulation. In all cases, the molecules bound at the lipid 
head group/solvent interface. However, 
occasionally the tertiary amine aromatic group of 
nicardipine and the methoxy terminal section of 
doxorubicin were observed to penetrate deeper 
into the membrane, just below the head group 
region. This result is consistent with NMR 
studies, which show that doxorubicin, 
nicardipine and other P-gp substrates 
predominately partition into the interfacial region 
of DMPC bilayers33. This is evident in Figure 2A, 
which shows a snapshot from one of the 
simulations of doxorubicin interacting with a 
POPC: cholesterol (9:1) bilayer after 
approximately 100 ns. A representative plot of 
the mass density of doxorubicin and of the head 
groups of the POPC lipids along the z-axis from 
one of the spontaneous binding simulations averaged over the last 240 ns is given in Figure 2B. As 
can be seen, the location of doxorubicin overlaps with that of the head groups. The concentration of 
substrate in the unbiased simulations was approximately 30 mM for doxorubicin and paclitaxel. The 
simulated concentrations of morphine and nicardipine were 90 mM and 80 mM respectively. The 
Figure 2: Spontaneous binding of doxorubicin to 
POPC + 10% cholesterol membrane system. (A) 
A snapshot showing the accumulation of 
doxorubicin (green spacefill) at the lipid water 
interface of the bilayer. (B) A graph showing the 
density of the doxorubicin (green, solid line) with 
respect to the density of the phosphate head 
groups of the bilayer (black, dotted line). 
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approximate in vivo therapeutic concentration of each of these drugs for humans (post drug 
administration) is on the order of 4 mM, 1 mM, 70 mM and 60 mM for doxorubicin, paclitaxel, 
morphine and nicardipine respectively.  
4.1.1 Orientation of substrates  
The nature of the interaction between the substrates and the bilayers was characterized in 
more detail, by calculating the angle between a reference vector that ran along a rigid section of the 
drug and the membrane normal, to determine 
the orientation of each drug molecule. The 
reference vector for each drug is given in 
Figure 3 (red dotted line). None of the 
substrate molecules clearly showed a preferred 
orientation. Doxorubicin, morphine and 
nicardipine adopted angles between 20o and 
160o to the normal when binding to the bilayer. 
The range of angles for paclitaxel was slightly 
narrower, between 20o and 145o. This may be 
due to the overall bulkiness of paclitaxel 
compared to the other three molecules. 
4.1.2 Substrate aggregation  
In the unrestrained MD simulations, different aggregation patterns for each substrate on 
both membranes were observed. Representative snapshots of the aggregation pattern for each 
substrate in both membranes are shown in Figure 4. In the pure POPC membrane simulations, 
morphine displayed little tendency to aggregate on the membrane surface. Nicardipine molecules 
tended to form chain-like structures on the surface of POPC membranes. Doxorubicin molecules 
also formed extended structures on the membrane surface, but not as extensive as nicardipine. 
Figure 3: Chemical structures of the P-gp 
substrates doxorubicin (A), paclitaxel (B), 
nicardipine (C) and morphine (D). The reference 
vector used to calculate the orientation of the 
substrates is shown by the red dotted line. The 
protonated group at pH 7 is shown in pink.  
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Paclitaxel molecules tended to aggregate on the POPC membrane surface. In solution, paclitaxel 
tended to aggregate, forming dimers. On the surface of the POPC: cholesterol (9:1) bilayer, 
doxorubicin and paclitaxel tended to form high order aggregates. The addition of 10% cholesterol 
had only a minor effect on the interaction pattern of each substrate. The main difference was that 
doxorubicin and paclitaxel molecules tended to aggregate more readily in the presence of 10% 
cholesterol-enriched POPC membrane. Additional details on the substrate orientation and 
aggregation states are given below. Note that given the limited duration of the simulations 
compared to the rate of diffusion of the molecules once bound to the bilayer, it is not possible to 
make definitive conclusions regarding the aggregation state of these molecules at the surface of the 
membranes based on these simulations. 
 
Figure 4: Representative aggregation patterns for the four different drug molecules studied, on the pure 
POPC membrane and the POPC + 10% cholesterol membrane. The drug molecules are shown in space-
fill representation (morphine: magenta, nicardipine: cyan, doxorubicin: green, paclitaxel: tan) and the 
POPC heads are shown in pink, using a scaled space-filling representation. The POPC tails are shown 
as grey lines and the cholesterol molecules are shown in gold using a stick representation. 
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4.2 Partitioning of the drugs into the model membranes  
 
To investigate how the substrates partition across the bilayer at equilibrium, the PMF of 
each substrate was calculated along the z-axis from z = -6 nm to z = 6 nm. The PMFs for each drug 
across a POPC or POPC: cholesterol (9:1) bilayer is shown in Figure 5. The PMF gives the relative 
free energy along a chosen reaction coordinate, with respect to a given reference location. The 
relative free energies for each substrate along the PMF are given in Table 3. The PMF was set to 
zero at the reference location, z = -6 nm, where the substrate molecules are in bulk solution.  
 
Figure 5: The potential of mean force (PMF) for doxorubicin (A and B), morphine (C and D), 
nicardipine (E and F) and paclitaxel (G and H) to partition into a pure POPC bilayer (solid line) and a 
POPC + 10% cholesterol bilayer (dashed line). Error bars indicate the cumulative average standard 
error over the equilibrated simulation. 
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Membrane 
Bilayer 
Substrates 
Energy minimum 1 Energy minimum 2 
Reaction 
coordinate 
Relative free 
energy 
(kJ/mol) 
Reaction 
coordinate 
Relative free 
energy 
(kJ/mol) 
POPC  
Doxorubicin z = -2 nm -9 ± 1 z = 2 nm -11 ± 2 
Morphine z = -2.3 nm -11 ± 2 z = 2.2 nm -12 ± 5 
Nicardipine z = -1.7 nm -13 ± 1 z = 1.6 nm -13 ± 2 
Paclitaxel z = -1.9 nm -6 ± 1 z =-2.3 nm -6 ± 2 
POPC + 
10% 
cholesterol 
Doxorubicin z = -2 nm -21 ± 3 z = 2 nm -21 ± 3 
Morphine z = -2 nm -4 ± 1 z = 2 nm -4 ± 2 
Nicardipine z = -1.5 nm -31 ± 3 z = 1.3 nm -31 ± 6 
Paclitaxel z = -1.7 nm -7 ± 1 z = 1.8 nm -8 ± 1 
 
 
Table 3: Relative free energy of four P-gp substrates calculated in both pure POPC and POPC + 10% 
cholesterol bilayers at each of the energy minimum windows. 
Figure 6: Snapshots of paclitaxel partitioning into a POPC bilayer. (A) At z = 0.75 nm, paclitaxel is 
orientated parallel to the membrane. (B) At z = -0.75 nm, the orientation of paclitaxel is approximately 
normal to the plane of the membrane. (C) and (D) The orientations of paclitaxel  at z = 2 nm and (D) at z 
= -2 nm, are not the same, however they are not significantly distinct. Paclitaxel is shown in a yellow 
space-fill representation. The POPC head groups are shown as red and blue sticks and the lipid tails are 
shown in a line representation (grey). 
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Figure 5C shows that there is a large energy barrier of approximately 30 kJ/mol for 
morphine to cross the POPC bilayer from the solution. This barrier is not present for any of the 
other three substrates. Indeed for doxorubicin, paclitaxel and nicardipine, the difference between the 
free energy in solution and that in the bilayer is on the order of kT as shown in Figure 5. Note, in 
principle the PMF across the membrane should be symmetric. However, as can be seen in Figure 5, 
they clearly are not. While the initial regions of the PMFs for doxorubicin, paclitaxel and 
nicardipine are almost identical up to the central plane of the membrane (from z = -6 nm to z = 0 
nm); they diverge somewhat past the central plane (from z = 0 nm to z = 6 nm). This indicates that 
despite extensive equilibration (Table 2), the simulations are not fully converged. This is most 
evident in the case of paclitaxel (Figure 5G), which is the largest and bulkiest of the substrates 
studied. This asymmetry arises due to variations in both the conformation and the orientation of the 
substrate with respect to the membrane that are not fully sampled on the timescales examined. This 
is most evident when the COM of paclitaxel is ±0.75 nm from the center of mass of the pure POPC 
membrane. At z = 0.75 nm, the long axis of paclitaxel is oriented approximately parallel to the 
plane of the membrane; while at z = -0.75 nm it is almost perpendicular to the membrane (Figure 6). 
These appear to represent different local minima on the free energy surface and interconvert very 
slowly. Despite this, the overall shape of the curves is clear. The PMFs for each substrate show 
energy minima at each of the lipid head regions, corresponding to the location where drugs 
spontaneously bound in the unrestrained simulations.  
The presence of energy minima in the head group regions most likely stems from 
interactions between the tertiary amine groups of the substrates and the phosphate groups of the 
POPC lipids. The formation of the hydrogen bonds between the substrates and the phosphate group 
of POPC in their energy wells identified from the PMF across pure POPC and POPC + 10% 
cholesterol is given in Figures 7 and 8 respectively. Each substrate form different numbers of 
hydrogen bonds with the phosphate head groups. Doxorubicin up to two hydrogen bonds (Figure 
7A-B and 8A-B), morphine forms three hydrogen bonds (Figure 7C-D and 8C-D), nicardipine 
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forms only one hydrogen bond (Figure 7E-F and 8E-F) and paclitaxel could form up to four 
hydrogen bonds with the lipid head groups (Figure 7G-H and 8G-H).  
 
The PMFs for each substrate across a POPC: cholesterol (9:1) bilayer is shown in Figure 5. 
As can be seen, substituting POPC with 10% cholesterol has a marked effect on each of the profiles. 
In fact, in the case of morphine the energy barrier to cross the bilayer evident in Figure 5C is almost 
completely removed in Figure 5D. The depth of the energy wells in the region of the POPC head 
groups has also been reduced in the case of morphine, with the resulting PMF being approximately 
flat. The PMFs of the other three substrates in a POPC: cholesterol (9:1) bilayer is also shifted 
systematically lower, leading to increases in the depth of the energy wells. Experimentally, 
cholesterol is known to enhance doxorubicin accumulation within cell membranes17, 18. 
Figure 7: The formation of hydrogen bonds between the substrates (A) and (B) doxorubicin (DOX), 
(C) and (D) morphine (MOI), (E) and (F) nicardipine (NCP), (G) and (H) paclitaxel (PXL) and the 
phosphate groups of POPC during the last 20ns of the equilibrated simulation in their respective 
energy wells across the pure POPC bilayer obtained from Table 3. 
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Our results show that the incorporation of cholesterol into a POPC bilayer lowers the relative free 
energy of the PMF at the lipid head group region, increasing the likelihood of doxorubicin being 
found within the bilayer. This effect is most apparent for nicardipine, which has energy wells of 
approximately -30 kJ/mol just below the lipid head group region, at approximately z = ±1 nm 
(Figure 5F). As can be seen from Figure 5, the depth of the minima in the head group regions of the 
PMFs of doxorubicin (Figure 5B), nicardipine (Figure 5F) and paclitaxel (Figure 5H) have changed 
from approximately -10 kJ/mol in the absence of cholesterol to between -10 and -30 kJ/mol in the 
presence of 10% cholesterol. It is predicted that paclitaxel would also accumulate to a greater 
degree in the presence of cholesterol. As the maximum value of the free energy in the membrane is 
always either similar to or lower than that of these substrates in solution, there is no net barrier to 
Figure 8: The formation of hydrogen bonds between the substrates (A) and (B) doxorubicin (DOX), 
(C) and (D) morphine (MOI), (E) and (F) nicardipine (NCP), (G) and (H) paclitaxel (PXL) and the 
phosphate groups of POPC during the last 20ns of the equilibrated simulation in their respective 
energy wells across the POPC with 10% cholesterol bilayer obtained from Table 3. 
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crossing the membrane. All four substrates are predicted to be able to passively diffuse across a 
POPC: cholesterol (9:1) bilayer. The PMFs shown in Figure 5 suggest that doxorubicin and 
nicardipine in particular should spontaneously embed in the membrane at ±1 nm from the center of 
the bilayer, within the span of the hydrophobic lipid tails. This would also be expected from the fact 
that these molecules have substantial hydrophobic regions but was not observed in the unrestrained 
simulations. Instead, the molecules remained located at the surface of the membranes and only 
rarely dipped below the head group region. This is most likely simply a reflection of the timescales 
of the simulations and the fact that large molecules such as doxorubicin and paclitaxel, once bound 
to a membrane, diffuse very little on a nanosecond timescale. Experimental studies have estimated 
the time taken for doxorubicin to cross the bilayer via diffusion in the presence and absence of 
cholesterol to be approximately 1 min and 0.7 min, respectively34.  
4.3 Implications for drug uptake  
The combination of the spontaneous binding simulations and the PMF calculations suggest 
that each of the compounds investigated binds readily to phospholipid bilayers. Only in the case of 
morphine was a significant barrier to crossing the bilayer observed. The high barrier in the case of 
morphine could reflect the fact that morphine has the highest charge density and must be partly 
desolvated to cross the membrane. Indeed, during the PMF calculations water molecules were 
observed to remain associated with morphine throughout the calculations, even when morphine was 
in the center of the bilayer. Water molecules also remained associated with the polar groups of 
doxorubicin, paclitaxel and nicardipine.  
Based on the PMFs in Figures 9A and B, all of the substrates would be expected to 
passively cross the bilayers. For doxorubicin, paclitaxel and nicardipine, there was no net barrier in 
the case of a pure POPC bilayer (Figure 9A). Although the barrier for morphine is on the order of 
30 kJ/mol, it is still expected that morphine would spontaneously cross cholesterol-depleted cell 
membranes on a physiologically relevant time scale. The presence of cholesterol removes this 
barrier (Figure 9B). The fact that regions of the PMF for all substrates are negative relative to water 
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suggests that they would all preferentially 
partition into the bilayer until it is saturated. 
The extent to which doxorubicin, 
paclitaxel and nicardipine will accumulate 
in the membrane will be greatly enhanced 
by the presence of cholesterol. For 
example, in the case of nicardipine the 
difference in the depth of the energy 
minima in the presence or absence of 
cholesterol is on the order of 20 kJ/mol, 
which would correspond to an increase in 
its concentration in the bilayer of more 
than 3 orders of magnitude at physiological 
temperatures. As noted earlier, various models have been proposed to account for how alternative 
drug molecules may be taken up by P-gp. It is generally assumed that substrate molecules are either 
trafficked to P-gp from the cytosol or directly sequestered from the inner leaflet of the membrane. 
Membrane cholesterol has been shown to increase the pumping efficiency of P-gp. If P-gp uptakes 
substrate molecules directly from the membrane, the large increase in substrate concentration in a 
POPC: cholesterol (9:1) bilayer suggested by this study could explain the increase in efficiency of 
P-gp.   
Figure 9: The potential of mean force of the four P-gp 
substrates across  (A) POPC bilayer (solid line) and (B) 
POPC + 10% Cholesterol bilayer (dashed line). 
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5 CONCLUSION 
In this study, a combination of MD simulations and PMF calculations are used to 
investigate the effect of cholesterol on the partitioning of four P-gp substrates across a POPC lipid 
bilayer. It was found that the P-gp substrates doxorubicin, paclitaxel, morphine and nicardipine all 
spontaneously interacted with the lipid head group region of a POPC or POPC: cholesterol (9:1) 
bilayer as expected. The PMFs indicated that while the most energetically favorable position for the 
drugs in a membrane with or without 10% cholesterol is at the lipid head region, all four substrates 
are predicted to passively cross both bilayers on a physiologically relevant timescale. The PMFs 
clearly show that, in the presence of cholesterol, the free energy associated with entering the middle 
of the bilayer is greatly reduced. In the case of morphine the barrier to cross the membrane is 
lowered by approximately 30 kJ/mol. In the case of the other three substrates, cholesterol is 
expected to give rise to an increase in membrane solubility. The effect was small in the case of 
paclitaxel. However, in the case of doxorubicin and nicardipine the presence of cholesterol is 
predicted to increase the local concentration of the substrate significantly. These findings are in line 
with previous experimental studies involving doxorubicin. They suggest that the enhanced pumping 
activity of P-gp in the presence of cholesterol may be related to the preferential accumulation of P-
gp substrates in cholesterol-rich regions of the membrane, as opposed to the direct effect of 
cholesterol on the activity of P-gp itself. The work also suggests that the effect of cholesterol on the 
efficiency of P-gp may be highly substrate dependent. 
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1 ABSTRACT 
 P-glycoprotein (P-gp) is a multidrug transporter and an integral membrane protein of clinical 
significance. To understand P-gp's mechanism of transport, and use relevant starting points for 
rational inhibitor development, it is crucial that reliable structural information is available. While 
multiple crystal structures of P-gp are available, inconsistences between these structures leave many 
questions related to the underlying mechanism of transport unanswered. In particular, three 
alternative structures of mouse P-gp all solved at 3.8 Å resolution have different assignments in the 
amino acid register in four of the twelve transmembrane helices. These are the structures 3G5U 
published in 2009, 4KSB published in 2013 and 4M1M published in 2014, which is a revised 
version of 3G5U. In this work, molecular dynamics (MD) simulations have been used to investigate 
the stability of these three structures in order to identify which structure may best represent that of 
P-gp under physiological conditions. Each P-gp structure was incorporated into a cholesterol-
enriched POPC membrane and simulated under conditions that closely match those in which P-gp is 
functionally active. The results obtained from the simulations offer valuable insights into the 
dynamics of P-gp. They show that while the protein is able to adopt a wide range of conformations, 
some common features are evident between the three structures. In particular, the registry of amino 
acids in the TM helices 3, 4 and 5 in all three simulations converge to a similar conformation, 
which nevertheless varied, among all of the crystal structures. 
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2 INTRODUCTION 
 The multidrug efflux pump, P-glycoprotein (P-gp) is a member of the ABC transporter 
superfamily. X-ray crystallographic studies have been conducted on multiple prokaryotic and 
eukaryotic members of this superfamily1-9. Indeed, there are currently more than 50 structures of 
homologous ABC transporters, solved in isolation or in complex with ATP analogues, cyclic 
inhibitors or nanobodies, in a variety of conformations2-4, 6, 8, 9. The known structures of ABC 
transporters can be broadly grouped as outward facing, in which the transmembrane (TM) pore is 
open to the extracellular side (a V-shape) and the nucleotide binding domains (NBDs) are 
dimerized; or inward facing, in which the TM pore is open to the cytoplasmic side (an inverted V-
shape). Thus there may be great structural diversity within the ABC transporter family. However, to 
obtain these structures it has been necessary to remove the protein from its membrane environment 
and solubilize it in detergent, which makes interpretations of the biologically relevant 
conformation(s) less reliable. Indeed, in the case of the inward facing P-gp structures, questions 
have been raised as to the physiological relevance of the widely splayed inverted V-shape10. Despite 
these structures becoming available in recent years, a detailed understanding of the mechanism by 
which many ABC transporter proteins, in particular, P-gp operate remains elusive.  
 The structure of mouse P-gp, which has 87% amino acid sequence identity to human P-gp, 
was first solved using X-ray diffraction techniques in 2009, at a resolution of 3.8 Å (PDBID 3G5U) 
by Aller et al2. The asymmetric unit of the crystals, shown in Figures 1A and B, obtained in the apo 
(substrate and nucleotide free) form contains two molecules of P-gp, referred to as P-gp-A and P-
gp-B. In addition to the apo form, Aller et al. were able to crystallize and solve the structure for P-
gp in complex with two stereoisomers of a hexapeptide inhibitor, cyclic-tris-(R)-valineselenazole 
(QZ59-RRR, PDBID 3G60) and cyclic-tris-(S)-valineselenazole (QZ59-SSS, PDBID 3G61). These 
inhibitor-bound structures were solved at a resolution of 4.40 Å and 4.35Å, respectively2. The 
conformation of P-gp in these structures corresponds to the inward-open conformation with the 
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NBDs separated by ~4.4 nm measured between the centers of mass (COM) of each NBD. The 
flexible linker region (residues 627-683) connecting NBD1 and transmembrane domain 2 (TMD2) 
could not be resolved and is missing from the model. However, previous studies of co-expressed 
half-transporters of P-gp devoid of the linker region have demonstrated that the drug-stimulated 
ATPase activity is similar to that of the complete transporter, suggesting that an intact linker is not 
required for drug-coupled ATPase hydrolysis11. Residues 1–33 and 1272–1276 at the N- and C- 
termini, respectively, are also missing from the 3G5U structural model. 
 
Figure 1: The packing for P-glycoprotein (P-gp) in the 3G5U/4M1M crystals and for the 4KSB 
crystals. The asymmetric unit of 3G5U/4M1M contains two P-gp molecules: (A) P-gp-A shown in front 
and (B) P-gp-B shown in front. (C) shows the view with nucleotide binding domain 1 (NBD1) is on the 
right (green) and (D) The NBD1 is on the left of the 4KSB structure surrounded by the closest 
molecules in the crystal packing. In all cases, the transmembrane domains (TMDs) are shown in 
multicolor cartoon representation. NBD1 is green and NBD2 is red. The crystal packing of (A) and (B) 
are shown in cyan and green and (C) and (D) are shown in cyan. 
 160 
 In 2012, a P-gp structure was reported for C.elegans, resolved to 3.4 Å resolution4 and 
captured in an inward-open state similar to that of mouse P-gp, but with an even larger separation of 
the NBDs (~6.0 nm, measured between the center of mass of each NBD). While the sequence 
identity between C.elegans and mouse P-gp is only 46%, comparison of the two structures 
suggested a possible registry shift in three of the transmembrane helices in the mouse P-gp structure. 
Previous molecular dynamics (MD) simulations carried out using the 3G5U P-gp also showed a 
number of discrepancies between distances inferred from experimental cross-linking studies and the 
3G5U structure12. These findings prompted Aller and coworkers to revisit the original diffraction 
data and refine the structure in the light of this new information. They used a different phasing 
approach, namely single-wavelength anomalous dispersion (SAD), where the original work was 
based on the multi-wavelength anomalous dispersion (MAD) with mercury labeled protein. The 
advantage of SAD phasing is that only a single dataset from a single crystal is required compared to 
at least two being required for MAD. This minimizes the radiation damage to the crystal13. In this 
case, SAD phasing also resulted in a more complete model than the original structure, indicated by 
the reduction in the final Rwork and Rfree values of the revised structure (a 9.4 and a 8.1% decrease, 
respectively). Rwork is a measure of the agreement between the crystallographic model and the 
diffraction data. Rfree is the value of R calculated with a portion of the dataset that is omitted from 
the complete dataset and is a measure of the degree of over fitting the data. The resulting refined 
model (PDB ID: 4M1M)8 contained multiple corrections throughout the structure with respect to 
the 3G5U crystal structure. Overall, the new model contained significant improvements in the 
backbone compared to the original structure, namely, the extent to which the ψ-φ values were in 
favorable regions of the Ramachandran plot, bond angles and reductions in steric clashes between 
residues, in addition to the decreased Rwork and Rfree values. Of the comprehensive set of changes 
listed by Aller and coworkers8, the register shifts in TM3, TM4, TM5 and TM12 are the most 
notable, and comprised of (1) a 90° rotation (one residue register shift) of TM3; (2) a four-residue 
registry shift (360° rotation and one-turn translation) of TM4; (3) a 90° rotation of TM5 and (4) a 
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rebuild of TM12 residues 968–987 to correct for a gradual and increasing registry error. In addition, 
the improved density map allowed the N-terminus to be extended for 3 residues into a region, which 
could not be resolved previously. However, there was no difference in the NBDs between the 3G5U 
and 4M1M crystal structures. The mouse structures containing the heptapeptide inhibitors were also 
re-refined (PDB ID: 4M2S, 4M2T)8.  
 Recently, Ward et al. solved the crystallographic structure of mouse P-gp in the presence 
and absence of a nanobody bound to NBD19. Three new structures were made available under PDB 
IDs: 4KSB, 4KSC and 4KSD9. The two apo forms 4KSB (3.8 Å resolution) and 4KSC (4.0 Å 
resolution), resulted from two different crystal forms obtained under experimental conditions 
different to those used by Aller et al9. An image of the unit cell for the crystal models of 4KSB P-gp 
is shown in Figures 1C and D. The three structural models (PDB ID: 4KSB, 4KSC and 4KSD) all 
feature a splayed conformation with the two NBDs being well separated. Indeed, the distances 
between the COMs of the two NBDs (~6 nm) was comparable to that observed in the C.elegans P-
gp model. Again, the flexible linker region between NBD1 and TMD2 was not resolved and the 
residues corresponding to the N-terminus (1–33) and C-terminus (1272–1276) are also missing. 
Although not explicitly commented on by Ward et al9, this structure contained a one-residue 
register shift in TM3; a four-residue registry shift in TM4, and a one-residue registry shift in TM12 
compared to the 3G5U structure. Comparing the highest resolution structure from each publication, 
namely 3G5U, 4M1M and 4KSB, one finds three alternate structures for mouse P-gp, each resolved 
at 3.8 Å, and none of which contain the same amino acid register assignment throughout the entire 
protein.  
 The separation between the NBDs also varies in these structures. A range of distances has 
been reported for the different bacterial and eukaryotic P-gp homologues in the presence and 
absence of ATP and its derivatives solved under different crystallization conditions14-16 implying 
that there is significant conformational flexibility for ABC transporters. Figure 2 shows a 
superposition of the three crystal structure models (PDB ID: 3G5U, 4M1M and 4KSB) for mouse 
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P-gp in the apo form. Table 1 lists the root mean squared deviations (RMSD) between these models 
based on the backbone atoms of the entire protein, and of the TMDs only. The structures of 3G5U 
(black) and 4M1M (blue) are very similar with respect to 4KSB (green). However, there is 
difference in the NBD separation between 4KSB and 3G5U/4M1M. The difference in the RMSD 
between 3G5U and 4M1M is ~0.2 nm when come comparing the whole protein or the TMDs. This 
difference in the RMSD comes from the registry shifts among various residues in TM 3, 4, 5 and 12. 
However, the difference between 3G5U or 4M1M and 4KSB is ~0.6nm, which is mainly due to the 
widely splayed conformation and the distance between the NBDs.  
 
Mouse P-gp Protein RMSD (nm) TMDs RMSD (nm) 
3G5U-A 0 0 
4M1M-A 0.22 0.25 
4KSB 0.64 0.36 
Figure 2: Three different crystal structures overlapped by aligning backbone atoms of the TMDs (A) 
front view, (B) side view with NBD1 at front, (C) back view and (D) side view with NBD2 facing front. 
The 3G5U crystal structure is black, 4M1M in blue and 4KSB in green. Proline residues in the TMD 
regions are in red, orange and yellow, for the three crystal structures respectively. 
Table 1: RMS deviation (RMSD) of the protein backbone for two more recent mouse P-gp structures 
(4M1M, 4KSB) compared to the originally published structure (3G5U). RMSD for the backbone atoms 
of TM helices is also shown. 
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 While P-gp is assumed to sample a range of conformations as a part of its transport cycle, 
the question arises as to whether any of the crystallographic structures correspond to a 
physiologically relevant conformation for this transmembrane protein. The physiological relevance 
of these structures has implications for our understanding of the spectrum of conformations that P-
gp can adopt in its native state and the dynamics that modulate protein function. One of the 
approaches used to address this issue is MD simulation. MD simulations performed under 
conditions that closely replicated the crystallographic liqueur demonstrated that the splayed 
crystallographic conformation is maintained in the presence of detergent12. In these simulations, 
detergent bound to the TMDs and aggregated between the widely splayed NBDs, stabilizing the 
crystallographic conformation12. In contrast, MD simulations of membrane-embedded P-gp 
demonstrated that the conformation of P-gp is sensitive to the phospholipid composition of the 
membrane. Simulations of 3G5U P-gp embedded within a pure DMPC17 or POPC12 bilayer showed 
the protein tilt and become progressively more deformed throughout the simulations. This was 
attributed to a mismatch between the hydrophobic belt of the protein and the thickness of the 
membrane due to the absence of cholesterol17. Experimentally, the ATPase activity of P-gp is 
known to be highly dependent on membrane composition18. MD simulations have consistently 
shown that when P-gp is incorporated into a membrane environment mimicking conditions under 
which P-gp is functionally active, its conformation diverges from the proposed crystal structures12, 
14, 16, 17, 19, 20. It has been also shown that the conformations obtained from these simulations provide 
a better match to the majority of the biochemical cross-linking data than any of the available crystal 
structures12.  
 In this Chapter, the structural and conformational stability of the three 3.8 Å 
crystallographic models of mouse P-gp (PDB ID: 3G5U, 4M1M and 4KSB) are examined. 
Specifically, each P-gp structure, embedded in a cholesterol-enriched POPC bilayer, has been 
simulated for 100 ns. The resulting conformations have been compared to their respective 
crystallographic conformation as well as to each other. It has been shown that all three structures 
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undergo significant conformational fluctuations. While the exact starting structure was not retained 
in any of the simulations, suggesting none of the proposed crystal structures may truly represent the 
physiologically relevant membrane bound conformation, however, some consistent trends were 
observed. 
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3 METHODOLOGY 
3.1 System setup 
 The starting configurations of the three P-gp structures for the MD simulations were taken 
from the crystal structures of 3G5U2, 4KSB9 and 4M1M8. The protonation states of all three P-gp 
structures were assigned using the protocol described by O’Mara and Mark12. Specifically, the 
pKa values of all ionizable groups of the all three P-gp structures were predicted using the PROPKA 
server21, 22 and the initial protonation states of the relevant groups at pH 7.4 were assigned 
accordingly.  In all three P-gp structures, a number of residues at the N- and C- termini, and the ~60 
residue linker between NBD1 and TMD2 were not resolved. Thus, the crystal structures of P-gp all 
consist of two polypeptide chains corresponding to the N- and C-terminal halves of the transporter. 
To avoid the incorporation of inappropriate charges into each protein, the N-terminal residue of 
each polypeptide chain was acetylated and the C-terminal residue was aminated.  
 To compare the flexibility of the three P-gp structures, each structure was embedded in a 
POPC bilayer enriched with 10% cholesterol. The parameters for POPC were taken from Poger et 
al.23 and the parameters for cholesterol were the same as used by O’Mara and Mark12. All 
simulation systems were solvated with SPC water and an electrolyte concentration of 150 mM NaCl 
and 1.5 mM MgCl2 was added to the system to mimic the experimental conditions under which P-
gp remains functionally active. In each case, additional Cl- counter ions were added to neutralize the 
charge of the system. Each system was energy minimized using a steepest descent algorithm. To 
initiate the simulations, the 3G5U and 4M1M P-gp systems were equilibrated while the position 
restraints on the protein backbone were gradually relaxed over 10 ns. In the case of 4KSB, the 
position restraints were released over a period of 30 ns to allow additional time for the splayed 
conformation of the NBDs to gradually adjust to the solvated membrane environment. After the 
removal of the restraints, new velocities were assigned and each system was run in triplicate for 100 
ns. The simulation parameters used were identical to those described in Chapter 2. 
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3.2 Analysis 
Root mean squared deviation (RMSD) 
 As a measure of the difference between configurations extracted from the trajectories or 
clusters, the RMSD was calculated using the method of Maiorov and Crippin24 after first 
performing a rotational and translational fit of each frame of the trajectory to a reference structure 
or domain. In order to make the RMSD effectively independent of the number of atoms, Maiorov 
and Crippin proposed a normalization of the mean in their RMSD calculation; making it the best 
method available, while the conventional method of RMSD calculation will fail.  
Cluster Analysis 
 To determine the relative populations of specific conformations the trajectories were 
clustered using the method of Daura et al.25, 26. The RMSD between the two molecules of P-gp in 
the asymmetric unit is 0.33 nm, which can be attributed to small lateral translations between the 
positions of the elongated TM helices. Structurally, both adopt the same conformation and are 
considered to be conformational neighbors. To ensure that these conformations were clustered 
together, a C RMSD cut-off of 0.4 nm was used for clustering.  
Separation of the NBDS 
 The distance between the NBDs was measured as the distance between the geometric center 
of mass (COM) of NBD1 and NBD2.  
Helix geometry 
 The geometry of the TM helices was analyzed using the tool HELANAL, which computes 
the local helix axes and local helix origins for 4 contiguous C atoms in helices that are at least 9 
residues long27.  This method can be used to characterize whether a helix is linear, curved or kinked 
in terms of local parameters, such as the unit twist and unit height of the -helix. The local helix 
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origins traces the path described by the helix in three-dimensional space i.e. the centroid line 
through the center of helix.  
 168 
4 RESULTS AND DISCUSSION 
4.1 Overall conformation of P-gp 
A series of nine unrestrained MD simulations, three for each of the P-gp structures (3G5U, 
4M1M and 4KSB) were performed to examine the stability and conformational flexibility of the 
protein when embedded within a membrane. Each simulation was performed for 100 ns. In all cases, 
the protein deviated from the starting crystal 
structures by a similar amount. The RMSDs of 
the entire protein backbone are shown in 
Figures 3 for all three systems. In the first 10 
ns of the simulations, the RMSDs of the 
protein backbone rapidly increase to between 
0.6 and 0.8 nm for 3G5U, 0.55 and 0.7 nm for 
4M1M and 0.6 and 1.0 nm for 4KSB 
simulations. The rate of change in the 
backbone RMSD asymptotes after the first 10 
ns of simulation gives a final RMSD of 
between 0.6 and 1.1 nm after 100 ns of 
simulation. The overall protein backbone 
RMSD fluctuates throughout the simulation 
and increases from 0.6 to 1.1 nm in the case of 
run1 of the 3G5U P-gp simulations (Figure 
3A). A similar trend for the protein backbone RMSD of 4M1M was observed with the RMSDs 
increasing from 0.45 to 0.9 nm (Figure 3B). The protein backbone RMSD for the 3G5U and 4M1M 
simulations averaged over the last 80 ns of the all runs are 0.77  0.12 nm and 0.75  0.10 nm 
respectively. The protein backbone RMSD in the case of the 4KSB simulations fluctuates during 
Figure 3: RMSD of P-gp backbone atoms for (A) 
3G5U, (B) 4M1M and (C) 4KSB system from the 
starting structure coordinates during 100 ns. The 
runs 1, 2 and 3 are in black, magenta and cyan 
respectively. 
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the first 10-15 ns and then plateaus after approximately 25 ns of simulation (Figure 3C). The protein 
RMSD of all three runs of 4KSB stabilizes at approximately at 0.9, 1.0 and 1.0 nm respectively. 
The protein backbone RMSD of 4KSB is 1.01  0.08 nm averaged over the last 80 ns of all three 
simulations. It should be noted that the RMSD is a non-linear measure of the positional deviation of 
the protein. Here these changes are due to the large translational (and rotational) motion of the 
NBDs, the motion of the TMD-NBD interface and the conformational changes in the TMDs. 
Overall, the RMSD can provide information about the existence of deviation (motion), but not 
about the origin of the change in coordinates.  
4.2 Association of NBDs 
 All of the P-gp structures (3G5U, 4M1M and 4KSB) undergo significant conformational 
changes. The common characteristic in all cases was the rapid association of the NBDs, which takes 
place within first 10 ns of each simulation. The distances between the between the COMs of the 
NBDs in each of the three runs of the 3G5U, 4M1M and 4KSB structures are shown in Figures 4A-
C respectively. The change in the distance between the NBDs for 3G5U and 4M1M compared to 
the starting structures are ~0.9 and ~1.0 nm respectively. The change is most dramatic in the 
simulations of 4KSB (~2.3 nm) where the initial separation between the NBDs was the largest. 
Figure 4: Distances between the center of mass of the two NBDs in (A) 3G5U P-gp system, (B) 4M1M and 
(C) 4KSB as a function of the simulation time (3x100 ns for each system). The triplicate runs are shown 
in black (run1), magenta (run2) and cyan (run3). 
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 After the rapid association of the NBDs, they stay in close contact throughout the remainder 
of the simulation in most cases. In the simulations of 3G5U, the distance between the two NBDs 
fluctuates between 3.3 nm and 4.0 nm throughout the simulation (Figure 4A). The most drastic 
change in the distance between the NBDs is observed for run2 of 3G5U, where the distance varied 
between 2.9 nm and 4.1 nm. The distance between the COM of the NBDs in 3G5U averaged over 
the last 80 ns of all three runs is 3.55  0.25 nm. In the 4M1M simulations, the distance between the 
Figure 5: Snapshot of P-gp showing the conformations of the NBDs. (A) A compact conformation of 
the NBDs observed in run1 of the 4M1M P-gp simulations shown in front and top view (viewed from 
the extracellular side). (B) An example of a highly diverged conformation of the NBDs with respect to 
the starting conformation observed in the run3 of the 4KSB P-gp simulations shown in front and top 
view (viewed from the extracellular side). The TMDs are shown in in white cartoon representation. 
NBD1 and NBD2 are in ice blue and pink respectively. 
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COM of the NBDs in run1 and run3 varies around 3.4 nm and 3.3 nm respectively. However, large 
variations in the NBD distances were observed in run3, where the distances fluctuated from 3.5 nm 
to 4.3 nm. The average distance between the COM of the NBDs in 4M1M simulations calculated 
over the last 80ns is 3.34  0.30 nm. As the 4KSB had the most splayed NBD conformation, the 
distance between the NBDs rapidly fluctuated in the first 25 ns of the simulation. During the first 25 
ns the NBD distances ranged from 3.5 nm to 5.0 nm in the case of run1, from 3.3 nm to 4.7 nm for 
run2 and from 3.9 nm to 4.8 nm for run3. The final distance between the COM of the NBDs in all 
three runs converged to 3.75 nm. The distance between the COM of the NBDs in 4KSB simulations 
averaged over the last 80 ns of all three runs is 3.71  0.16 nm only slightly greater than 3G5U or 
4M1M.  
 Despite the close association of the NBDs, the NBDs did not make necessary interactions 
with each other to form a “nucleotide sandwich dimer” which is important for the hydrolysis of the 
ATPs as proposed by Jones et al.28, 29. This could be mainly due to the absence of the nucleotides. 
However, the interaction between the NBDs is non-specific, giving rise to a range of different 
conformations in this loose NBD1/NBD2 complex. Figure 5 shows the conformational extremes 
observed for the association of the NBDs. In simulations arising from all three P-gp structures, the 
conformation of both NBD1 and NBD2 are relatively compact (Figure 5A) and are preserved 
during the entire simulations (~3.5 nm RMSD compared to each respective crystal structure). 
However, as it can be seen in Figure 5B, the TMD-NBD contact interface is not extensive and 
consists of a loose association between the domains. There is a partial or complete dissociation of 
either the NBD1-TMD1 or NBD2-TMD2 interface in 4 of the 9 simulations. This might be a 
consequence of the association of the NBDs. The association of NBD1 and NBD2 occurs more 
rapidly than the corresponding motion of the TMDs, suggesting that longer sampling times are 
needed to allow the entire system to adapt to the new conformation of the NBDs.  
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 The relatively large separation of the NBDs in the crystal structures could be due to crystal 
packing effects. The closest contacts in the crystal environment for 3G5U and 4M1M are shown in 
Figures 1 A and B. In both crystals, the NBDs are nested in the cavity created by at least three of 
the surrounding P-gp molecules. These interactions may stabilize the relatively large separation of 
the NBDs in the crystal. Previous MD simulations of the 3G5U structure in the presence of the 
detergent cholate showed that the detergent stabilized the separated NBDs12. The crystal contacts of 
4KSB, shown in Figures 1C and D, reveal that the space between the widely splayed NBDs is 
occupied by the vortex of an adjacent P-gp molecule, which may play a role in stabilizing the large 
separation of the NBDs observed in this structure.   
4.3 Structural changes in the NBDs 
 To see if the conformation of the NBDs diverged from that of their respective crystal 
structure, over the course of the simulation the backbone RMSD of the NBDs was calculated. The 
RMSDs of NBD1 and NBD2 calculated over the 100 ns simulation for all three P-gp structures are 
given in Figure 6. The RMSD of NBD1 of 3G5U, 4M1M and 4KSB for each run is gradually 
increased throughout each simulation. The final RMSD of 3G5U NBD1 for each run is 0.32 nm, 
0.32 nm and 0.34 nm. The NBD1 RMSDs of 4M1M are 0.29 nm, 0.28 nm and 0.29 nm for runs 1, 
2 and 3 respectively. The RMSD of the 4KSB NBD1 for run1 is 0.32 nm, run2 is 0.30 nm and run 3 
are 0.38 nm. The RMSD of the NBD2 in all 9 simulations fluctuated between 0.16 and 0.51 nm. 
The RMSDs of 3G5U NBD2 are 0.37, 0.30 and 0.37 for runs 1, 2 and 3 respectively. The highest 
fluctuations of the NBD2 RMSD was observed for run3, where the highest RMSD was ~0.5 nm. 
The final RMSD of 4M1M NBD2 in all three runs are 0.28 nm, 0.30 nm and 0.32 nm. In the 4KSB 
simulations, the RMSDs of NBD2 gradually increased throughout the simulation to 0.29 nm for 
run1, 0.37 for run2 and 0.31 for run3. The average RMSDs of NBD1 and NBD2 calculated over the 
last 80 ns of the 3G5U simulations are 0.29  0.03 nm and 0.28  0.04 nm respectively. The 
average RMSDs for NBD1 and NBD2 for 4M1M are 0.27  0.02 nm and 0.30  0.03 nm and that 
of 4KSB are 0.34  0.03 nm and 0.29  0.04 nm respectively. 
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4.4 Structural changes in the TMDs 
The TMDs of P-gp consist of 12 helices, which extend past the membrane and into the 
cytosol. During the simulations the TMDs do not undergo the large translational motions like those 
observed for the NBDs. Nevertheless, the TMDs are quite dynamic. The overall motion of the 
TMDs cannot be described in terms of rigid body motion. A plot showing the backbone RMSD of 
the TMDs for all three structures is shown in Figure 7. In the simulations of 3G5U and 4M1M P-gp 
structures, the backbone RMSD of the TMD regions fluctuated in the first 10 ns of the simulation in 
all three runs. The final TMD backbone RMSD of 3G5U and 4M1M varied between 0.37 and 0.49 
nm; and 0.35 and 0.45 nm respectively. The TMD backbone RMSD of 4KSB fluctuated for the first 
Figure 6: The backbone RMSD of NBD1 and NBD2 of (A) 3G5U, (B) 4M1M and (C) 4KSB P-gp 
simulations, measured from their starting structures over 100 ns. Run 1 is black, run 2 is cyan and run 3 
is magenta. 
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20 ns and the final RMSD range from 0.36 
to 0.51 nm. The TMD backbone RMSDs 
calculated for all three P-gp structures 
averaged over the last 80 ns of the all runs 
are 0.38  0.03 nm, 0.34  0.04 nm and 
0.36  0.04 nm for 3G5U, 4M1M and 
4KSB P-gp respectively. However, in all 
the 9 simulations, the TMD backbone 
RMSDs were similar for the 100 ns 
simulations. The backbone RMSD in 
isolation may be an inadequate quantifier 
of these changes, especially if it is 
performed collectively on all 12 helices of 
P-gp, as in Figures 7A, B and C. The 
conformational changes taking place in the 
TMDs are localized and involve 
deformations or fluctuations in the TM helices, such as unfolding, kinking and bending.
Figure 7: RMSD of the backbone atoms of the 
TMDs alone for (A) 3G5U, (B) 4M1M and (C) 4KSB 
system from the starting structure during 100 ns. 
The runs 1, 2 and 3 are in black, magenta and cyan 
respectively. 
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Figure 8: RMS deviation of 12 TM helices in (A) 3G5U, (B) 4M1M and (C) 4KSB P-gp simulations compared to the starting structure coordinates. 
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Figure 9: Overlap of the representative conformations for the most populated clusters derived from three 
independent runs with the starting structure conformation for each simulated system: (A) 3G5U (black); 
(B) 4M1M (blue); (C) 4KSB (green). Proline residues Pro219 (TM4) and Pro962 (TM10) surrounding 
kink of the helices are highlighted with red and yellow circles, respectively. 
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4.4.1 TM helix geometry  
 To provide additional insights into the structural dynamics of each of the TM helices, the 
RMSD for each TM helix has been calculated independently. This has also allowed the 
determination of the degree to which each helix deviated the most from its initial conformation in 
each given system. Figure 8 shows the RMSD of all 12 TM helices from the triplicate runs of all 
three P-gp structures. In 7 of the 9 simulations TM helix 12 deviates strongly from the initial 
coordinates. The major contributing factor to this is a localized unfolding in the central region of 
TM12, in the vicinity of the hinge residue, Pro992. Previous studies have indicated that the presence 
of proline residues within a TM helix can induce kinking of the TMDs12, 14, 19. This kinking of the 
TM helix was also observed for the pseudo-symmetric TM helix 6 in all three structures, which also 
contains a proline residue (Pro346). Note the RMSD of TM6 with respect to the crystal structure is 
relatively low in simulations of 3G5U P-gp compared with 4M1M and 4KSB. TM helices 4 and 10 
also contain a proline residue, Pro219 and Pro862, respectively. TM helices 4, 6, 10 and 12 were 
most likely to kink, bend or unwind during the simulations. The position in the structure 
corresponding to the location of the proline residues in TM helices 4, 6, 10 and 12 has been 
proposed to be involved in substrate uptake from the lipid bilayer2. In each of the three P-gp 
systems, proline-containing TM helices show increased bending/kinking compared to that observed 
in the crystal structures and also when compared with the other TM helices in the all MD 
simulations. A snapshot showing the bending/kinking of the TM helices 4, 6, 10 and 12 for all three 
systems is shown in Figure 9. 
For each of the three P-gp systems, a representative conformation of P-gp from the 
simulations with amongst the highest TM RMSD (calculated from cluster analysis, with respect to 
the corresponding crystal structure) was used to analyze the helix geometry is shown in Figure 10. 
The lines were drawn through the center of each TM helix to emphasize helical deformations, 
calculated using HELANAL tool as described above. Based on helix geometry analysis and cluster 
analysis of the individual TM helices, the 4M1M conformation remained closest to the starting 
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conformation (Figure 10B), while the 3G5U (Figure 10A) and 4KSB (Figure 10C) structures 
showed larger deformations of their TM helices. The registry shifts in the 4M1M model may 
explain the increase in stability observed. However, it should be noted that the helices of 4M1M 
still deviate from the crystal model to a similar degree to that of 3G5U and 4KSB, but with less 
unfolding. 
 
Figure 10: Representative conformations for three structural models (A) 3G5U, (B) 4M1M and (C) 
4KSB resulting from the simulations with the highest RMSD for the TMD regions compared to the 
initial crystal structure coordinates. Lines were drawn through the center of each helix to emphasize 
the change in helical geometry. 
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4.5 Comparison of the TM helices for registry corrections 
 
Dominant Cluster  Structure 1 RMSD (nm) Structure 2 RMSD (nm) 
3G5U  4M1M 0.48 4KSB 0.47 
4M1M 4KSB 0.42 3G5U 0.48 
4KSB 3G5U 0.47 4M1M 0.42 
     
 The three crystal structures of mouse P-gp, all had differences in the amino acid register 
assigned in TM helices 3, 4, 5 and 12. In previous MD simulations of 3G5U P-gp, discrepancies 
between the distances inferred from the cross-linking experiments involving the TM helices and the 
distances calculated from both the 3G5U P-gp crystal structure and MD simulations from this 
structure were noted12. In order to address the registry mismatches for amino acids in the TM 
helices 3, 4, 5 and 12, cluster analysis of all three P-gp structures was performed using a C RMSD 
cutoff of 0.4 nm for the TMD regions alone. The cluster analysis revealed 4 clusters for the 3G5U 
simulations, of which 83% of the simulated conformations formed the dominant cluster. Cluster 
analysis of 4KSB also revealed 4 clusters with the top 3 clusters corresponding to 46%, 27% and 18% 
of the simulation, respectively. Cluster analysis of 4M1M showed that 4M1M P-gp occupied a 
single cluster throughout the simulation.  
 Comparison of the central conformation from the dominant cluster arising from the 3G5U, 
4KSB and 4M1M simulations revealed that the TMDs of these conformations were very similar as 
shown in Figure 11A. The relative TMD backbone RMSDs between these three central 
conformations obtained from cluster analysis are also given in Table 2. When the central 
conformation of the dominant cluster for 3G5U is used as the reference, the TMD backbone RMSD 
of the 4M1M and 4KSB conformation is 0.48 nm and 0.47 nm, respectively. When the 4M1M 
central conformation was used as a reference, the backbone RMSD of the 4KSB TMDs is 0.42 nm.  
Table 2: Relative TMD backbone RMSD of the central conformations of the dominant clusters 
obtained from cluster analysis of 3G5U, 4M1M and 4KSB simulations. 
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Figure 11B shows an overlay of TM helices 3, 4 and 5 highlighting the alignment of the helices 
obtained in the simulations. In particular, the register within the helices, which differed between the 
alternative models have converged. This can be readily seen when the position and orientation of 
selected residues in the TM helices 3, 4 
and 5 from the three central 
conformations obtained from cluster 
analysis are shown. Figure 11B shows 
the side chain of every 10th residue. 
While the relative position of TM 
helices 3, 4 and 5 varied slightly, that 
the registry of the amino acids in these 
conformations is the same. Figure 11C 
shows the comparison of TM12 in the 
central conformations of the dominant 
clusters. While the TM12 in the central 
conformations of both 3G5U and 
4KSB P-gp shows kinking and 
unwinding, the conformation of TM12 
in the central conformation of the 
dominant cluster obtained for the 
4M1M simulations remained close to 
its initial conformation. Analysis of the 
helix geometry, shown in Figure 10, 
indicates that TM 12 of 3G5U and 
4KSB undergoes unwinding and 
kinking. In contrast, Figure 10 shows 
Figure 11: Superimpositions of the dominant clusters 
from 3G5U (grey), 4M1M (blue) and 4KSB (green) P-gp 
simulations. (A) Comparison of the TMD regions from 
all three P-gp structures. (B) Superposition of the TM 
helices 3, 4 and 5; and (C) TM12.  
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that TM12 of 4M1M remains helical throughout the simulations. Again a comparison of every 10th 
residue in the TM12 revealed that the three central conformations have not only converged to a 
similar conformation but that the orientation of the amino acids in the TM helix 12 is essentially the 
same (Figure 11C).  
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5 CONCLUSION 
 The outcomes of the MD simulations of P-gp in a membrane environment show that all 
three P-gp structures deviated from the crystal structures. One of the main reasons for the deviation 
from the starting crystal structures is the tendency of the NBDs to rapidly associate (within ~10 ns). 
This is consistent across all three simulated systems. This has also been observed in independent 
simulations of P-gp suggesting that the NBDs prefer to stay in close contact under physiological 
conditions.   
 Despite the association of the NBDs, P-gp remained highly flexible and dynamic on the time 
scales sampled in this set of MD simulations, consistent with numerous experimental observations14, 
16. Figure 12A shows an overlay of three conformations extracted from the simulations starting 
from the alternative crystal models, with the lowest overall RMSD showing the degree to which the 
structures have converged or sample the same region of conformational space during the 
simulations. In contrast, Figure 12B shows an overlay of three conformations extracted from the 
same simulation with the greatest difference in RMSD illustrating the extent to which a wide range 
of alternative conformations are sampled. In addition to the translational motion of the TMDs which 
Figure 12: Overlap of the MD simulation conformation of 3G5U (black), 4M1M (blue) and 4KSB (green) 
P-gp structures. (A) The front and side view of cluster representatives that have good overlap. (B) The 
divergent overlap between the cluster representatives of all three P-gp structures. 
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is driven by the association of the NBDs, the TM helices in all three systems are prone to local 
unfolding, kinking and bending, especially within the TM helices 4, 6, 10 and 12, which have been 
proposed to be involved in substrate uptake from the bilayer. The least amount of localized 
unfolding was observed in the 4M1M P-gp simulations, indicating that this structure has the highest 
conformational stability. Although 4M1M is highlighted as the most stable conformation of the 
three, it is also possible to obtain comparable conformations from the 3G5U and 4KSB simulations 
on the time scales used in this study. The simulations also revealed that the registry of all amino 
acids in the TM helices, which differ between the three P-gp structures, converged during the 
simulations.  
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1 CONCLUSION 
Since the discovery of the P-glycoprotein (P-gp) in the 70’s, this biologically important ATP-
binding cassette (ABC) transport protein and its mechanism has been a target of extensive research. 
The discovery in the 80’s that P-gp is over expressed in cancer cells and is responsible for imparting 
multidrug resistance (MDR), focused even more attention onto this efflux pump. Over the past 
decade, interest in P-gp has continued to grow due to the potential for developing new strategies 
and therapies for reversing multidrug resistance for cancers mediated through P-gp. Although P-gp 
is an attractive therapeutic target, the role it plays in promoting multidrug resistance by the transport 
of chemotherapeutics is largely unknown. Basic questions such as, (i) how P-gp recognizes such 
numerous molecules, (ii) how the molecules enter P-gp and (iii) how the molecules are transported 
are still unclear. Several attempts were made by various research groups to develop inhibitors to 
reverse the effect of multidrug resistance caused by P-gp. However, to date all P-gp inhibitors have 
failed during Phase III clinical trials because they are non-specific and affecting the transport of a 
wide range of substrates as opposed to blocking the transport of specific therapeutics as intended.  
To understand how the action of P-gp leads to multidrug resistance, I have used molecular 
dynamics (MD) simulations to study ligand recognition by P-gp.  As a first approach, I calculated 
the potential of mean force (PMF) for two P-gp substrates morphine and nicardipine and identified 
their binding locations with the transmembrane (TM) pore of P-gp. These binding locations were 
identified to be different but not entirely distinct from one another. They had overlapping set of 
residues from the TM helices 1 and 12. I also found that the permeation pathway adopted by the 
two substrates were overlapping and the individual residues that made direct contacts with these 
substrates in their respective pathways were previously implicated in the binding and transport of 
other P-gp substrates such as verapamil, vinblastine, colchicine and Rhodamine 123. Overall, these 
results suggested that the binding location and the permeation pathway taken by these two 
substrates are not distinct and it is difficult to define a specific binding site for morphine and 
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nicardipine in P-gp. This led me to question whether the alternate pharmacological sites proposed 
based on binding and mutation studies truly correspond to distinct physical sites.  
To address this fundamental question in more detail, I performed the PMF calculations to 
identify the binding locations of other molecules known to either be transported by P-gp such as 
Hoechst 33342, Rhodamine 123, paclitaxel, verapamil or to block the transport of P-gp such as 
tariquidar. From these PMF calculations, the pair of substrates, Hoechst 33342 and Rhodamine 123 
that bind non-competitively were identified to have distinct primary binding locations within the 
nucleotide binding domains (NBDs). However, their secondary binding locations within the TM 
pore region, which is assumed to be the transport active site clearly overlap. This suggests that 
although these two substrates may bind to P-gp at distinct locations in a non-competitive manner, 
they could still compete directly for transport. The second substrate pair paclitaxel and nicardipine, 
which bind non-competitively also, have their primary binding locations at distinct locations within 
P-gp. Though paclitaxel and nicardipine bind non-competitively, their PMFs suggest that they may 
also compete for transport. The binding of tariquidar causes structural changes to P-gp that brings 
the TMDs together. This partially occludes the TM pore for the substrate entry, making it a 
competitive inhibitor to substrates such as Hoechst 33342. Note in the case of tariquidar, the full 
PMF was not calculated, and it is possible that tariquidar could also bind to the primary binding 
location of Hoechst 33342 in the NBDs. Based on the PMFs of all 7 compounds, it has been 
identified that all these molecules whether they bind competitively or non-competitively have a 
binding location within the TM pore. This suggests all may compete with each other for transport. 
The availability of the experimental data on the residues that were implicated in the binding and 
transport of substrates by P-gp and the locations identified from this thesis suggest that it is nearly 
impossible to identify specific set of residues that form the binding site for individual substrates. 
Having answered the question of locating the binding locations of various molecules in P-gp, 
the next important question to address was how various molecules are taken up by P-gp and how 
the presence of cholesterol in the bilayer affects the substrate uptake and function of ATPase 
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activity of P-gp. It has been previously proposed that substrates first partition into the bilayer and 
then is taken up by P-gp. To understand substrate uptake by P-gp, unrestrained simulations were 
carried out with morphine and nicardipine. It was found that both the substrates did not enter the 
TM pore within the timescales sampled. However, it was found that the substrates interacted with 
the membrane. It has also been proposed that the presence of cholesterol in the membrane improves 
the transport properties of P-gp. To understand if cholesterol plays a direct role in the process of 
substrate uptake, I performed PMF calculations and unrestrained MD simulations using four P-gp 
substrates morphine, nicardipine, doxorubicin and paclitaxel in the presence and absence of 10% 
cholesterol in the bilayer. It was identified that the presence of cholesterol greatly reduced the 
barrier for substrates to cross the bilayer in some cases and in others it promoted the accumulation 
of substrates within the bilayer. This suggests that cholesterol retains the substrates in the bilayer 
thereby facilitating uptake by P-gp for transport. 
While I was attempting to answer the questions on substrate binding and uptake, Li et al. 
released a revised structure of the original mouse P-gp. At the same time, Ward et al. crystallized an 
inward apo form of P-gp leaving us with 3 medium resolution (3.8 Å) crystal structures of P-gp 
each with significant differences. To understand which of these three structures may best represent 
P-gp in its physiological environment, nanosecond timescale unrestrained MD simulations were 
carried out. The outcomes of the MD simulations showed all three P-gp structures deviated from 
their initial starting crystal conformation. It was also observed that the there was a rapid association 
of the NBDs within 10 ns in all the simulations. Despite this, P-gp adopted some similar 
conformations across all the simulations. However, some highly divergent conformations were also 
observed. This suggests that P-gp is a highly dynamic and flexible system. Though there were 
structural changes such as kinking/bending and unwinding were observed within the TM helices 
across all the simulations, the three P-gp structures could adopt a fairly similar conformation. 
Specifically, this was observed when certain parts of the dominant representative cluster of each of 
the three P-gp structures were overlaid, the registry of the amino acids that were different in the 
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crystal structures converge to a single conformation. However, they are different from their 
respective crystal structures. This suggests that none of the three crystal structures represent a 
physiological state of P-gp.      
Overall, in this thesis, I have examined the binding locations of various substrates to P-gp, 
implicated the role of cholesterol in the substrate partitioning across bilayers and finally 
investigated the flexibility and conformational plasticity in P-gp. The thesis has expanded our 
understanding of P-gp and how potential inhibitors may be able to treat multidrug resistance. 
Understanding ligand recognition by P-gp could be the key to solve the substrate promiscuity and 
develop new MDR reversing agents. The knowledge obtained by attempting to address these 
critical questions about a multidrug efflux pump such as P-gp could be also applied to understand 
the role of similar efflux pumps and transporters. Though there were significant amounts of 
research had been taken place to address the multifaceted problem of multidrug resistance, much 
still needs to be understood. With the recent developments in combining more powerful 
computational hardware with new algorithms, MD simulations are becoming an increasingly 
powerful toolkit to study quantitatively the properties of larger and more complex biological 
systems including the mechanism of transport by P-glycoprotein.  
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1 APPENDIX A 
1.1 Morphine  
;-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-  
;This file was generated by the Automatic Topology Builder (ATB) and Edited by 
Nandhitha Subramanian 
;# Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; Morphine protonated at N with a charge of +1.0 
; 
[ moleculetype ] 
; Name   nrexcl 
MOI      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1    OA    1     MOI      O    1   -0.513  15.9994  
    2     H    1     MOI      H    1    0.513   1.0080      ;  0.000 
    3   CH0    1     MOI      C    2    0.175  12.0110  
    4     C    1     MOI      C    2   -0.175  12.0110      ;  0.000 
    5     C    1     MOI      C    3    0.151  12.0110  
    6     C    1     MOI      C    3    0.256  12.0110  
    7    OE    1     MOI      O    3   -0.629  15.9994      ; -0.222 
    8   CH2    1     MOI      C    4   -0.104  14.0270  
    9   CH2    1     MOI      C    4    0.165  14.0270  
   10    NL    1     MOI      N    4    0.170  14.0067  
   11     H    1     MOI      H    4    0.336   1.0080  
   12   CH3    1     MOI      C    4    0.164  15.0350  
   13   CH1    1     MOI      C    4    0.104  13.0190  
   14   CH1    1     MOI      C    4    0.165  13.0190      ;  1.000 
   15   CH2    1     MOI      C    5    0.165  14.0270  
   16     C    1     MOI      C    5   -0.165  12.0110      ;  0.000 
   17     C    1     MOI      C    6   -0.245  12.0110  
   18    HC    1     MOI      H    6    0.245   1.0080      ;  0.000 
   19     C    1     MOI      C    7   -0.235  12.0110  
   20    HC    1     MOI      H    7    0.235   1.0080      ;  0.000 
   21   CH1    1     MOI      C    8    0.222  13.0190  
   22   CH1    1     MOI      C    8    0.276  13.0190      ;  0.498 
   23     C    1     MOI      C    9   -0.162  12.0110  
   24    HC    1     MOI      H    9    0.162   1.0080      ;  0.000 
   25     C    1     MOI      C   10   -0.225  12.0110  
   26    HC    1     MOI      H   10    0.225   1.0080      ;  0.000 
   27    OA    1     MOI      O   11   -0.682  15.9994  
   28     H    1     MOI      H   11    0.406   1.0080      ; -0.276 
; total charge of the molecule:   1.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1000   1.5700e+07 
    1    6    2   0.1360   1.0200e+07 
    3    4    2   0.1520   5.4300e+06 
    3    8    2   0.1530   7.1500e+06 
    3   13    2   0.1530   7.1500e+06 
    3   21    2   0.1530   7.1500e+06 
    4    5    2   0.1390   8.6600e+06 
    4   16    2   0.1390   8.6600e+06 
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    5    6    2   0.1390   8.6600e+06 
    5    7    2   0.1360   1.0200e+07 
    6   19    2   0.1390   8.6600e+06 
    7   21    2   0.1435   6.1000e+06 
    8    9    2   0.1520   5.4300e+06 
    9   10    2   0.1480   5.7300e+06 
   10   11    2   0.1000   1.8700e+07 
   10   12    2   0.1480   5.7300e+06 
   10   14    2   0.1480   5.7300e+06 
   13   14    2   0.1530   7.1500e+06 
   13   25    2   0.1520   5.4300e+06 
   14   15    2   0.1530   7.1500e+06 
   15   16    2   0.1520   5.4300e+06 
   16   17    2   0.1390   8.6600e+06 
   17   18    2   0.1100   1.2100e+07 
   17   19    2   0.1390   8.6600e+06 
   19   20    2   0.1100   1.2100e+07 
   21   22    2   0.1530   7.1500e+06 
   22   23    2   0.1520   5.4300e+06 
   22   27    2   0.1430   8.1800e+06 
   23   24    2   0.1100   1.2100e+07 
   23   25    2   0.1330   1.1800e+07 
   25   26    2   0.1100   1.2100e+07 
   27   28    2   0.1000   1.5700e+07 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    4    1 
    1    7    1 
    1   17    1 
    2    5    1 
    2   19    1 
    3    6    1 
    3   10    1 
    3   15    1 
    3   17    1 
    3   23    1 
    3   26    1 
    3   27    1 
    4    9    1 
    4   14    1 
    4   18    1 
    4   22    1 
    4   25    1 
    5    8    1 
    5   13    1 
    5   15    1 
    5   20    1 
    5   22    1 
    6   18    1 
    6   21    1 
    7    8    1 
    7   13    1 
    7   16    1 
    7   19    1 
    7   23    1 
    7   27    1 
    8   11    1 
    8   12    1 
    8   14    1 
    8   16    1 
    8   22    1 
    8   25    1 
    9   13    1 
    9   15    1 
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    9   21    1 
   10   16    1 
   10   25    1 
   11   13    1 
   11   15    1 
   12   13    1 
   12   15    1 
   13   16    1 
   13   22    1 
   13   24    1 
   14   17    1 
   14   21    1 
   14   23    1 
   14   26    1 
   15   19    1 
   15   25    1 
   16   20    1 
   16   21    1 
   21   24    1 
   21   25    1 
   21   28    1 
   22   26    1 
   23   28    1 
   24   26    1 
   24   27    1 
   25   27    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    2    1    6    2    108.53   443.00 
    4    3    8    2    111.00   530.00 
    4    3   13    2    109.50   285.00 
    4    3   21    2    100.00   475.00 
    8    3   13    2    109.50   285.00 
    8    3   21    2    111.00   530.00 
   13    3   21    2    120.00   560.00 
    3    4    5    2    109.50   285.00 
    3    4   16    2    126.00   640.00 
    5    4   16    2    120.00   560.00 
    4    5    6    2    120.00   560.00 
    4    5    7    2    111.00   530.00 
    6    5    7    2    126.00   640.00 
    1    6    5    2    126.00   640.00 
    1    6   19    2    117.00   635.00 
    5    6   19    2    120.00   560.00 
    5    7   21    2    109.50   380.00 
    3    8    9    2    111.00   530.00 
    8    9   10    2    111.00   530.00 
    9   10   11    2    109.50   425.00 
    9   10   12    2    116.00   620.00 
    9   10   14    2    116.00   620.00 
   11   10   12    2    109.50   425.00 
   11   10   14    2    109.50   425.00 
   12   10   14    2    116.00   620.00 
    3   13   14    2    109.50   285.00 
    3   13   25    2    111.00   530.00 
   14   13   25    2    111.00   530.00 
   10   14   13    2    108.00   465.00 
   10   14   15    2    111.00   530.00 
   13   14   15    2    111.00   530.00 
   14   15   16    2    111.00   530.00 
    4   16   15    2    120.00   560.00 
    4   16   17    2    120.00   560.00 
   15   16   17    2    125.00   750.00 
   16   17   18    2    120.00   505.00 
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   16   17   19    2    120.00   560.00 
   18   17   19    2    120.00   505.00 
    6   19   17    2    120.00   560.00 
    6   19   20    2    120.00   505.00 
   17   19   20    2    120.00   505.00 
    3   21    7    2    109.50   320.00 
    3   21   22    2    111.00   530.00 
    7   21   22    2    111.00   530.00 
   21   22   23    2    111.00   530.00 
   21   22   27    2    111.00   530.00 
   23   22   27    2    111.00   530.00 
   22   23   24    2    120.00   505.00 
   22   23   25    2    120.00   560.00 
   24   23   25    2    120.00   505.00 
   13   25   23    2    120.00   560.00 
   13   25   26    2    120.00   505.00 
   23   25   26    2    120.00   505.00 
   22   27   28    2    108.53   443.00 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
   16    4   15   17    2      0.00   167.36 
    4    3    5   16    2      0.00   167.36 
    5    4    6    7    2      0.00   167.36 
    6    1    5   19    2      0.00   167.36 
   19    6   17   20    2      0.00   167.36 
   17   16   18   19    2      0.00   167.36 
   23   22   24   25    2      0.00   167.36 
   25   13   23   26    2      0.00   167.36 
   13    3   14   25    2     35.26   334.72 
   14   13   10   15    2     35.26   334.72 
   21    7    3   22    2     35.26   334.72 
   22   21   23   27    2     35.26   334.72 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    2    1    6    5    1    180.00     7.11    2 
    8    3    4   16    1      0.00     1.00    6 
   13    3    8    9    1      0.00     3.77    3 
    8    3   13   14    1      0.00     3.77    3 
    8    3   21    7    1      0.00     1.05    3 
    3    4    5    6    1    180.00     1.53    2 
    3    4   16   15    1    180.00     1.53    2 
    4    5    6   19    1    180.00     1.53    2 
    4    5    7   21    1    180.00     7.11    2 
    5    6   19   17    1    180.00     1.53    2 
    5    7   21    3    1      0.00     1.05    3 
    3    8    9   10    1      0.00     3.77    3 
    8    9   10   12    1      0.00     1.05    3 
   12   10   14   13    1      0.00     1.05    3 
    3   13   14   10    1      0.00     3.77    3 
    3   13   25   23    1      0.00     1.00    6 
   10   14   15   16    1      0.00     3.77    3 
   14   15   16    4    1    180.00     1.00    6 
   15   16   17   19    1    180.00     1.53    2 
   16   17   19    6    1    180.00     1.53    2 
    3   21   22   23    1      0.00     3.77    3 
   21   22   23   25    1      0.00     1.00    6 
   21   22   27   28    1      0.00     1.26    3 
   22   23   25   13    1    180.00     1.53    2 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    1   20 
    4   19 
    5   17 
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    6   16 
   15   18 
   18   20 
 
1.2 Nicardipine 
;-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=- 
; This file was generated at 13:50 on 2010-12-17 by 
; 
;                  Automatic Topology Builder   
; 
;                                   REVISION 2010-12-16 
;----------------------------------------------------------------------- 
; Authors     : Alpeshkumar Malde, Le Zuo, Matthew Breeze,  
;               Pramod Nair, Martin Stroet, Nikhil Biyani, Alan Mark 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
; URL         : http://compbio.biosci.uq.edu.au/atb 
; Attention   :  
;      The topology files generated by this program come with no 
;      warranty, use them at your own discretion. The topology is 
;      based on the inputed PDB file and quantum mechanical 
;      optimization results. Bond, angle and dihedral type code may 
;      as well contain non-standard GROMOS types or rough guesses, 
;      which are marked as "non-standard" or "uncertain" in comments. 
;      "%%" is used as a place holder for the fields that could 
;      not be determined. These fields must be filled in manually 
;      before the files can be used. 
; Known Issues :  
;      - only GROMOS 53A6 force field is supported. 
;      - bond/angle/dihedral type calculations may yield more than 
;        one possible type. Alternative type codes are placed in 
;        comments at the end of the line. Check to make sure the 
;        appropriate type code is used. 
;----------------------------------------------------------------------- 
; Input Structure : NCP 
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=-=- 
;Initial Guess Topology Generation:  
;The topology was guessed from AM1 optimized geometry and MOPAC charges 
; 
; Topology file generated at 13:12 on 17 Dec 2010 for molecule 
; Nicardipine (IUPAC: (R)-benzyl({2-[(4-{3-[(hydroxyimino)-$l^{1}-
oxidanyl]phenyl}-5-(methoxycarbonyl)-2,6-dimethylpyridin-3-
yl)carbonyloxy]ethyl})methylazanium, database identifier: NCP) 
; by Automatic Topology Builder(revision 2010-12-16). 
; 
[ moleculetype ] 
; Name   nrexcl 
NCP      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1     C    1     NCP      C    1    0.126  12.0110  
    2     C    1     NCP      C    1   -0.126  12.0110      ;  0.000 
    3     C    1     NCP      C    2    0.077  12.0110  
    4   CH3    1     NCP      C    2    0.129  15.0350  
    5     C    1     NCP      C    2   -0.184  12.0110  
    6     C    1     NCP      C    2    0.375  12.0110  
    7     O    1     NCP      O    2   -0.293  15.9994  
    8    OE    1     NCP      O    2   -0.315  15.9994  
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    9   CH2    1     NCP      C    2    0.232  14.0270  
   10   CH2    1     NCP      C    2    0.169  14.0270  
   11    NL    1     NCP      N    2   -0.002  14.0067  
   12     H    1     NCP      H    2    0.245   1.0080  
   13   CH3    1     NCP      C    2    0.248  15.0350  
   14   CH2    1     NCP      C    2    0.220  14.0270  
   15    NR    1     NCP      N    2   -0.139  14.0067  
   16     C    1     NCP      C    2    0.077  12.0110  
   17   CH3    1     NCP      C    2    0.161  15.0350      ;  1.000 
   18     C    1     NCP      C    3   -0.100  12.0110  
   19     C    1     NCP      C    3   -0.069  12.0110  
   20    HC    1     NCP      H    3    0.169   1.0080      ;  0.000 
   21     C    1     NCP      C    4    0.350  12.0110  
   22     O    1     NCP      O    4   -0.300  15.9994  
   23    OE    1     NCP      O    4   -0.282  15.9994  
   24   CH3    1     NCP      C    4    0.232  15.0350      ;  0.000 
   25     C    1     NCP      C    5   -0.048  12.0110  
   26    HC    1     NCP      H    5    0.190   1.0080  
   27     C    1     NCP      C    5   -0.138  12.0110  
   28    NT    1     NCP      N    5    0.562  14.0067  
   29     O    1     NCP      O    5   -0.346  15.9994  
   30     O    1     NCP      O    5   -0.346  15.9994  
   31     C    1     NCP      C    5   -0.052  12.0110  
   32    HC    1     NCP      H    5    0.178   1.0080      ;  0.000 
   33     C    1     NCP      C    6   -0.151  12.0110  
   34    HC    1     NCP      H    6    0.151   1.0080      ;  0.000 
   35     C    1     NCP      C    7   -0.171  12.0110  
   36     C    1     NCP      C    7   -0.101  12.0110  
   37    HC    1     NCP      H    7    0.142   1.0080  
   38     C    1     NCP      C    7   -0.100  12.0110  
   39    HC    1     NCP      H    7    0.165   1.0080  
   40     C    1     NCP      C    7   -0.100  12.0110  
   41    HC    1     NCP      H    7    0.165   1.0080      ; -0.000 
   42     C    1     NCP      C    8   -0.121  12.0110  
   43    HC    1     NCP      H    8    0.121   1.0080      ;  0.000 
   44     C    1     NCP      C    9   -0.132  12.0110  
   45    HC    1     NCP      H    9    0.132   1.0080      ;  0.000 
; total charge of the molecule:   1.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1390   8.6600e+06 
    1    5    2   0.1390   8.6600e+06 
    1   18    2   0.1520   5.4300e+06 
    2   16    2   0.1390   8.6600e+06 
    2   21    2   0.1520   5.4300e+06 
    3    4    2   0.1520   5.4300e+06 
    3    5    2   0.1390   8.6600e+06 
    3   15    2   0.1350   1.0300e+07 
    5    6    2   0.1520   5.4300e+06 
    6    7    2   0.1230   1.6600e+07 
    6    8    2   0.1360   1.0200e+07 
    8    9    2   0.1430   8.1800e+06 
    9   10    2   0.1530   7.1500e+06 
   10   11    2   0.1480   5.7300e+06 
   11   12    2   0.1000   1.8700e+07 
   11   13    2   0.1480   5.7300e+06 
   11   14    2   0.1480   5.7300e+06 
   14   35    2   0.1520   5.4300e+06 
   15   16    2   0.1350   1.0300e+07 
   16   17    2   0.1520   5.4300e+06 
   18   19    2   0.1390   8.6600e+06 
   18   25    2   0.1390   8.6600e+06 
   19   20    2   0.1100   1.2100e+07 
   19   33    2   0.1390   8.6600e+06 
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   21   22    2   0.1230   1.6600e+07 
   21   23    2   0.1360   1.0200e+07 
   23   24    2   0.1430   8.1800e+06 
   25   26    2   0.1100   1.2100e+07 
   25   27    2   0.1390   8.6600e+06 
   27   28    2   0.1480   5.7300e+06 
   27   31    2   0.1390   8.6600e+06 
   28   29    2   0.1230   1.2830e+07 
   28   30    2   0.1230   1.2830e+07 
   31   32    2   0.1100   1.2100e+07 
   31   33    2   0.1390   8.6600e+06 
   33   34    2   0.1100   1.2100e+07 
   35   36    2   0.1390   8.6600e+06 
   35   42    2   0.1390   8.6600e+06 
   36   37    2   0.1100   1.2100e+07 
   36   38    2   0.1390   8.6600e+06 
   38   39    2   0.1100   1.2100e+07 
   38   40    2   0.1390   8.6600e+06 
   40   41    2   0.1100   1.2100e+07 
   40   44    2   0.1390   8.6600e+06 
   42   43    2   0.1100   1.2100e+07 
   42   44    2   0.1390   8.6600e+06 
   44   45    2   0.1100   1.2100e+07 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    7    1 
    1    8    1 
    1   22    1 
    1   23    1 
    2   19    1 
    2   24    1 
    2   25    1 
    3    7    1 
    3    8    1 
    5    9    1 
    5   19    1 
    5   25    1 
    6   10    1 
    7    9    1 
    8   11    1 
    9   12    1 
    9   13    1 
    9   14    1 
   10   35    1 
   11   36    1 
   11   42    1 
   12   35    1 
   13   35    1 
   16   22    1 
   16   23    1 
   22   24    1 
   25   29    1 
   25   30    1 
   29   31    1 
   30   31    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    2    1    5    2    120.00   560.00 
    2    1   18    2    120.00   560.00 
    5    1   18    2    120.00   560.00 
    1    2   16    2    120.00   560.00 
    1    2   21    2    120.00   560.00 
   16    2   21    2    120.00   560.00 
    4    3    5    2    120.00   560.00 
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    4    3   15    2    120.00   560.00 
    5    3   15    2    120.00   560.00 
    1    5    3    2    120.00   560.00 
    1    5    6    2    120.00   560.00 
    3    5    6    2    120.00   560.00 
    5    6    7    2    126.00   640.00 
    5    6    8    2    115.00   610.00 
    7    6    8    2    109.50   320.00 
    6    8    9    2    109.50   380.00 
    8    9   10    2    109.50   320.00 
    9   10   11    2    115.00   610.00 
   10   11   12    2    109.50   425.00 
   10   11   13    2    116.00   620.00 
   10   11   14    2    116.00   620.00 
   12   11   13    2    109.50   425.00 
   12   11   14    2    109.50   425.00 
   13   11   14    2    116.00   620.00 
   11   14   35    2    111.00   530.00 
    3   15   16    2    120.00   560.00 
    2   16   15    2    120.00   560.00 
    2   16   17    2    120.00   560.00 
   15   16   17    2    120.00   560.00 
    1   18   19    2    120.00   560.00 
    1   18   25    2    120.00   560.00 
   19   18   25    2    120.00   560.00 
   18   19   20    2    120.00   505.00 
   18   19   33    2    120.00   560.00 
   20   19   33    2    120.00   505.00 
    2   21   22    2    126.00   640.00 
    2   21   23    2    115.00   610.00 
   22   21   23    2    124.00   730.00 
   21   23   24    2    109.50   380.00 
   18   25   26    2    120.00   505.00 
   18   25   27    2    120.00   560.00 
   26   25   27    2    120.00   505.00 
   25   27   28    2    120.00   560.00 
   25   27   31    2    120.00   560.00 
   28   27   31    2    120.00   560.00 
   27   28   29    2    125.00   750.00 
   27   28   30    2    125.00   750.00 
   29   28   30    2    125.00   750.00 
   27   31   32    2    120.00   505.00 
   27   31   33    2    120.00   560.00 
   32   31   33    2    120.00   505.00 
   19   33   31    2    120.00   560.00 
   19   33   34    2    120.00   505.00 
   31   33   34    2    120.00   505.00 
   14   35   36    2    120.00   560.00 
   14   35   42    2    120.00   560.00 
   36   35   42    2    120.00   560.00 
   35   36   37    2    120.00   505.00 
   35   36   38    2    120.00   560.00 
   37   36   38    2    120.00   505.00 
   36   38   39    2    120.00   505.00 
   36   38   40    2    120.00   560.00 
   39   38   40    2    120.00   505.00 
   38   40   41    2    120.00   505.00 
   38   40   44    2    120.00   560.00 
   41   40   44    2    120.00   505.00 
   35   42   43    2    120.00   505.00 
   35   42   44    2    120.00   560.00 
   43   42   44    2    120.00   505.00 
   40   44   42    2    120.00   560.00 
   40   44   45    2    120.00   505.00 
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   42   44   45    2    120.00   505.00 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
    5    3   15   16    2      0.00   167.36 
    3   15   16    2    2      0.00   167.36 
   15   16    2    1    2      0.00   167.36 
   16    2    1    5    2      0.00   167.36 
    2    1    5    3    2      0.00   167.36 
    1    5    3   15    2      0.00   167.36 
   18   25   27   31    2      0.00   167.36 
   25   27   31   33    2      0.00   167.36 
   27   31   33   19    2      0.00   167.36 
   31   33   19   18    2      0.00   167.36 
   33   19   18   25    2      0.00   167.36 
   19   18   25   27    2      0.00   167.36 
   35   36   38   40    2      0.00   167.36 
   36   38   40   44    2      0.00   167.36 
   38   40   44   42    2      0.00   167.36 
   40   44   42   35    2      0.00   167.36 
   44   42   35   36    2      0.00   167.36 
   42   35   36   38    2      0.00   167.36 
   28   27   29   30    2      0.00   167.36 
    1    2    5   18    2      0.00   167.36 
    5    1    3    6    2      0.00   167.36 
    2    1   16   21    2      0.00   167.36 
   18    1   19   25    2      0.00   167.36 
    3    4    5   15    2      0.00   167.36 
   16    2   15   17    2      0.00   167.36 
    6    5    7    8    2      0.00   167.36 
   25   18   26   27    2      0.00   167.36 
   19   18   20   33    2      0.00   167.36 
   21    2   22   23    2      0.00   167.36 
   27   25   28   31    2      0.00   167.36 
   33   19   31   34    2      0.00   167.36 
   31   27   32   33    2      0.00   167.36 
   35   14   36   42    2      0.00   167.36 
   42   35   43   44    2      0.00   167.36 
   36   35   37   38    2      0.00   167.36 
   44   40   42   45    2      0.00   167.36 
   38   36   39   40    2      0.00   167.36 
   40   38   41   44    2      0.00   167.36 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    5    1   18   25    1   180.000     5.86    2   ; gd_10  %%       %%   %% 
    1    2   21   23    1    180.00     5.86    2 
    1    5    6    8    1    180.00     5.86    2 
    7    6    8    9    1   180.000    24.0     2   ; gd_13  %%       %%   %% 
    6    8    9   10    1    180.00     0.50    3 
    8    9   10   11    1      0.00     3.77    3 
    9   10   11   14    1     0.000     3.77    3   ; gd_29  %%       %%   %% 
   10   11   14   35    1    180.00     0.50    3 
   11   14   35   42    1      0.00     1.00    6 
   22   21   23   24    1   180.000    24.0     2   ; gd_13  %%       %%   %% 
   25   27   28   29    1      0.00     0.00    2 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    1    4 
    1   15 
    1   17 
    1   20 
    1   26 
    1   27 
    1   33 
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    2    3 
    2    6 
    3   17 
    3   18 
    4    6 
    4   16 
    5   16 
    5   21 
    6   15 
    6   18 
   14   37 
   14   38 
   14   43 
   14   44 
   15   21 
   16   18 
   17   21 
   18   21 
   18   28 
   18   31 
   18   34 
   19   26 
   19   27 
   19   32 
   20   25 
   20   31 
   20   34 
   25   32 
   25   33 
   26   28 
   26   31 
   27   34 
   28   32 
   28   33 
   32   34 
   35   39 
   35   40 
   35   45 
   36   41 
   36   43 
   36   44 
   37   39 
   37   40 
   37   42 
   38   42 
   38   45 
   39   41 
   39   44 
   40   43 
   41   42 
   41   45 
   43   45 
 
1.3 Hoechst 33342 
;----------------------------TITLE ------------------------------------------- 
;   Hoechst33342 carrying a 1+ charge 
; 
; This file was generated at 15:39 on 2012-08-23 by 
; 
;                  Automatic Topology Builder   
; 
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;                   REVISION 2012-08-21 
; 
; 
; file is edited by Nandhitha 2012-10-13 
;----------------------------------------------------------------------------- 
; Authors     : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, 
Alan E. Mark 
; 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
; URL         : http://compbio.biosci.uq.edu.au/atb 
; Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; 
; Disclaimer  :  
;      While every effort has been made to ensure the accuracy and validity of 
parameters provided below 
;      the assignment of parameters is being based on an automated procedure 
combining data provided by a 
;      given user as well as calculations performed using third party software. 
They are provided as a guide. 
;      The authors of the ATB cannot guarantee that the parameters are complete 
or that the parameters provided 
;      are appropriate for use in any specific application. Users are advised to 
treat these parameters with discretion 
;      and to perform additional validation tests for their specific application 
if required. Neither the authors 
;      of the ATB or The University of Queensland except any responsibly for how 
the parameters may be used. 
; 
; Release notes and warnings:  
;  (1) The topology is based on a set of atomic coordinates and other data 
provided by the user after 
;      after quantum mechanical optimization of the structure using different 
levels of theory depending on 
;      the nature of the molecule. 
;  (2) In some cases the automatic bond, bond angle and dihedral type assignment 
is ambiguous. 
;      In these cases alternative type codes are provided at the end of the 
line. 
;  (3) While bonded parameters are taken where possible from the nominated force 
field non-standard bond, angle and dihedral 
;      type code may be incorporated in cases where an exact match could not be 
found. These are marked as "non-standard" 
;      or "uncertain" in comments. 
;  (4) In some cases it is not possible to assign an appropriate parameter 
automatically. "%" is used as a place holder 
;      for those fields that could not be determined automatically. The 
parameters in these fields must be assigned manually 
;      before the file can be used. 
;----------------------------------------------------------------------------- 
; Input Structure : HST 
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;---------------------------------------------------------------------------- 
; Initial Guess Topology Generation:  
; The topology was guessed from AM1 optimized geometry and MOPAC charges 
; 
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[ moleculetype ] 
; Name   nrexcl 
HST      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1   CH3    1     HST    C25    1    0.150  15.0350  
    2    NL    1     HST     N6    1    0.066  14.0067  
    3     H    1     HST    H29    1    0.366   1.0080  
    4   CH2    1     HST    C22    1    0.096  14.0270  
    5   CH2    1     HST    C21    1    0.222  14.0270  
    6    NT    1     HST     N5    1   -0.364  14.0067  
    7     C    1     HST    C19    1    0.065  12.0110  
    8   CH2    1     HST    C24    1    0.222  14.0270  
    9   CH2    1     HST    C23    1    0.149  14.0270      ;  0.972 
   10     C    1     HST    C18    2   -0.185  12.0110  
   11    HC    1     HST    H11    2    0.185   1.0080      ;  0.000 
   12     C    1     HST    C17    3   -0.185  12.0110  
   13    HC    1     HST    H10    3    0.185   1.0080      ;  0.000 
   14    NR    1     HST     N3    4   -0.759  14.0067  
   15     C    1     HST    C14    4    0.624  12.0110  
   16     C    1     HST    C15    4    0.395  12.0110      ;  0.260 
   17     C    1     HST    C16    5    0.000  12.0110      ;  0.000 
   18    NR    1     HST     N4    6   -0.568  14.0067  
   19     H    1     HST     H9    6    0.414   1.0080      ; -0.154 
   20     C    1     HST    C20    7   -0.151  12.0110  
   21    HC    1     HST    H12    7    0.151   1.0080      ;  0.000 
   22     C    1     HST    C12    8   -0.000  12.0110      ;  0.000 
   23     C    1     HST    C11    9   -0.185  12.0110  
   24    HC    1     HST     H7    9    0.185   1.0080      ;  0.000 
   25     C    1     HST    C10   10   -0.185  12.0110  
   26    HC    1     HST     H6   10    0.185   1.0080      ;  0.000 
   27    NR    1     HST     N1   11   -0.706  14.0067  
   28     C    1     HST     C7   11    0.615  12.0110  
   29     C    1     HST     C8   11    0.208  12.0110      ;  0.117 
   30     C    1     HST     C9   12    0.000  12.0110      ;  0.000 
   31    NR    1     HST     N2   13   -0.610  14.0067  
   32     H    1     HST     H5   13    0.415   1.0080      ; -0.195 
   33     C    1     HST    C13   14   -0.151  12.0110  
   34    HC    1     HST     H8   14    0.151   1.0080      ;  0.000 
   35     C    1     HST     C4   15    0.000  12.0110      ;  0.000 
   36     C    1     HST     C3   16   -0.139  12.0110  
   37    HC    1     HST     H2   16    0.139   1.0080      ;  0.000 
   38     C    1     HST     C2   17   -0.151  12.0110  
   39    HC    1     HST     H1   17    0.151   1.0080      ;  0.000 
   40     C    1     HST     C1   18    0.415  12.0110  
   41    OE    1     HST     O1   18   -0.415  15.9994      ;  0.000 
   42     C    1     HST     C6   19   -0.185  12.0110  
   43    HC    1     HST     H4   19    0.185   1.0080      ;  0.000 
   44     C    1     HST     C5   20   -0.185  12.0110  
   45    HC    1     HST     H3   20    0.185   1.0080      ;  0.000 
   46   CH2    1     HST    C26   21    0.000  14.0270      ;  0.000 
   47   CH3    1     HST    C27   22   -0.000  15.0350      ;  0.000 
; total charge of the molecule:   1.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1480   5.7300e+06 
    2    3    2   0.1000   1.8700e+07 
    2    4    2   0.1480   5.7300e+06 
    2    9    2   0.1480   5.7300e+06 
    4    5    2   0.1530   7.1500e+06 
    5    6    2   0.1470   8.7100e+06 
    6    7    2   0.1470   8.7100e+06 
    6    8    2   0.1470   8.7100e+06 
    7   10    2   0.1390   8.6600e+06 
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    7   20    2   0.1390   8.6600e+06 
    8    9    2   0.1530   7.1500e+06 
   10   11    2   0.1100   1.2100e+07 
   10   12    2   0.1390   8.6600e+06 
   12   13    2   0.1100   1.2100e+07 
   12   17    2   0.1390   8.6600e+06 
   14   15    2   0.1350   1.0300e+07 
   14   16    2   0.1400   8.5400e+06 
   15   18    2   0.1400   8.5400e+06 
   15   22    2   0.1480   5.7300e+06 
   16   17    2   0.1435   6.1000e+06 
   16   20    2   0.1390   8.6600e+06 
   17   18    2   0.1400   8.5400e+06 
   18   19    2   0.1000   1.8700e+07 
   20   21    2   0.1100   1.2100e+07 
   22   23    2   0.1390   8.6600e+06 
   22   33    2   0.1390   8.6600e+06 
   23   24    2   0.1100   1.2100e+07 
   23   25    2   0.1390   8.6600e+06 
   25   26    2   0.1100   1.2100e+07 
   25   30    2   0.1390   8.6600e+06 
   27   28    2   0.1350   1.0300e+07 
   27   29    2   0.1400   8.5400e+06 
   28   31    2   0.1400   8.5400e+06 
   28   35    2   0.1480   5.7300e+06 
   29   30    2   0.1435   6.1000e+06 
   29   33    2   0.1390   8.6600e+06 
   30   31    2   0.1400   8.5400e+06 
   31   32    2   0.1000   1.8700e+07 
   33   34    2   0.1100   1.2100e+07 
   35   36    2   0.1390   8.6600e+06 
   35   44    2   0.1390   8.6600e+06 
   36   37    2   0.1100   1.2100e+07 
   36   38    2   0.1390   8.6600e+06 
   38   39    2   0.1100   1.2100e+07 
   38   40    2   0.1390   8.6600e+06 
   40   41    2   0.1360   1.0200e+07 
   40   42    2   0.1390   8.6600e+06 
   41   46    2   0.1435   6.1000e+06 
   42   43    2   0.1100   1.2100e+07 
   42   44    2   0.1390   8.6600e+06 
   44   45    2   0.1100   1.2100e+07 
   46   47    2   0.1520   5.4300e+06 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    5    1 
    1    8    1 
    2    6    1 
    3    5    1 
    3    8    1 
    4    7    1 
    4    8    1 
    5    9    1 
    5   10    1 
    5   20    1 
    7    9    1 
    8   10    1 
    8   20    1 
   14   23    1 
   14   33    1 
   18   23    1 
   18   33    1 
   27   36    1 
   27   44    1 
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   31   36    1 
   31   44    1 
   38   46    1 
   40   47    1 
   42   46    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    1    2    3    2    109.50   425.00 
    1    2    4    2    116.00   620.00 
    1    2    9    2    116.00   620.00 
    3    2    4    2    109.50   425.00 
    3    2    9    2    109.50   425.00 
    4    2    9    2    109.50   285.00 
    2    4    5    2    111.00   530.00 
    4    5    6    2    111.00   530.00 
    5    6    7    2    116.00   620.00 
    5    6    8    2    116.00   620.00 
    7    6    8    2    116.00   620.00 
    6    7   10    2    120.00   560.00 
    6    7   20    2    120.00   560.00 
   10    7   20    2    120.00   560.00 
    6    8    9    2    111.00   530.00 
    2    9    8    2    111.00   530.00 
    7   10   11    2    120.00   505.00 
    7   10   12    2    120.00   560.00 
   11   10   12    2    120.00   505.00 
   10   12   13    2    120.00   505.00 
   10   12   17    2    120.00   560.00 
   13   12   17    2    120.00   505.00 
   15   14   16    2    108.00   465.00 
   14   15   18    2    117.20  636.00 
   14   15   22    2    125.00   750.00 
   18   15   22    2    125.00   750.00 
   14   16   17    2    109.50   285.00 
   14   16   20    2    126.00   640.00 
   17   16   20    2    120.00   560.00 
   12   17   16    2    120.00   560.00 
   12   17   18    2    132.00   760.00 
   16   17   18    2    108.00   465.00 
   15   18   17    2    108.00   465.00 
   15   18   19    2    125.00   750.00 
   17   18   19    2    125.00   750.00 
    7   20   16    2    120.00   560.00 
    7   20   21    2    120.00   505.00 
   16   20   21    2    120.00   505.00 
   15   22   23    2    120.00   560.00 
   15   22   33    2    120.00   560.00 
   23   22   33    2    120.00   560.00 
   22   23   24    2    120.00   505.00 
   22   23   25    2    120.00   560.00 
   24   23   25    2    120.00   505.00 
   23   25   26    2    120.00   505.00 
   23   25   30    2    120.00   560.00 
   26   25   30    2    120.00   505.00 
   28   27   29    2    108.00   465.00 
   27   28   31    2    117.20   636.00 
   27   28   35    2    125.00   750.00 
   31   28   35    2    120.00   560.00 
   27   29   30    2    109.50   285.00 
   27   29   33    2    126.00   640.00 
   30   29   33    2    120.00   560.00 
   25   30   29    2    120.00   560.00 
   25   30   31    2    132.00   760.00 
   29   30   31    2    108.00   465.00 
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   28   31   30    2    108.00   465.00 
   28   31   32    2    125.00   750.00 
   30   31   32    2    125.00   750.00 
   22   33   29    2    120.00   560.00 
   22   33   34    2    120.00   505.00 
   29   33   34    2    120.00   505.00 
   28   35   36    2    120.00   560.00 
   28   35   44    2    120.00   560.00 
   36   35   44    2    120.00   560.00 
   35   36   37    2    120.00   505.00 
   35   36   38    2    120.00   560.00 
   37   36   38    2    120.00   505.00 
   36   38   39    2    120.00   505.00 
   36   38   40    2    120.00   560.00 
   39   38   40    2    120.00   505.00 
   38   40   41    2    115.00   610.00 
   38   40   42    2    120.00   560.00 
   41   40   42    2    125.00   750.00 
   40   41   46    2    116.00   620.00 
   40   42   43    2    120.00   505.00 
   40   42   44    2    120.00   560.00 
   43   42   44    2    120.00   505.00 
   35   44   42    2    120.00   560.00 
   35   44   45    2    120.00   505.00 
   42   44   45    2    120.00   505.00 
   41   46   47    2    109.50   320.00 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
   40   42   44   35    2      0.00   167.36 
   42   44   35   36    2      0.00   167.36 
   44   35   36   38    2      0.00   167.36 
   35   36   38   40    2      0.00   167.36 
   36   38   40   42    2      0.00   167.36 
   38   40   42   44    2      0.00   167.36 
   28   31   30   29    2      0.00   167.36 
   31   30   29   27    2      0.00   167.36 
   30   29   27   28    2      0.00   167.36 
   29   27   28   31    2      0.00   167.36 
   27   28   31   30    2      0.00   167.36 
   29   33   22   23    2      0.00   167.36 
   33   22   23   25    2      0.00   167.36 
   22   23   25   30    2      0.00   167.36 
   23   25   30   29    2      0.00   167.36 
   25   30   29   33    2      0.00   167.36 
   30   29   33   22    2      0.00   167.36 
   15   18   17   16    2      0.00   167.36 
   18   17   16   14    2      0.00   167.36 
   17   16   14   15    2      0.00   167.36 
   16   14   15   18    2      0.00   167.36 
   14   15   18   17    2      0.00   167.36 
   16   20    7   10    2      0.00   167.36 
   20    7   10   12    2      0.00   167.36 
    7   10   12   17    2      0.00   167.36 
   10   12   17   16    2      0.00   167.36 
   12   17   16   20    2      0.00   167.36 
   17   16   20    7    2      0.00   167.36 
   40   38   41   42    2      0.00   167.36 
   38   36   39   40    2      0.00   167.36 
   31   28   30   32    2      0.00   167.36 
   36   35   37   38    2      0.00   167.36 
   35   28   36   44    2      0.00   167.36 
   18   15   17   19    2      0.00   167.36 
   44   35   42   45    2      0.00   167.36 
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   42   40   43   44    2      0.00   167.36 
   28   27   31   35    2      0.00   167.36 
   29   27   30   33    2      0.00   167.36 
   30   25   29   31    2      0.00   167.36 
   25   23   26   30    2      0.00   167.36 
   23   22   24   25    2      0.00   167.36 
   22   15   23   33    2      0.00   167.36 
   33   22   29   34    2      0.00   167.36 
   15   14   18   22    2      0.00   167.36 
   16   14   17   20    2      0.00   167.36 
   17   12   16   18    2      0.00   167.36 
   12   10   13   17    2      0.00   167.36 
   10    7   11   12    2      0.00   167.36 
    7    6   10   20    2      0.00   167.36 
   20    7   16   21    2      0.00   167.36 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    9    2    4    5    1      0.00     1.05    3 
    4    2    9    8    1      0.00     1.05    3 
    2    4    5    6    1      0.00     3.77    3 
    4    5    6    7    1    180.00     1.00    6 
    5    6    7   10    1      0.00     0.42    2 
    7    6    8    9    1    180.00     1.00    6 
    6    8    9    2    1      0.00     3.77    3 
   14   15   22   23    1    180.00    33.50    2 
   27   28   35   36    1    180.00    33.50    2 
   38   40   41   46    1    180.00     7.11    2 
   40   41   46   47    1      0.00     1.26    3 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    6   11 
    6   12 
    6   16 
    6   21 
    7   13 
    7   14 
    7   17 
   10   16 
   10   18 
   10   21 
   11   13 
   11   17 
   11   20 
   12   14 
   12   15 
   12   19 
   12   20 
   13   16 
   13   18 
   14   19 
   14   21 
   15   20 
   15   24 
   15   25 
   15   29 
   15   34 
   16   19 
   16   22 
   17   21 
   17   22 
   18   20 
   19   22 
   22   26 
   22   27 
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   22   30 
   23   29 
   23   31 
   23   34 
   24   26 
   24   30 
   24   33 
   25   27 
   25   28 
   25   32 
   25   33 
   26   29 
   26   31 
   27   32 
   27   34 
   28   33 
   28   37 
   28   38 
   28   42 
   28   45 
   29   32 
   29   35 
   30   34 
   30   35 
   31   33 
   32   35 
   35   39 
   35   40 
   35   43 
   36   41 
   36   42 
   36   45 
   37   39 
   37   40 
   37   44 
   38   43 
   38   44 
   39   41 
   39   42 
   40   45 
   41   43 
   41   44 
   43   45 
 
 
1.4 Rhodamine 123 
;----------------------------TITLE ------------------------------------------- 
;   Rhodamine123 
; 
; This file was generated at 14:32 on 2012-10-04 by 
; 
;                  Automatic Topology Builder   
; 
;                   REVISION 2012-09-19 
;----------------------------------------------------------------------------- 
; Authors     : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, 
Alan E. Mark 
; 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
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; URL         : http://compbio.biosci.uq.edu.au/atb 
; Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; 
; Disclaimer  :  
;      While every effort has been made to ensure the accuracy and validity of 
parameters provided below 
;      the assignment of parameters is being based on an automated procedure 
combining data provided by a 
;      given user as well as calculations performed using third party software. 
They are provided as a guide. 
;      The authors of the ATB cannot guarantee that the parameters are complete 
or that the parameters provided 
;      are appropriate for use in any specific application. Users are advised to 
treat these parameters with discretion 
;      and to perform additional validation tests for their specific application 
if required. Neither the authors 
;      of the ATB or The University of Queensland except any responsibly for how 
the parameters may be used. 
; 
; Release notes and warnings:  
;  (1) The topology is based on a set of atomic coordinates and other data 
provided by the user after 
;      after quantum mechanical optimization of the structure using different 
levels of theory depending on 
;      the nature of the molecule. 
;  (2) In some cases the automatic bond, bond angle and dihedral type assignment 
is ambiguous. 
;      In these cases alternative type codes are provided at the end of the 
line. 
;  (3) While bonded parameters are taken where possible from the nominated force 
field non-standard bond, angle and dihedral 
;      type code may be incorporated in cases where an exact match could not be 
found. These are marked as "non-standard" 
;      or "uncertain" in comments. 
;  (4) In some cases it is not possible to assign an appropriate parameter 
automatically. "%" is used as a place holder 
;      for those fields that could not be determined automatically. The 
parameters in these fields must be assigned manually 
;      before the file can be used. 
;----------------------------------------------------------------------------- 
; Input Structure :  ROD 
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;---------------------------------------------------------------------------- 
; Intermediate Topology Generation was performed using:  
;  A B3LYP/6-31G* optimized geometry. 
;  Bonded and non-bonded parameters were taken from the GROMOS 53A6 parameter 
set. 
;  Initial charges were estimated using the ESP method of Merz-Kollman. 
;  Final charges and charge groups were generated by method described in the ATB 
paper. 
; 
; Topology file generated at 14:10 on 04 Oct 2012 for molecule 
; Rhodamine123 (IUPAC: methyl 2-[(3S,6R,8aS)-3,6-diamino-6,8a-dihydro-3H-
xanthen-9-yl]benzoate, database identifier:  ROD) 
; by Automatic Topology Builder(revision 2012-09-19). 
; 
[ moleculetype ] 
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; Name   nrexcl 
 ROD     3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1    NT    1     ROD     N2    1   -0.868  14.0067  
    2     H    1     ROD    H14    1    0.434   1.0080  
    3     H    1     ROD    H15    1    0.434   1.0080      ;  0.000 
    4    OE    1     ROD     O1    2   -0.310  15.9994  
    5     C    1     ROD     C2    2    0.796  12.0110  
    6     O    1     ROD     O2    2   -0.524  15.9994  
    7     C    1     ROD     C3    2   -0.424  12.0110  
    8     C    1     ROD     C8    2    0.492  12.0110  
    9     C    1     ROD     C9    2    0.006  12.0110  
   10     C    1     ROD    C10    2   -0.130  12.0110  
   11     C    1     ROD    C15    2    0.488  12.0110  
   12    OE    1     ROD     O3    2   -0.317  15.9994  
   13     C    1     ROD    C16    2    0.488  12.0110  
   14     C    1     ROD    C21    2   -0.130  12.0110  
   15   CH3    1     ROD     C1    2    0.223  15.0350  
   16     C    1     ROD    C17    2   -0.542  12.0110  
   17    HC    1     ROD    H13    2    0.239   1.0080  
   18     C    1     ROD    C18    2    0.578  12.0110  
   19     C    1     ROD    C19    2   -0.298  12.0110  
   20    HC    1     ROD    H16    2    0.194   1.0080  
   21     C    1     ROD    C14    2   -0.542  12.0110  
   22    HC    1     ROD    H12    2    0.239   1.0080  
   23     C    1     ROD    C13    2    0.578  12.0110  
   24     C    1     ROD    C12    2   -0.298  12.0110  
   25    HC    1     ROD     H9    2    0.194   1.0080      ;  1.000 
   26     C    1     ROD     C4    3   -0.156  12.0110  
   27    HC    1     ROD     H4    3    0.156   1.0080      ;  0.000 
   28     C    1     ROD     C5    4   -0.123  12.0110  
   29    HC    1     ROD     H5    4    0.123   1.0080      ;  0.000 
   30     C    1     ROD     C6    5   -0.123  12.0110  
   31    HC    1     ROD     H6    5    0.123   1.0080      ;  0.000 
   32     C    1     ROD     C7    6   -0.156  12.0110  
   33    HC    1     ROD     H7    6    0.156   1.0080      ;  0.000 
   34     C    1     ROD    C11    7   -0.156  12.0110  
   35    HC    1     ROD     H8    7    0.156   1.0080      ;  0.000 
   36     C    1     ROD    C20    8   -0.156  12.0110  
   37    HC    1     ROD    H17    8    0.156   1.0080      ;  0.000 
   38    NT    1     ROD     N1    9   -0.868  14.0067  
   39     H    1     ROD    H10    9    0.434   1.0080  
   40     H    1     ROD    H11    9    0.434   1.0080      ;  0.000 
; total charge of the molecule:   1.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1000   1.8700e+07 
    1    3    2   0.1000   1.8700e+07 
    1   18    2   0.1350   1.0300e+07 
    4    5    2   0.1360   1.0200e+07 
    4   15    2   0.1435   6.1000e+06 
    5    6    2   0.1230   1.6600e+07 
    5    7    2   0.1520   5.4300e+06 
    7    8    2   0.1390   8.6600e+06 
    7   26    2   0.1390   8.6600e+06 
    8    9    2   0.1520   5.4300e+06 
    8   32    2   0.1390   8.6600e+06 
    9   10    2   0.1390   8.6600e+06 
    9   14    2   0.1390   8.6600e+06 
   10   11    2   0.1390   8.6600e+06 
   10   34    2   0.1390   8.6600e+06 
   11   12    2   0.1360   1.0200e+07 
   11   21    2   0.1390   8.6600e+06 
211 
 
   12   13    2   0.1360   1.0200e+07 
   13   14    2   0.1390   8.6600e+06 
   13   16    2   0.1390   8.6600e+06 
   14   36    2   0.1390   8.6600e+06 
   16   17    2   0.1090   1.2300e+07 
   16   18    2   0.1390   8.6600e+06 
   18   19    2   0.1430   4.4700e+06 
   19   20    2   0.1090   1.2300e+07 
   19   36    2   0.1390   8.6600e+06 
   21   22    2   0.1090   1.2300e+07 
   21   23    2   0.1390   8.6600e+06 
   23   24    2   0.1430   4.4700e+06 
   23   38    2   0.1350   1.0300e+07 
   24   25    2   0.1090   1.2300e+07 
   24   34    2   0.1390   8.6600e+06 
   26   27    2   0.1090   1.2300e+07 
   26   28    2   0.1390   8.6600e+06 
   28   29    2   0.1090   1.2300e+07 
   28   30    2   0.1390   8.6600e+06 
   30   31    2   0.1090   1.2300e+07 
   30   32    2   0.1390   8.6600e+06 
   32   33    2   0.1090   1.2300e+07 
   34   35    2   0.1090   1.2300e+07 
   36   37    2   0.1090   1.2300e+07 
   38   39    2   0.1000   1.8700e+07 
   38   40    2   0.1000   1.8700e+07 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    2   16    1 
    2   19    1 
    3   16    1 
    3   19    1 
    4    8    1 
    4   26    1 
    6    8    1 
    6   15    1 
    6   26    1 
    7   10    1 
    7   14    1 
    7   15    1 
   10   32    1 
   14   32    1 
   21   39    1 
   21   40    1 
   24   39    1 
   24   40    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    2    1    3    2    120.00   445.00 
    2    1   18    2    120.00   390.00 
    3    1   18    2    120.00   390.00 
    5    4   15    2    118.00  1080.00 
    4    5    6    2    124.00   730.00 
    4    5    7    2    111.00   530.00 
    6    5    7    2    125.00   750.00 
    5    7    8    2    120.00   560.00 
    5    7   26    2    120.00   560.00 
    8    7   26    2    120.00   560.00 
    7    8    9    2    125.00   750.00 
    7    8   32    2    120.00   560.00 
    9    8   32    2    120.00   560.00 
    8    9   10    2    120.00   560.00 
    8    9   14    2    120.00   560.00 
   10    9   14    2    120.00   560.00 
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    9   10   11    2    120.00   560.00 
    9   10   34    2    125.00   750.00 
   11   10   34    2    120.00   560.00 
   10   11   12    2    121.00   685.00 
   10   11   21    2    125.00   750.00 
   12   11   21    2    117.00   635.00 
   11   12   13    2    125.00   750.00 
   12   13   14    2    121.00   685.00 
   12   13   16    2    117.00   635.00 
   14   13   16    2    125.00   750.00 
    9   14   13    2    120.00   560.00 
    9   14   36    2    125.00   750.00 
   13   14   36    2    120.00   560.00 
   13   16   17    2    120.00   505.00 
   13   16   18    2    120.00   560.00 
   17   16   18    2    120.00   505.00 
    1   18   16    2    120.00   560.00 
    1   18   19    2    120.00   560.00 
   16   18   19    2    120.00   560.00 
   18   19   20    2    120.00   505.00 
   18   19   36    2    120.00   560.00 
   20   19   36    2    120.00   505.00 
   11   21   22    2    120.00   505.00 
   11   21   23    2    120.00   560.00 
   22   21   23    2    120.00   505.00 
   21   23   24    2    120.00   560.00 
   21   23   38    2    120.00   560.00 
   24   23   38    2    120.00   560.00 
   23   24   25    2    120.00   505.00 
   23   24   34    2    120.00   560.00 
   25   24   34    2    120.00   505.00 
    7   26   27    2    120.00   505.00 
    7   26   28    2    120.00   560.00 
   27   26   28    2    120.00   505.00 
   26   28   29    2    120.00   505.00 
   26   28   30    2    120.00   560.00 
   29   28   30    2    120.00   505.00 
   28   30   31    2    120.00   505.00 
   28   30   32    2    120.00   560.00 
   31   30   32    2    120.00   505.00 
    8   32   30    2    120.00   560.00 
    8   32   33    2    120.00   505.00 
   30   32   33    2    120.00   505.00 
   10   34   24    2    120.00   560.00 
   10   34   35    2    120.00   505.00 
   24   34   35    2    120.00   505.00 
   14   36   19    2    120.00   560.00 
   14   36   37    2    120.00   505.00 
   19   36   37    2    120.00   505.00 
   23   38   39    2    120.00   390.00 
   23   38   40    2    120.00   390.00 
   39   38   40    2    120.00   445.00 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
    7    8   32   30    2      0.00   167.36 
    8   32   30   28    2      0.00   167.36 
   32   30   28   26    2      0.00   167.36 
   30   28   26    7    2      0.00   167.36 
   28   26    7    8    2      0.00   167.36 
   26    7    8   32    2      0.00   167.36 
    9   14   13   12    2      0.00   167.36 
   14   13   12   11    2      0.00   167.36 
   13   12   11   10    2      0.00   167.36 
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   12   11   10    9    2      0.00   167.36 
   11   10    9   14    2      0.00   167.36 
   10    9   14   13    2      0.00   167.36 
   10   11   21   23    2      0.00   167.36 
   11   21   23   24    2      0.00   167.36 
   21   23   24   34    2      0.00   167.36 
   23   24   34   10    2      0.00   167.36 
   24   34   10   11    2      0.00   167.36 
   34   10   11   21    2      0.00   167.36 
   14   36   19   18    2      0.00   167.36 
   36   19   18   16    2      0.00   167.36 
   19   18   16   13    2      0.00   167.36 
   18   16   13   14    2      0.00   167.36 
   16   13   14   36    2      0.00   167.36 
   13   14   36   19    2      0.00   167.36 
    5    4    6    7    2      0.00   167.36 
    7    5    8   26    2      0.00   167.36 
   26    7   27   28    2      0.00   167.36 
   28   26   29   30    2      0.00   167.36 
   30   28   31   32    2      0.00   167.36 
   32    8   30   33    2      0.00   167.36 
    8    7    9   32    2      0.00   167.36 
    9    8   10   14    2      0.00   167.36 
   10    9   11   34    2      0.00   167.36 
   34   10   24   35    2      0.00   167.36 
   24   23   25   34    2      0.00   167.36 
   23   21   24   38    2      0.00   167.36 
   38   23   39   40    2      0.00   167.36 
   21   11   22   23    2      0.00   167.36 
   11   10   12   21    2      0.00   167.36 
   13   12   14   16    2      0.00   167.36 
   16   13   17   18    2      0.00   167.36 
   18    1   16   19    2      0.00   167.36 
    1    2    3   18    2      0.00   167.36 
   19   18   20   36    2      0.00   167.36 
   36   14   19   37    2      0.00   167.36 
   14    9   13   36    2      0.00   167.36 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    2    1   18   16    1    180.00    33.50    2 
   15    4    5    6    1    180.00     7.11    2 
    4    5    7   26    1    180.00     5.86    2 
    7    8    9   10    1      0.00     0.42    2 
   24   23   38   39    1    180.00    33.50    2 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    1   13 
    1   17 
    1   20 
    1   36 
    5    9 
    5   27 
    5   28 
    5   32 
    7   29 
    7   30 
    7   33 
    8   11 
    8   13 
    8   27 
    8   28 
    8   31 
    8   34 
    8   36 
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    9   12 
    9   16 
    9   19 
    9   21 
    9   24 
    9   26 
    9   30 
    9   33 
    9   35 
    9   37 
   10   13 
   10   22 
   10   23 
   10   25 
   10   36 
   11   14 
   11   16 
   11   24 
   11   35 
   11   38 
   12   17 
   12   18 
   12   22 
   12   23 
   12   34 
   12   36 
   13   19 
   13   21 
   13   37 
   14   17 
   14   18 
   14   20 
   14   34 
   16   20 
   16   36 
   17   19 
   18   37 
   20   37 
   21   25 
   21   34 
   22   24 
   22   38 
   23   35 
   25   35 
   25   38 
   26   31 
   26   32 
   27   29 
   27   30 
   28   33 
   29   31 
   29   32 
   31   33 
   34   38 
 
1.5 Paclitaxel 
;----------------------------TITLE ------------------------------------------- 
;   Paclitaxel 
; 
; This file was generated at 15:17 on 2012-08-23 by 
; 
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;                  Automatic Topology Builder   
; 
;                   REVISION 2012-08-21 
; 
; File is edited by Nandhitha 2012-10-12 
; 
;----------------------------------------------------------------------------- 
; Authors     : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, 
Alan E. Mark 
; 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
; URL         : http://compbio.biosci.uq.edu.au/atb 
; Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; 
; Disclaimer  :  
;      While every effort has been made to ensure the accuracy and validity of 
parameters provided below 
;      the assignment of parameters is being based on an automated procedure 
combining data provided by a 
;      given user as well as calculations performed using third party software. 
They are provided as a guide. 
;      The authors of the ATB cannot guarantee that the parameters are complete 
or that the parameters provided 
;      are appropriate for use in any specific application. Users are advised to 
treat these parameters with discretion 
;      and to perform additional validation tests for their specific application 
if required. Neither the authors 
;      of the ATB or The University of Queensland except any responsibly for how 
the parameters may be used. 
; 
; Release notes and warnings:  
;  (1) The topology is based on a set of atomic coordinates and other data 
provided by the user after 
;      after quantum mechanical optimization of the structure using different 
levels of theory depending on 
;      the nature of the molecule. 
;  (2) In some cases the automatic bond, bond angle and dihedral type assignment 
is ambiguous. 
;      In these cases alternative type codes are provided at the end of the 
line. 
;  (3) While bonded parameters are taken where possible from the nominated force 
fieldnon standardbond, angle and dihedral 
;      type code may be incorporated in cases where an exact match could not be 
found. These are marked as "non-standard" 
;      or "uncertain" in comments. 
;  (4) In some cases it is not possible to assign an appropriate parameter 
automatically. "%" is used as a place holder 
;      for those fields that could not be determined automatically. The 
parameters in these fields must be assigned manually 
;      before the file can be used. 
;----------------------------------------------------------------------------- 
; Input Structure : PXL 
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;---------------------------------------------------------------------------- 
; Initial Guess Topology Generation:  
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; The topology was guessed from AM1 optimized geometry and MOPAC charges 
; 
[ moleculetype ] 
; Name   nrexcl 
PXL      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1    OA    1     PXL     O4    1   -0.718  15.9994  
    2     H    1     PXL    H22    1    0.421   1.0080  
    3   CH0    1     PXL     C6    1    0.405  12.0110      ;  0.108 
    4   CH0    1     PXL     C9    2    0.000  12.0110      ;  0.000 
    5     C    1     PXL    C13    3    0.000  12.0110      ;  0.000 
    6     C    1     PXL    C17    4    0.000  12.0110      ;  0.000 
    7   CH1    1     PXL     C5    5    0.200  13.0190  
    8    OE    1     PXL     O3    5   -0.360  15.9994  
    9     C    1     PXL    C22    5    0.540  12.0110  
   10     C    1     PXL    C26    5    0.000  12.0110  
   11     O    1     PXL    O10    5   -0.380  15.9994      ;  0.000 
   12   CH2    1     PXL    C12    6   -0.000  14.0270      ;  0.000 
   13   CH1    1     PXL    C16    7    0.200  13.0190  
   14    OE    1     PXL     O8    7   -0.360  15.9994  
   15     C    1     PXL    C25    7    0.540  12.0110  
   16     O    1     PXL    O12    7   -0.380  15.9994      ;  0.000 
   17   CH3    1     PXL    C18    8    0.000  15.0350      ;  0.000 
   18   CH3    1     PXL    C19    9    0.000  15.0350      ;  0.000 
   19   CH1    1     PXL    C15   10    0.200  13.0190  
   20    OE    1     PXL     O6   10   -0.360  15.9994  
   21     C    1     PXL    C24   10    0.540  12.0110  
   22     O    1     PXL    O11   10   -0.380  15.9994      ;  0.000 
   23   CH3    1     PXL    C20   11    0.000  15.0350      ;  0.000 
   24   CH1    1     PXL     C1   12    0.000  13.0190      ;  0.000 
   25    OE    1     PXL     O2   13   -0.360  15.9994  
   26   CH0    1     PXL     C2   13    0.200  12.0110  
   27     C    1     PXL    C21   13    0.540  12.0110      ;  0.380 
   28   CH1    1     PXL     C4   14    0.303  13.0190  
   29    OE    1     PXL     O1   14   -0.511  15.9994  
   30   CH2    1     PXL    C10   14    0.208  14.0270      ; -0.000 
   31     C    1     PXL    C29   15   -0.146  12.0110  
   32    HC    1     PXL    H34   15    0.146   1.0080      ;  0.000 
   33     C    1     PXL    C32   16   -0.146  12.0110  
   34    HC    1     PXL    H37   16    0.146   1.0080      ;  0.000 
   35     C    1     PXL    C34   17   -0.146  12.0110  
   36    HC    1     PXL    H40   17    0.146   1.0080      ;  0.000 
   37     C    1     PXL    C33   18   -0.146  12.0110  
   38    HC    1     PXL    H38   18    0.146   1.0080      ;  0.000 
   39     C    1     PXL    C30   19   -0.146  12.0110  
   40    HC    1     PXL    H35   19    0.146   1.0080      ;  0.000 
   41   CH1    1     PXL    C27   20    0.150  13.0190  
   42    OA    1     PXL    O13   20   -0.548  15.9994  
   43     H    1     PXL    H39   20    0.398   1.0080      ;  0.000 
   44     O    1     PXL     O7   21   -0.380  15.9994  
   45     C    1     PXL    C11   21    0.380  12.0110      ;  0.000 
   46   CH0    1     PXL     C3   22    0.000  12.0110      ;  0.000 
   47   CH1    1     PXL     C7   23    0.405  13.0190  
   48    OA    1     PXL     O5   23   -0.718  15.9994  
   49     H    1     PXL    H23   23    0.421   1.0080      ;  0.108 
   50   CH3    1     PXL    C28   24    0.000  15.0350      ;  0.000 
   51     O    1     PXL     O9   25   -0.380  15.9994      ; -0.380 
   52   CH3    1     PXL    C23   26    0.000  15.0350      ;  0.000 
   53   CH2    1     PXL     C8   27   -0.108  14.0270  
   54   CH1    1     PXL    C31   27   -0.108  13.0190      ; -0.216 
   55     N    1     PXL     N1   28   -0.280  14.0067  
   56     H    1     PXL    H41   28    0.280   1.0080      ;  0.000 
   57     O    1     PXL    O14   29   -0.380  15.9994  
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   58     C    1     PXL    C38   29    0.380  12.0110  
   59     C    1     PXL    C41   29   -0.000  12.0110      ;  0.000 
   60     C    1     PXL    C43   30   -0.146  12.0110  
   61    HC    1     PXL    H47   30    0.146   1.0080      ;  0.000 
   62     C    1     PXL    C45   31   -0.146  12.0110  
   63    HC    1     PXL    H49   31    0.146   1.0080      ;  0.000 
   64     C    1     PXL    C47   32   -0.146  12.0110  
   65    HC    1     PXL    H51   32    0.146   1.0080      ;  0.000 
   66     C    1     PXL    C46   33   -0.146  12.0110  
   67    HC    1     PXL    H50   33    0.146   1.0080      ;  0.000 
   68     C    1     PXL    C44   34   -0.146  12.0110  
   69    HC    1     PXL    H48   34    0.146   1.0080      ;  0.000 
   70   CH3    1     PXL    C14   35    0.000  15.0350      ;  0.000 
   71     C    1     PXL    C35   36   -0.000  12.0110      ;  0.000 
   72     C    1     PXL    C36   37   -0.146  12.0110  
   73    HC    1     PXL    H42   37    0.146   1.0080      ;  0.000 
   74     C    1     PXL    C39   38   -0.146  12.0110  
   75    HC    1     PXL    H44   38    0.146   1.0080      ;  0.000 
   76     C    1     PXL    C42   39   -0.146  12.0110  
   77    HC    1     PXL    H46   39    0.146   1.0080      ;  0.000 
   78     C    1     PXL    C40   40   -0.146  12.0110  
   79    HC    1     PXL    H45   40    0.146   1.0080      ;  0.000 
   80     C    1     PXL    C37   41   -0.146  12.0110  
   81    HC    1     PXL    H43   41    0.146   1.0080      ;  0.000 
; total charge of the molecule:   0.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1000   1.5700e+07 
    1    3    2   0.1430   8.1800e+06 
    3    4    2   0.1530   7.1500e+06 
    3    7    2   0.1530   7.1500e+06 
    3   12    2   0.1530   7.1500e+06 
    4    5    2   0.1520   5.4300e+06 
    4   17    2   0.1520   5.4300e+06 
    4   18    2   0.1530   7.1500e+06 
    5    6    2   0.1330   1.1800e+07 
    5   19    2   0.1520   5.4300e+06 
    6   13    2   0.1520   5.4300e+06 
    6   23    2   0.1530   7.1500e+06 
    7    8    2   0.1435   6.1000e+06 
    7   24    2   0.1530   7.1500e+06 
    8    9    2   0.1360   1.0200e+07 
    9   10    2   0.1530   7.1500e+06 
    9   11    2   0.1230   1.6600e+07 
   10   31    2   0.1390   8.6600e+06 
   10   39    2   0.1390   8.6600e+06 
   12   13    2   0.1530   7.1500e+06 
   13   14    2   0.1435   6.1000e+06 
   14   15    2   0.1360   1.0200e+07 
   15   16    2   0.1230   1.6600e+07 
   15   41    2   0.1520   5.4300e+06 
   19   20    2   0.1435   6.1000e+06 
   19   45    2   0.1530   7.1500e+06 
   20   21    2   0.1360   1.0200e+07 
   21   22    2   0.1230   1.6600e+07 
   21   50    2   0.1520   5.4300e+06 
   24   26    2   0.1530   7.1500e+06 
   24   46    2   0.1530   7.1500e+06 
   25   26    2   0.1430   8.1800e+06 
   25   27    2   0.1360   1.0200e+07 
   26   28    2   0.1530   7.1500e+06 
   26   30    2   0.1530   7.1500e+06 
   27   51    2   0.1230   1.6600e+07 
   27   52    2   0.1520   5.4300e+06 
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   28   29    2   0.1435   6.1000e+06 
   28   53    2   0.1520   5.4300e+06 
   29   30    2   0.1435   6.1000e+06 
   31   32    2   0.1100   1.2100e+07 
   31   33    2   0.1390   8.6600e+06 
   33   34    2   0.1100   1.2100e+07 
   33   35    2   0.1390   8.6600e+06 
   35   36    2   0.1100   1.2100e+07 
   35   37    2   0.1390   8.6600e+06 
   37   38    2   0.1100   1.2100e+07 
   37   39    2   0.1390   8.6600e+06 
   39   40    2   0.1100   1.2100e+07 
   41   42    2   0.1430   8.1800e+06 
   41   54    2   0.1530   7.1500e+06 
   42   43    2   0.1000   1.5700e+07 
   44   45    2   0.1230   1.6600e+07 
   45   46    2   0.1530   7.1500e+06 
   46   47    2   0.1530   7.1500e+06 
   46   70    2   0.1520   5.4300e+06 
   47   48    2   0.1430   8.1800e+06 
   47   53    2   0.1520   5.4300e+06 
   48   49    2   0.1000   1.5700e+07 
   54   55    2   0.1470   8.7100e+06 
   54   71    2   0.1520   5.4300e+06 
   55   56    2   0.1000   1.8700e+07 
   55   58    2   0.1380   1.1000e+07 
   57   58    2   0.1250   1.3400e+07 
   58   59    2   0.1520   5.4300e+06 
   59   60    2   0.1390   8.6600e+06 
   59   68    2   0.1390   8.6600e+06 
   60   61    2   0.1100   1.2100e+07 
   60   62    2   0.1390   8.6600e+06 
   62   63    2   0.1100   1.2100e+07 
   62   64    2   0.1390   8.6600e+06 
   64   65    2   0.1100   1.2100e+07 
   64   66    2   0.1390   8.6600e+06 
   66   67    2   0.1100   1.2100e+07 
   66   68    2   0.1390   8.6600e+06 
   68   69    2   0.1100   1.2100e+07 
   71   72    2   0.1390   8.6600e+06 
   71   80    2   0.1390   8.6600e+06 
   72   73    2   0.1100   1.2100e+07 
   72   74    2   0.1390   8.6600e+06 
   74   75    2   0.1100   1.2100e+07 
   74   76    2   0.1390   8.6600e+06 
   76   77    2   0.1100   1.2100e+07 
   76   78    2   0.1390   8.6600e+06 
   78   79    2   0.1100   1.2100e+07 
   78   80    2   0.1390   8.6600e+06 
   80   81    2   0.1100   1.2100e+07 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    5    1 
    1    8    1 
    1   13    1 
    1   17    1 
    1   18    1 
    1   24    1 
    2    4    1 
    2    7    1 
    2   12    1 
    3    6    1 
    3    9    1 
    3   14    1 
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    3   19    1 
    3   26    1 
    3   46    1 
    4    8    1 
    4   13    1 
    4   20    1 
    4   23    1 
    4   24    1 
    4   45    1 
    5    7    1 
    5   12    1 
    5   14    1 
    5   21    1 
    5   44    1 
    5   46    1 
    6   15    1 
    6   17    1 
    6   18    1 
    6   20    1 
    6   45    1 
    7   10    1 
    7   11    1 
    7   13    1 
    7   17    1 
    7   18    1 
    7   25    1 
    7   28    1 
    7   30    1 
    7   45    1 
    7   47    1 
    7   70    1 
    8   12    1 
    8   26    1 
    8   31    1 
    8   39    1 
    8   46    1 
    9   24    1 
   11   31    1 
   11   39    1 
   12   15    1 
   12   17    1 
   12   18    1 
   12   23    1 
   12   24    1 
   13   16    1 
   13   19    1 
   13   41    1 
   14   23    1 
   14   42    1 
   14   54    1 
   15   43    1 
   15   55    1 
   15   71    1 
   16   42    1 
   16   54    1 
   17   19    1 
   18   19    1 
   19   22    1 
   19   23    1 
   19   24    1 
   19   47    1 
   19   50    1 
   19   70    1 
   20   44    1 
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   20   46    1 
   21   45    1 
   24   27    1 
   24   29    1 
   24   44    1 
   24   48    1 
   24   53    1 
   25   29    1 
   25   46    1 
   25   53    1 
   26   45    1 
   26   47    1 
   26   51    1 
   26   52    1 
   26   70    1 
   27   28    1 
   27   30    1 
   28   46    1 
   28   48    1 
   29   47    1 
   30   46    1 
   30   53    1 
   41   56    1 
   41   58    1 
   41   72    1 
   41   80    1 
   42   55    1 
   42   71    1 
   43   54    1 
   44   47    1 
   44   70    1 
   45   48    1 
   45   53    1 
   46   49    1 
   48   70    1 
   49   53    1 
   53   70    1 
   54   57    1 
   54   59    1 
   55   60    1 
   55   68    1 
   55   72    1 
   55   80    1 
   56   57    1 
   56   59    1 
   56   71    1 
   57   60    1 
   57   68    1 
   58   71    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    2    1    3    2    108.53   443.00 
    1    3    4    2    109.50   320.00 
    1    3    7    2    109.50   320.00 
    1    3   12    2    109.50   320.00 
    4    3    7    2    109.50   285.00 
    4    3   12    2    111.00   530.00 
    7    3   12    2    111.00   530.00 
    3    4    5    2    111.00   530.00 
    3    4   17    2    111.00   530.00 
    3    4   18    2    111.00   530.00 
    5    4   17    2    120.00   560.00 
    5    4   18    2    111.00   530.00 
   17    4   18    2    109.50   285.00 
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    4    5    6    2    120.00   560.00 
    4    5   19    2    120.00   560.00 
    6    5   19    2    120.00   560.00 
    5    6   13    2    120.00   560.00 
    5    6   23    2    125.00   750.00 
   13    6   23    2    120.00   560.00 
    3    7    8    2    109.50   320.00 
    3    7   24    2    120.00   560.00 
    8    7   24    2    111.00   530.00 
    7    8    9    2    117.00   635.00 
    8    9   10    2    115.00   610.00 
    8    9   11    2    117.00   635.00 
   10    9   11    2    126.00   640.00 
    9   10   31    2    120.00   560.00 
    9   10   39    2    120.00   560.00 
   31   10   39    2    120.00   560.00 
    3   12   13    2    111.00   530.00 
    6   13   12    2    111.00   530.00 
    6   13   14    2    109.50   320.00 
   12   13   14    2    109.50   320.00 
   13   14   15    2    117.00   635.00 
   14   15   16    2    124.00   730.00 
   14   15   41    2    111.00   530.00 
   16   15   41    2    126.00   640.00 
    5   19   20    2    110.30   524.00 
    5   19   45    2    109.50   285.00 
   20   19   45    2    109.50   320.00 
   19   20   21    2    117.00   635.00 
   20   21   22    2    124.00   730.00 
   20   21   50    2    111.00   530.00 
   22   21   50    2    126.00   640.00 
    7   24   26    2    111.00   530.00 
    7   24   46    2    111.00   530.00 
   26   24   46    2    111.00   530.00 
   26   25   27    2    125.00   750.00 
   24   26   25    2    117.00   635.00 
   24   26   28    2    120.00   560.00 
   24   26   30    2    120.00   560.00 
   25   26   28    2    111.00   530.00 
   25   26   30    2    115.00   610.00 
   28   26   30    2     90.00   380.00 
   25   27   51    2    124.00   730.00 
   25   27   52    2    111.00   530.00 
   51   27   52    2    126.00   640.00 
   26   28   29    2     90.00   380.00 
   26   28   53    2    120.00   560.00 
   29   28   53    2    109.50   320.00 
   28   29   30    2     90.00   380.00 
   26   30   29    2     90.00   380.00 
   10   31   32    2    120.00   505.00 
   10   31   33    2    120.00   560.00 
   32   31   33    2    120.00   505.00 
   31   33   34    2    120.00   505.00 
   31   33   35    2    120.00   560.00 
   34   33   35    2    120.00   505.00 
   33   35   36    2    120.00   505.00 
   33   35   37    2    120.00   560.00 
   36   35   37    2    120.00   505.00 
   35   37   38    2    120.00   505.00 
   35   37   39    2    120.00   560.00 
   38   37   39    2    120.00   505.00 
   10   39   37    2    120.00   560.00 
   10   39   40    2    120.00   505.00 
   37   39   40    2    120.00   505.00 
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   15   41   42    2    109.50   320.00 
   15   41   54    2    109.50   285.00 
   42   41   54    2    115.00   610.00 
   41   42   43    2    108.53   443.00 
   19   45   44    2    117.00   635.00 
   19   45   46    2    125.00   750.00 
   44   45   46    2    121.00   685.00 
   24   46   45    2    111.00   530.00 
   24   46   47    2    109.50   285.00 
   24   46   70    2    111.00   530.00 
   45   46   47    2    104.00   490.00 
   45   46   70    2    109.50   285.00 
   47   46   70    2    109.50   285.00 
   46   47   48    2    110.30   524.00 
   46   47   53    2    111.00   530.00 
   48   47   53    2    109.50   320.00 
   47   48   49    2    108.53   443.00 
   28   53   47    2    111.00   530.00 
   41   54   55    2    111.00   530.00 
   41   54   71    2    109.50   285.00 
   55   54   71    2    115.00   610.00 
   54   55   56    2    116.00   465.00 
   54   55   58    2    125.00   750.00 
   56   55   58    2    116.00   465.00 
   55   58   57    2    121.40  690.00 
   55   58   59    2    120.00   560.00 
   57   58   59    2    121.00   685.00 
   58   59   60    2    120.00   560.00 
   58   59   68    2    120.00   560.00 
   60   59   68    2    120.00   560.00 
   59   60   61    2    120.00   505.00 
   59   60   62    2    120.00   560.00 
   61   60   62    2    120.00   505.00 
   60   62   63    2    120.00   505.00 
   60   62   64    2    120.00   560.00 
   63   62   64    2    120.00   505.00 
   62   64   65    2    120.00   505.00 
   62   64   66    2    120.00   560.00 
   65   64   66    2    120.00   505.00 
   64   66   67    2    120.00   505.00 
   64   66   68    2    120.00   560.00 
   67   66   68    2    120.00   505.00 
   59   68   66    2    120.00   560.00 
   59   68   69    2    120.00   505.00 
   66   68   69    2    120.00   505.00 
   54   71   72    2    120.00   560.00 
   54   71   80    2    120.00   560.00 
   72   71   80    2    120.00   560.00 
   71   72   73    2    120.00   505.00 
   71   72   74    2    120.00   560.00 
   73   72   74    2    120.00   505.00 
   72   74   75    2    120.00   505.00 
   72   74   76    2    120.00   560.00 
   75   74   76    2    120.00   505.00 
   74   76   77    2    120.00   505.00 
   74   76   78    2    120.00   560.00 
   77   76   78    2    120.00   505.00 
   76   78   79    2    120.00   505.00 
   76   78   80    2    120.00   560.00 
   79   78   80    2    120.00   505.00 
   71   80   78    2    120.00   560.00 
   71   80   81    2    120.00   505.00 
   78   80   81    2    120.00   505.00 
[ dihedrals ] 
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; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
   10   39   37   35    2      0.00   167.36 
   39   37   35   33    2      0.00   167.36 
   37   35   33   31    2      0.00   167.36 
   35   33   31   10    2      0.00   167.36 
   33   31   10   39    2      0.00   167.36 
   31   10   39   37    2      0.00   167.36 
   59   68   66   64    2      0.00   167.36 
   68   66   64   62    2      0.00   167.36 
   66   64   62   60    2      0.00   167.36 
   64   62   60   59    2      0.00   167.36 
   62   60   59   68    2      0.00   167.36 
   60   59   68   66    2      0.00   167.36 
   71   80   78   76    2      0.00   167.36 
   80   78   76   74    2      0.00   167.36 
   78   76   74   72    2      0.00   167.36 
   76   74   72   71    2      0.00   167.36 
   74   72   71   80    2      0.00   167.36 
   72   71   80   78    2      0.00   167.36 
   55   54   56   58    2      0.00   167.36 
   45   19   44   46    2      0.00   167.36 
    5    4    6   19    2      0.00   167.36 
    6    5   13   23    2      0.00   167.36 
   27   25   51   52    2      0.00   167.36 
    9    8   10   11    2      0.00   167.36 
   21   20   22   50    2      0.00   167.36 
   15   14   16   41    2      0.00   167.36 
   10    9   31   39    2      0.00   167.36 
   31   10   32   33    2      0.00   167.36 
   39   10   37   40    2      0.00   167.36 
   33   31   34   35    2      0.00   167.36 
   37   35   38   39    2      0.00   167.36 
   35   33   36   37    2      0.00   167.36 
   71   54   72   80    2      0.00   167.36 
   72   71   73   74    2      0.00   167.36 
   80   71   78   81    2      0.00   167.36 
   58   55   57   59    2      0.00   167.36 
   74   72   75   76    2      0.00   167.36 
   78   76   79   80    2      0.00   167.36 
   59   58   60   68    2      0.00   167.36 
   76   74   77   78    2      0.00   167.36 
   60   59   61   62    2      0.00   167.36 
   68   59   66   69    2      0.00   167.36 
   62   60   63   64    2      0.00   167.36 
   66   64   67   68    2      0.00   167.36 
   64   62   65   66    2      0.00   167.36 
   24   26   46    7    2     35.26   334.72 
   28   26   29   53    2     35.26   334.72 
    7   24    8    3    2     35.26   334.72 
   47   48   46   53    2     35.26   334.72 
   19   20   45    5    2     35.26   334.72 
   13   12   14    6    2     35.26   334.72 
   41   15   42   54    2     35.26   334.72 
   54   55   41   71    2     35.26   334.72 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    2    1    3    7    1      0.00     1.26    3 
    1    3    4    5    1      0.00     3.77    3 
    1    3    7    8    1      0.00     5.35    1 
    1    3   12   13    1      0.00     2.79    1 
    3    4    5   19    1    180.00     1.00    6 
    4    5    6   13    1    180.00     1.53    2 
    4    5   19   20    1    180.00     1.00    6 
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    5    6   13   14    1      0.00     1.00    6 
   24    7    8    9    1    180.00    24.00    2 
    8    7   24   26    1    180.00    24.00    2 
    7    8    9   11    1    180.00     7.11    2 
    8    9   10   31    1    180.00     5.86    2 
    3   12   13   14    1      0.00     1.05    3 
   12   13   14   15    1    180.00    24.00    2 
   13   14   15   16    1    180.00     7.11    2 
   14   15   41   42    1    180.00     1.00    6 
   45   19   20   21    1    180.00    24.00    2 
   20   19   45   44    1    180.00     1.00    6 
   19   20   21   22    1    180.00     7.11    2 
   46   24   26   25    1      0.00     1.05    3 
   26   24   46   47    1      0.00     3.77    3 
   27   25   26   24    1      0.00     1.26    3 
   26   25   27   51    1    180.00     7.11    2 
   25   26   28   29    1      0.00     2.09    2 
   25   26   30   29    1      0.00     1.05    3 
   26   28   29   30    1      0.00     1.05    3 
   29   28   53   47    1      0.00     1.05    3 
   28   29   30   26    1      0.00     1.05    3 
   15   41   42   43    1      0.00     1.26    3 
   42   41   54   55    1      0.00     3.77    3 
   44   45   46   24    1    180.00     1.00    6 
   24   46   47   48    1      0.00     3.77    3 
   46   47   48   49    1      0.00     3.90    3 
   48   47   53   28    1      0.00     3.77    3 
   41   54   55   58    1      0.00     3.77    6 
   55   54   71   72    1    180.00     1.00    6 
   54   55   58   57    1    180.00    33.50    2 
   57   58   59   60    1      0.00     0.42    2 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    9   32 
    9   33 
    9   37 
    9   40 
   10   34 
   10   35 
   10   38 
   31   36 
   31   37 
   31   40 
   32   34 
   32   35 
   32   39 
   33   38 
   33   39 
   34   36 
   34   37 
   35   40 
   36   38 
   36   39 
   38   40 
   54   73 
   54   74 
   54   78 
   54   81 
   58   61 
   58   62 
   58   66 
   58   69 
   59   63 
   59   64 
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   59   67 
   60   65 
   60   66 
   60   69 
   61   63 
   61   64 
   61   68 
   62   67 
   62   68 
   63   65 
   63   66 
   64   69 
   65   67 
   65   68 
   67   69 
   71   75 
   71   76 
   71   79 
   72   77 
   72   78 
   72   81 
   73   75 
   73   76 
   73   80 
   74   79 
   74   80 
   75   77 
   75   78 
   76   81 
   77   79 
   77   80 
   79   81 
 
1.6 Tariquidar 
;----------------------------TITLE ------------------------------------------- 
;   tariquidar 
; 
; This file was generated at 13:34 on 2012-10-03 by 
; 
;                  Automatic Topology Builder   
; 
;                   REVISION 2012-09-19 
; 
; file is edited by Nandhitha on 2012-10-15  
; 
;----------------------------------------------------------------------------- 
; Authors     : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, 
Alan E. Mark 
; 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
; URL         : http://compbio.biosci.uq.edu.au/atb 
; Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; 
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; Disclaimer  :  
;      While every effort has been made to ensure the accuracy and validity of 
parameters provided below 
;      the assignment of parameters is being based on an automated procedure 
combining data provided by a 
;      given user as well as calculations performed using third party software. 
They are provided as a guide. 
;      The authors of the ATB cannot guarantee that the parameters are complete 
or that the parameters provided 
;      are appropriate for use in any specific application. Users are advised to 
treat these parameters with discretion 
;      and to perform additional validation tests for their specific application 
if required. Neither the authors 
;      of the ATB or The University of Queensland except any responsibly for how 
the parameters may be used. 
; 
; Release notes and warnings:  
;  (1) The topology is based on a set of atomic coordinates and other data 
provided by the user after 
;      after quantum mechanical optimization of the structure using different 
levels of theory depending on 
;      the nature of the molecule. 
;  (2) In some cases the automatic bond, bond angle and dihedral type assignment 
is ambiguous. 
;      In these cases alternative type codes are provided at the end of the 
line. 
;  (3) While bonded parameters are taken where possible from the nominated force 
field non-standard bond, angle and dihedral 
;      type code may be incorporated in cases where an exact match could not be 
found. These are marked as "non-standard" 
;      or "uncertain" in comments. 
;  (4) In some cases it is not possible to assign an appropriate parameter 
automatically. "%" is used as a place holder 
;      for those fields that could not be determined automatically. The 
parameters in these fields must be assigned manually 
;      before the file can be used. 
;----------------------------------------------------------------------------- 
; Input Structure : TQR 
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;---------------------------------------------------------------------------- 
; Initial Guess Topology Generation:  
; The topology was guessed from PM3 optimized geometry and MOPAC charges 
; 
[ moleculetype ] 
; Name   nrexcl 
TQR      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1    OA    1     TQR     O5    1   -0.436  15.9994  
    2     H    1     TQR    H22    1    0.436   1.0080      ;  0.000 
    3     C    1     TQR    C13    2    0.746  12.0110  
    4     O    1     TQR     O2    2   -0.624  15.9994  
    5     C    1     TQR    C14    2   -0.664  12.0110  
    6     C    1     TQR    C21    2    0.636  12.0110  
    7    NR    1     TQR     N3    2   -0.739  14.0067  
    8     C    1     TQR    C22    2    0.525  12.0110  
    9     C    1     TQR    C23    2    0.392  12.0110  
   10     N    1     TQR     N2    2   -0.662  14.0067  
   11     H    1     TQR    H13    2    0.390   1.0080      ;  0.000 
   12     C    1     TQR    C12    3    0.113  12.0110  
   13     C    1     TQR    C11    3   -0.288  12.0110  
   14    HC    1     TQR    H12    3    0.175   1.0080      ;  0.000 
   15     C    1     TQR    C10    4   -0.121  12.0110  
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   16    HC    1     TQR    H11    4    0.121   1.0080      ;  0.000 
   17     C    1     TQR     C9    5    0.000  12.0110      ;  0.000 
   18   CH2    1     TQR     C8    6    0.000  14.0270      ;  0.000 
   19   CH2    1     TQR     C7    7    0.192  14.0270  
   20    NL    1     TQR     N1    7    0.096  14.0067  
   21     H    1     TQR    H39    7    0.354   1.0080  
   22   CH2    1     TQR     C6    7    0.205  14.0270  
   23     C    1     TQR     C4    7   -0.037  12.0110  
   24     C    1     TQR     C5    7   -0.032  12.0110      ;  0.778 
   25     C    1     TQR     C3    8   -0.153  12.0110  
   26    HC    1     TQR     H4    8    0.153   1.0080      ;  0.000 
   27    OE    1     TQR     O1    9   -0.366  15.9994  
   28     C    1     TQR     C2    9    0.241  12.0110  
   29     C    1     TQR    C37    9    0.241  12.0110  
   30    OE    1     TQR     O6    9   -0.366  15.9994  
   31   CH3    1     TQR     C1    9    0.148  15.0350      ; -0.102 
   32     C    1     TQR    C15   10   -0.099  12.0110  
   33    HC    1     TQR    H14   10    0.099   1.0080      ;  0.000 
   34     C    1     TQR    C16   11    0.246  12.0110  
   35    OE    1     TQR     O3   11   -0.334  15.9994  
   36     C    1     TQR    C18   11    0.246  12.0110  
   37    OE    1     TQR     O4   11   -0.334  15.9994  
   38   CH3    1     TQR    C17   11    0.176  15.0350      ; -0.000 
   39     C    1     TQR    C20   12   -0.202  12.0110  
   40    HC    1     TQR    H21   12    0.202   1.0080      ;  0.000 
   41     C    1     TQR    C24   13    0.378  12.0110  
   42    HC    1     TQR    H23   13    0.266   1.0080  
   43    NR    1     TQR     N4   13   -0.713  14.0067  
   44     C    1     TQR    C25   13    0.153  12.0110  
   45     C    1     TQR    C30   13   -0.180  12.0110      ; -0.096 
   46     C    1     TQR    C26   14   -0.138  12.0110  
   47    HC    1     TQR    H24   14    0.138   1.0080      ;  0.000 
   48     C    1     TQR    C27   15   -0.138  12.0110  
   49    HC    1     TQR    H25   15    0.138   1.0080      ;  0.000 
   50     C    1     TQR    C28   16   -0.138  12.0110  
   51    HC    1     TQR    H26   16    0.138   1.0080      ;  0.000 
   52     C    1     TQR    C29   17   -0.138  12.0110  
   53    HC    1     TQR    H27   17    0.138   1.0080      ;  0.000 
   54     C    1     TQR    C31   18   -0.033  12.0110  
   55    HC    1     TQR    H28   18    0.135   1.0080      ;  0.102 
   56     C    1     TQR    C32   19   -0.288  12.0110  
   57    HC    1     TQR    H29   19    0.175   1.0080      ; -0.113 
   58     C    1     TQR    C33   20   -0.121  12.0110  
   59    HC    1     TQR    H30   20    0.121   1.0080      ;  0.000 
   60   CH2    1     TQR    C34   21    0.035  14.0270  
   61   CH2    1     TQR    C35   21    0.072  14.0270      ;  0.107 
   62     C    1     TQR    C36   22   -0.153  12.0110  
   63    HC    1     TQR    H35   22    0.153   1.0080      ;  0.000 
   64   CH3    1     TQR    C38   23    0.148  15.0350      ;  0.148 
   65   CH3    1     TQR    C19   24    0.176  15.0350      ;  0.176 
; total charge of the molecule:   1.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2 gb_1 
    1    8    2 gb_13 
    3    4    2 gb_5 
    3    5    2 gb_26 
    3   10    2 gb_17 
    5    6    2 gb_15 
    5   32    2 gb_15 
    6    7    2 gb_17 
    6   39    2 gb_15 
    7    8    2 gb_7 
    8    9    2 gb_25 
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    9   41    2 gb_20 
    9   54    2 gb_15 
   10   11    2 gb_2 
   10   12    2 gb_17 
   12   13    2 gb_15 
   12   56    2 gb_15 
   13   14    2 gb_39 
   13   15    2 gb_15 
   15   16    2 gb_39 
   15   17    2 gb_15 
   17   18    2 gb_26 
   17   58    2 gb_15 
   18   19    2 gb_27 
   19   20    2 gb_22 
   20   21    2 gb_2 
   20   22    2 gb_22 
   20   60    2 gb_22 
   22   24    2 gb_26 
   23   24    2 gb_15 
   23   25    2 gb_15 
   23   61    2 gb_26 
   24   62    2 gb_15 
   25   26    2 gb_39 
   25   28    2 gb_15 
   27   28    2 gb_13 
   27   31    2 gb_18 
   28   29    2 gb_20 
   29   30    2 gb_13 
   29   62    2 gb_15 
   30   64    2 gb_18 
   32   33    2 gb_39 
   32   34    2 gb_15 
   34   35    2 gb_13 
   34   36    2 gb_15 
   35   38    2 gb_18 
   36   37    2 gb_13 
   36   39    2 gb_15 
   37   65    2 gb_18 
   39   40    2 gb_39 
   41   42    2 gb_39 
   41   43    2 gb_7 
   43   44    2 gb_17 
   44   45    2 gb_15 
   44   46    2 gb_15 
   45   52    2 gb_15 
   45   54    2 gb_15 
   46   47    2 gb_39 
   46   48    2 gb_15 
   48   49    2 gb_39 
   48   50    2 gb_15 
   50   51    2 gb_39 
   50   52    2 gb_15 
   52   53    2 gb_39 
   54   55    2 gb_39 
   56   57    2 gb_39 
   56   58    2 gb_15 
   58   59    2 gb_39 
   60   61    2 gb_26 
   62   63    2 gb_39 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    6    1 
    1   41    1 
    1   54    1 
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    2    7    1 
    2    9    1 
    3   13    1 
    3   56    1 
    4    6    1 
    4   11    1 
    4   12    1 
    4   32    1 
    5    8    1 
    5   11    1 
    5   12    1 
    6    9    1 
    6   10    1 
    7   41    1 
    7   54    1 
    8   39    1 
   10   32    1 
   11   13    1 
   11   56    1 
   15   19    1 
   17   20    1 
   18   21    1 
   18   22    1 
   18   60    1 
   19   24    1 
   19   58    1 
   19   61    1 
   20   23    1 
   20   62    1 
   21   24    1 
   21   61    1 
   24   60    1 
   25   31    1 
   25   60    1 
   28   64    1 
   29   31    1 
   32   38    1 
   34   65    1 
   36   38    1 
   39   65    1 
   62   64    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    2    1    8    2 ga_12 
    4    3    5    2 ga_35 
    4    3   10    2 ga_54 ;non standard 
    5    3   10    2 ga_19 
    3    5    6    2 ga_27 
    3    5   32    2 ga_27 
    6    5   32    2 ga_27 
    5    6    7    2 ga_27 
    5    6   39    2 ga_27 
    7    6   39    2 ga_27 
    6    7    8    2 ga_33 
    1    8    7    2 ga_35 
    1    8    9    2 ga_19 
    7    8    9    2 ga_27 
    8    9   41    2 ga_27 
    8    9   54    2 ga_27 
   41    9   54    2 ga_27 
    3   10   11    2 ga_20 
    3   10   12    2 ga_35 
   11   10   12    2 ga_20 
   10   12   13    2 ga_27 
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   10   12   56    2 ga_27 
   13   12   56    2 ga_27 
   12   13   14    2 ga_25 
   12   13   15    2 ga_27 
   14   13   15    2 ga_25 
   13   15   16    2 ga_25 
   13   15   17    2 ga_27 
   16   15   17    2 ga_25 
   15   17   18    2 ga_27 
   15   17   58    2 ga_27 
   18   17   58    2 ga_27 
   17   18   19    2 ga_8 
   18   19   20    2 ga_19 
   19   20   21    2 ga_11 
   19   20   22    2 ga_21 
   19   20   60    2 ga_21 
   21   20   22    2 ga_11 
   21   20   60    2 ga_11 
   22   20   60    2 ga_11 
   20   22   24    2 ga_15 
   24   23   25    2 ga_27 
   24   23   61    2 ga_27 
   25   23   61    2 ga_27 
   22   24   23    2 ga_27 
   22   24   62    2 ga_27 
   23   24   62    2 ga_27 
   23   25   26    2 ga_25 
   23   25   28    2 ga_27 
   26   25   28    2 ga_25 
   28   27   31    2 ga_53 ;non standard 
   25   28   27    2 ga_35 
   25   28   29    2 ga_27 
   27   28   29    2 ga_19 
   28   29   30    2 ga_19 
   28   29   62    2 ga_27 
   30   29   62    2 ga_35 
   29   30   64    2 ga_53 ;non standard 
    5   32   33    2 ga_25 
    5   32   34    2 ga_27 
   33   32   34    2 ga_25 
   32   34   35    2 ga_35 
   32   34   36    2 ga_27 
   35   34   36    2 ga_19 
   34   35   38    2 ga_53 ;non standard 
   34   36   37    2 ga_19 
   34   36   39    2 ga_27 
   37   36   39    2 ga_35 
   36   37   65    2 ga_53 ;non standard 
    6   39   36    2 ga_27 
    6   39   40    2 ga_25 
   36   39   40    2 ga_25 
    9   41   42    2 ga_25 
    9   41   43    2 ga_27 
   42   41   43    2 ga_25 
   41   43   44    2 ga_27 
   43   44   45    2 ga_27 
   43   44   46    2 ga_27 
   45   44   46    2 ga_27 
   44   45   52    2 ga_27 
   44   45   54    2 ga_27 
   52   45   54    2 ga_27 
   44   46   47    2 ga_25 
   44   46   48    2 ga_27 
   47   46   48    2 ga_25 
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   46   48   49    2 ga_25 
   46   48   50    2 ga_27 
   49   48   50    2 ga_25 
   48   50   51    2 ga_25 
   48   50   52    2 ga_27 
   51   50   52    2 ga_25 
   45   52   50    2 ga_27 
   45   52   53    2 ga_25 
   50   52   53    2 ga_25 
    9   54   45    2 ga_27 
    9   54   55    2 ga_25 
   45   54   55    2 ga_25 
   12   56   57    2 ga_25 
   12   56   58    2 ga_27 
   57   56   58    2 ga_25 
   17   58   56    2 ga_27 
   17   58   59    2 ga_25 
   56   58   59    2 ga_25 
   20   60   61    2 ga_15 
   23   61   60    2 ga_15 
   24   62   29    2 ga_27 
   24   62   63    2 ga_25 
   29   62   63    2 ga_25 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
   28   29   62   24    2 gi_1 
   29   62   24   23    2 gi_1 
   62   24   23   25    2 gi_1 
   24   23   25   28    2 gi_1 
   23   25   28   29    2 gi_1 
   25   28   29   62    2 gi_1 
   17   58   56   12    2 gi_1 
   58   56   12   13    2 gi_1 
   56   12   13   15    2 gi_1 
   12   13   15   17    2 gi_1 
   13   15   17   58    2 gi_1 
   15   17   58   56    2 gi_1 
    5    6   39   36    2 gi_1 
    6   39   36   34    2 gi_1 
   39   36   34   32    2 gi_1 
   36   34   32    5    2 gi_1 
   34   32    5    6    2 gi_1 
   32    5    6   39    2 gi_1 
    9   54   45   44    2 gi_1 
   54   45   44   43    2 gi_1 
   45   44   43   41    2 gi_1 
   44   43   41    9    2 gi_1 
   43   41    9   54    2 gi_1 
   41    9   54   45    2 gi_1 
   45   52   50   48    2 gi_1 
   52   50   48   46    2 gi_1 
   50   48   46   44    2 gi_1 
   48   46   44   45    2 gi_1 
   46   44   45   52    2 gi_1 
   44   45   52   50    2 gi_1 
   28   25   27   29    2 gi_1 
   25   23   26   28    2 gi_1 
   23   24   25   61    2 gi_1 
   24   22   23   62    2 gi_1 
   17   15   18   58    2 gi_1 
   15   13   16   17    2 gi_1 
   13   12   14   15    2 gi_1 
   12   10   13   56    2 gi_1 
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   10    3   11   12    2 gi_1 
    3    4    5   10    2 gi_1 
    5    3    6   32    2 gi_1 
   32    5   33   34    2 gi_1 
   34   32   35   36    2 gi_1 
   36   34   37   39    2 gi_1 
   39    6   36   40    2 gi_1 
    6    5    7   39    2 gi_1 
    8    1    7    9    2 gi_1 
    9    8   41   54    2 gi_1 
   41    9   42   43    2 gi_1 
   44   43   45   46    2 gi_1 
   46   44   47   48    2 gi_1 
   48   46   49   50    2 gi_1 
   50   48   51   52    2 gi_1 
   52   45   50   53    2 gi_1 
   45   44   52   54    2 gi_1 
   54    9   45   55    2 gi_1 
   56   12   57   58    2 gi_1 
   58   17   56   59    2 gi_1 
   62   24   29   63    2 gi_1 
   29   28   30   62    2 gi_1 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    2    1    8    7    1 gd_11 
   10    3    5   32    1 gd_17 
    4    3   10   12    1 gd_14 
    5    6    7    8    1 gd_17 
    6    7    8    1    1 gd_14 
    7    8    9   41    1 gd_14 
    3   10   12   13    1 gd_14 
   15   17   18   19    1 gd_39 
   17   18   19   20    1 gd_29 
   18   19   20   22    1 gd_22 
   19   20   22   24    1 gd_22 
   22   20   60   61    1 gd_22 
   20   22   24   23    1 gd_40 
   25   23   61   60    1 gd_39 
   31   27   28   25    1 gd_11 
   28   29   30   64    1 gd_11 
   32   34   35   38    1 gd_11 
   34   36   37   65    1 gd_11 
   20   60   61   23    1 gd_29 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    3    7 
    3   33 
    3   34 
    3   39 
    5   35 
    5   36 
    5   40 
    6   33 
    6   34 
    6   37 
    7   32 
    7   36 
    7   40 
    8   42 
    8   43 
    8   45 
    8   55 
    9   44 
    9   52 
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   10   14 
   10   15 
   10   57 
   10   58 
   12   16 
   12   17 
   12   59 
   13   18 
   13   57 
   13   58 
   14   16 
   14   17 
   14   56 
   15   56 
   15   59 
   16   18 
   16   58 
   17   57 
   18   56 
   18   59 
   22   25 
   22   29 
   22   61 
   22   63 
   23   27 
   23   29 
   23   63 
   24   26 
   24   28 
   24   30 
   25   30 
   25   62 
   26   27 
   26   29 
   26   61 
   27   30 
   27   62 
   28   61 
   28   63 
   30   63 
   32   37 
   32   39 
   33   35 
   33   36 
   34   40 
   35   37 
   35   39 
   37   40 
   41   45 
   41   46 
   41   55 
   42   44 
   42   54 
   43   47 
   43   48 
   43   52 
   43   54 
   44   49 
   44   50 
   44   53 
   44   55 
   45   47 
   45   48 
   45   51 
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   46   51 
   46   52 
   46   54 
   47   49 
   47   50 
   48   53 
   49   51 
   49   52 
   50   54 
   51   53 
   52   55 
   53   54 
   57   59 
   61   62 
 
1.7 Verapamil 
;----------------------------TITLE ------------------------------------------- 
;   Verapamil 
; 
; This file was generated at 12:39 on 2012-10-03 by 
; 
;                  Automatic Topology Builder   
; 
;                   REVISION 2012-09-19 
; 
; MTB file edited by Nandhitha on 2012-10-11 
;----------------------------------------------------------------------------- 
; Authors     : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, 
Alan E. Mark 
; 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
; URL         : http://compbio.biosci.uq.edu.au/atb 
; Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; 
; Disclaimer  :  
;      While every effort has been made to ensure the accuracy and validity of 
parameters provided below 
;      the assignment of parameters is being based on an automated procedure 
combining data provided by a 
;      given user as well as calculations performed using third party software. 
They are provided as a guide. 
;      The authors of the ATB cannot guarantee that the parameters are complete 
or that the parameters provided 
;      are appropriate for use in any specific application. Users are advised to 
treat these parameters with discretion 
;      and to perform additional validation tests for their specific application 
if required. Neither the authors 
;      of the ATB or The University of Queensland except any responsibly for how 
the parameters may be used. 
; 
; Release notes and warnings:  
;  (1) The topology is based on a set of atomic coordinates and other data 
provided by the user after 
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;      after quantum mechanical optimization of the structure using different 
levels of theory depending on 
;      the nature of the molecule. 
;  (2) In some cases the automatic bond, bond angle and dihedral type assignment 
is ambiguous. 
;      In these cases alternative type codes are provided at the end of the 
line. 
;  (3) While bonded parameters are taken where possible from the nominated force 
field non-standard bond, angle and dihedral 
;      type code may be incorporated in cases where an exact match could not be 
found. These are marked as "non-standard" 
;      or "uncertain" in comments. 
;  (4) In some cases it is not possible to assign an appropriate parameter 
automatically. "%" is used as a place holder 
;      for those fields that could not be determined automatically. The 
parameters in these fields must be assigned manually 
;      before the file can be used. 
;----------------------------------------------------------------------------- 
; Input Structure : VPL 
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;---------------------------------------------------------------------------- 
; Initial Guess Topology Generation:  
; The topology was guessed from PM3 optimized geometry and MOPAC charges 
; 
[ moleculetype ] 
; Name   nrexcl 
VPL      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1   CH3    1     VPL     C1    1    0.168  15.0350      ;  0.168 
    2    OE    1     VPL     O1    2   -0.331  15.9994  
    3     C    1     VPL     C2    2    0.240  12.0110  
    4     C    1     VPL    C26    2    0.240  12.0110  
    5    OE    1     VPL     O4    2   -0.331  15.9994      ; -0.182 
    6     C    1     VPL     C3    3   -0.153  12.0110  
    7    HC    1     VPL     H4    3    0.153   1.0080      ;  0.000 
    8     C    1     VPL     C4    4   -0.172  12.0110  
    9    HC    1     VPL     H5    4    0.172   1.0080      ;  0.000 
   10     C    1     VPL     C5    5    0.000  12.0110      ;  0.000 
   11   CH2    1     VPL     C6    6    0.166  14.0270      ;  0.166 
   12   CH2    1     VPL     C7    7    0.065  14.0270      ;  0.065 
   13    NL    1     VPL     N1    8   -0.017  14.0067  
   14     H    1     VPL    H39    8    0.217   1.0080      ;  0.200 
   15   CH3    1     VPL     C8    9    0.197  15.0350      ;  0.197 
   16     C    1     VPL    C25   10   -0.242  12.0110  
   17    HC    1     VPL    H35   10    0.242   1.0080      ;  0.000 
   18   CH3    1     VPL    C27   11    0.168  15.0350      ;  0.168 
   19   CH2    1     VPL     C9   12    0.000  14.0270      ;  0.000 
   20   CH2    1     VPL    C10   13    0.000  14.0270      ;  0.000 
   21   CH2    1     VPL    C11   14    0.000  14.0270      ;  0.000 
   22   CH0    1     VPL    C12   15   -0.143  12.0110  
   23     C    1     VPL    C13   15    0.020  12.0110  
   24    NR    1     VPL     N2   15   -0.572  14.0067  
   25     C    1     VPL    C17   15    0.426  12.0110      ; -0.269 
   26   CH1    1     VPL    C14   16    0.333  13.0190      ;  0.333 
   27   CH3    1     VPL    C15   17    0.000  15.0350      ;  0.000 
   28     C    1     VPL    C18   18   -0.241  12.0110  
   29    HC    1     VPL    H26   18    0.241   1.0080      ;  0.000 
   30     C    1     VPL    C19   19   -0.153  12.0110  
   31    HC    1     VPL    H27   19    0.153   1.0080      ;  0.000 
   32     C    1     VPL    C20   20    0.240  12.0110  
   33    OE    1     VPL     O2   20   -0.331  15.9994  
   34     C    1     VPL    C22   20    0.240  12.0110  
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   35    OE    1     VPL     O3   20   -0.331  15.9994      ; -0.182 
   36   CH3    1     VPL    C21   21    0.168  15.0350      ;  0.168 
   37     C    1     VPL    C24   22   -0.172  12.0110  
   38    HC    1     VPL    H34   22    0.172   1.0080      ;  0.000 
   39   CH3    1     VPL    C16   23    0.000  15.0350      ;  0.000 
   40   CH3    1     VPL    C23   24    0.168  15.0350      ;  0.168 
; total charge of the molecule:   1.000 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1430   8.1800e+06 
    2    3    2   0.1360   1.0200e+07 
    3    4    2   0.1390   8.6600e+06 
    3    6    2   0.1390   8.6600e+06 
    4    5    2   0.1360   1.0200e+07 
    4   16    2   0.1390   8.6600e+06 
    5   18    2   0.1430   8.1800e+06 
    6    7    2   0.1100   1.2100e+07 
    6    8    2   0.1390   8.6600e+06 
    8    9    2   0.1100   1.2100e+07 
    8   10    2   0.1390   8.6600e+06 
   10   11    2   0.1520   5.4300e+06 
   10   16    2   0.1390   8.6600e+06 
   11   12    2   0.1530   7.1500e+06 
   12   13    2   0.1470   8.7100e+06 
   13   14    2   0.1000   1.8700e+07 
   13   15    2   0.1480   5.7300e+06 
   13   19    2   0.1470   8.7100e+06 
   16   17    2   0.1100   1.2100e+07 
   19   20    2   0.1520   5.4300e+06 
   20   21    2   0.1520   5.4300e+06 
   21   22    2   0.1530   7.1500e+06 
   22   23    2   0.1530   7.1500e+06 
   22   25    2   0.1520   5.4300e+06 
   22   26    2   0.1530   7.1500e+06 
   23   24    2   0.1120   3.7000e+07 
   25   28    2   0.1390   8.6600e+06 
   25   37    2   0.1390   8.6600e+06 
   26   27    2   0.1520   5.4300e+06 
   26   39    2   0.1520   5.4300e+06 
   28   29    2   0.1100   1.2100e+07 
   28   30    2   0.1390   8.6600e+06 
   30   31    2   0.1100   1.2100e+07 
   30   32    2   0.1390   8.6600e+06 
   32   33    2   0.1360   1.0200e+07 
   32   34    2   0.1390   8.6600e+06 
   33   36    2   0.1430   8.1800e+06 
   34   35    2   0.1360   1.0200e+07 
   34   37    2   0.1390   8.6600e+06 
   35   40    2   0.1430   8.1800e+06 
   37   38    2   0.1100   1.2100e+07 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    4    1 
    1    6    1 
    3   18    1 
    8   12    1 
   10   13    1 
   11   14    1 
   11   15    1 
   11   19    1 
   12   16    1 
   12   20    1 
   13   21    1 
   14   20    1 
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   15   20    1 
   16   18    1 
   19   22    1 
   20   23    1 
   20   25    1 
   20   26    1 
   21   24    1 
   21   27    1 
   21   28    1 
   21   37    1 
   21   39    1 
   23   27    1 
   23   28    1 
   23   37    1 
   23   39    1 
   24   25    1 
   24   26    1 
   25   27    1 
   25   39    1 
   26   28    1 
   26   37    1 
   30   36    1 
   32   40    1 
   34   36    1 
   37   40    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    1    2    3    2    117.20   636.00 
    2    3    4    2    115.00   610.00 
    2    3    6    2    125.00   750.00 
    4    3    6    2    120.00   560.00 
    3    4    5    2    115.00   610.00 
    3    4   16    2    120.00   560.00 
    5    4   16    2    125.00   750.00 
    4    5   18    2    117.20   636.00 
    3    6    7    2    120.00   505.00 
    3    6    8    2    120.00   560.00 
    7    6    8    2    120.00   505.00 
    6    8    9    2    120.00   505.00 
    6    8   10    2    120.00   560.00 
    9    8   10    2    120.00   505.00 
    8   10   11    2    120.00   560.00 
    8   10   16    2    120.00   560.00 
   11   10   16    2    120.00   560.00 
   10   11   12    2    109.50   285.00 
   11   12   13    2    111.00   530.00 
   12   13   14    2    109.50   425.00 
   12   13   15    2    111.40   532.00 
   12   13   19    2    110.30   524.00 
   14   13   15    2    109.50   425.00 
   14   13   19    2    109.50   425.00 
   15   13   19    2    116.00   620.00 
    4   16   10    2    120.00   560.00 
    4   16   17    2    120.00   505.00 
   10   16   17    2    120.00   505.00 
   13   19   20    2    111.00   530.00 
   19   20   21    2    109.50   285.00 
   20   21   22    2    111.00   530.00 
   21   22   23    2    109.50   285.00 
   21   22   25    2    109.50   285.00 
   21   22   26    2    109.50   285.00 
   23   22   25    2    109.50   285.00 
   23   22   26    2    109.50   285.00 
   25   22   26    2    120.00   560.00 
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   22   23   24    2    180.00 91350.00 
   22   25   28    2    125.00   750.00 
   22   25   37    2    120.00   560.00 
   28   25   37    2    120.00   560.00 
   22   26   27    2    111.00   530.00 
   22   26   39    2    111.00   530.00 
   27   26   39    2    109.50   285.00 
   25   28   29    2    120.00   505.00 
   25   28   30    2    120.00   560.00 
   29   28   30    2    120.00   505.00 
   28   30   31    2    120.00   505.00 
   28   30   32    2    120.00   560.00 
   31   30   32    2    120.00   505.00 
   30   32   33    2    126.00   640.00 
   30   32   34    2    120.00   560.00 
   33   32   34    2    115.00   610.00 
   32   33   36    2    117.20   636.00 
   32   34   35    2    115.00   610.00 
   32   34   37    2    120.00   560.00 
   35   34   37    2    125.00   750.00 
   34   35   40    2    120.00   780.00 
   25   37   34    2    120.00   560.00 
   25   37   38    2    120.00   505.00 
   34   37   38    2    120.00   505.00 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
    3    4   16   10    2      0.00   167.36 
    4   16   10    8    2      0.00   167.36 
   16   10    8    6    2      0.00   167.36 
   10    8    6    3    2      0.00   167.36 
    8    6    3    4    2      0.00   167.36 
    6    3    4   16    2      0.00   167.36 
   25   37   34   32    2      0.00   167.36 
   37   34   32   30    2      0.00   167.36 
   34   32   30   28    2      0.00   167.36 
   32   30   28   25    2      0.00   167.36 
   30   28   25   37    2      0.00   167.36 
   28   25   37   34    2      0.00   167.36 
    3    2    4    6    2      0.00   167.36 
    6    3    7    8    2      0.00   167.36 
    8    6    9   10    2      0.00   167.36 
   10    8   11   16    2      0.00   167.36 
   25   22   28   37    2      0.00   167.36 
   28   25   29   30    2      0.00   167.36 
   30   28   31   32    2      0.00   167.36 
   32   30   33   34    2      0.00   167.36 
   34   32   35   37    2      0.00   167.36 
   37   25   34   38    2      0.00   167.36 
   16    4   10   17    2      0.00   167.36 
    4    3    5   16    2      0.00   167.36 
   26   27   22   39    2     35.26   334.72 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    1    2    3    6    1    180.00     7.11    2 
    3    4    5   18    1    180.00     7.11    2 
    8   10   11   12    1      0.00     1.00    6 
   10   11   12   13    1      0.00     3.77    3 
   11   12   13   15    1      0.00     1.05    3 
   12   13   19   20    1      0.00     1.05    3 
   13   19   20   21    1      0.00     3.77    3 
   19   20   21   22    1      0.00     3.77    3 
   20   21   22   23    1      0.00     3.77    3 
   21   22   25   28    1    180.00     1.00    6 
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   21   22   26   27    1      0.00     3.77    3 
   30   32   33   36    1    180.00     7.11    2 
   32   34   35   40    1    180.00     7.11    2 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    2    5 
    2    7 
    2    8 
    2   16 
    3    9 
    3   10 
    3   17 
    4    7 
    4    8 
    4   11 
    5    6 
    5   10 
    5   17 
    6   11 
    6   16 
    7    9 
    7   10 
    8   17 
    9   11 
    9   16 
   11   17 
   22   29 
   22   30 
   22   34 
   22   38 
   25   31 
   25   32 
   25   35 
   28   33 
   28   34 
   28   38 
   29   31 
   29   32 
   29   37 
   30   35 
   30   37 
   31   33 
   31   34 
   32   38 
   33   35 
   33   37 
   35   38 
 
1.8 Doxorubicin 
;----------------------------TITLE ------------------------------------------- 
;   doxorubicin 
; 
; This file was generated at 10:50 on 2013-09-23 by 
; Manually edited by Nandhitha Subramanian 2013-09-25 
; 
;                  Automatic Topology Builder   
; 
;                   REVISION 2013-07-25 
;----------------------------------------------------------------------------- 
; Authors     : Alpeshkumar K. Malde, Le Zuo, Matthew Breeze, Martin Stroet, 
Alan E. Mark 
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; 
; Institute   : Molecular Dynamics group,  
;               School of Chemistry and Molecular Biosciences (SCMB), 
;               The University of Queensland, QLD 4072, Australia 
; URL         : http://compbio.biosci.uq.edu.au/atb 
; Citation    : Malde AK, Zuo L, Breeze M, Stroet M, Poger D, Nair PC, 
Oostenbrink C, Mark AE. 
;               An Automated force field Topology Builder (ATB) and repository: 
version 1.0. 
;               Journal of Chemical Theory and Computation, 2011, 7(12), 4026-
4037. 
;               http://pubs.acs.org/doi/abs/10.1021/ct200196m 
; 
; Disclaimer  :  
;      While every effort has been made to ensure the accuracy and validity of 
parameters provided below 
;      the assignment of parameters is being based on an automated procedure 
combining data provided by a 
;      given user as well as calculations performed using third party software. 
They are provided as a guide. 
;      The authors of the ATB cannot guarantee that the parameters are complete 
or that the parameters provided 
;      are appropriate for use in any specific application. Users are advised to 
treat these parameters with discretion 
;      and to perform additional validation tests for their specific application 
if required. Neither the authors 
;      of the ATB or The University of Queensland except any responsibly for how 
the parameters may be used. 
; 
; Release notes and warnings:  
;  (1) The topology is based on a set of atomic coordinates and other data 
provided by the user after 
;      after quantum mechanical optimization of the structure using different 
levels of theory depending on 
;      the nature of the molecule. 
;  (2) In some cases the automatic bond, bond angle and dihedral type assignment 
is ambiguous. 
;      In these cases alternative type codes are provided at the end of the 
line. 
;  (3) While bonded parameters are taken where possible from the nominated force 
field non-standard bond, angle and dihedral 
;      type code may be incorporated in cases where an exact match could not be 
found. These are marked as "non-standard" 
;      or "uncertain" in comments. 
;  (4) In some cases it is not possible to assign an appropriate parameter 
automatically. "%" is used as a place holder 
;      for those fields that could not be determined automatically. The 
parameters in these fields must be assigned manually 
;      before the file can be used. 
;----------------------------------------------------------------------------- 
; Input Structure : DOX  
; Output          : UNITED ATOM topology 
; Use in conjunction with the corresponding united atom PDB file. 
;---------------------------------------------------------------------------- 
; Initial Guess Topology Generation:  
; The topology was guessed from PM3 optimized geometry and MOPAC charges 
; 
; Topology file generated at 10:09 on 23 Sep 2013 for molecule 
; doxorubicin (IUPAC: (1S,3S)-1-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-
methyloxan-2-yl]oxy}-3-hydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-
1,2,3,4,6,11-hexahydrotetracene-5,12-bis(olate), database identifier: DOX ) 
; by Automatic Topology Builder(revision 2013-07-25). 
; 
[ moleculetype ] 
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; Name   nrexcl 
DOX      3 
[ atoms ] 
;  nr  type  resnr  resid  atom  cgnr  charge    mass    total_charge 
    1   CH3    1    DOX      C1    1    0.022  15.0350       
    2    OE    1    DOX      O1    2   -0.262  15.9994  
    3     C    1    DOX      C2    2    0.444  12.0110  
    4     C    1    DOX      C7    2   -0.375  12.0110  
    5     C    1    DOX      C8    2    0.708  12.0110  
    6     O    1    DOX      O2    2   -0.576  15.9994  
    7     C    1    DOX      C9    2   -0.375  12.0110  
    8     C    1    DOX     C10    2    0.333  12.0110  
    9     C    1    DOX     C11    2    0.026  12.0110  
   10     C    1    DOX     C12    2    0.026  12.0110  
   11     C    1    DOX     C25    2    0.333  12.0110  
   12     C    1    DOX     C26    2    0.696  12.0110      ;  1.000 
   13     C    1    DOX      C3    3   -0.249  12.0110  
   14    HC    1    DOX     H12    3    0.160   1.0080       
   15     C    1    DOX      C4    4   -0.063  12.0110  
   16    HC    1    DOX     H13    4    0.152   1.0080       
   17     C    1    DOX      C5    5   -0.152  12.0110  
   18    HC    1    DOX     H14    5    0.152   1.0080      ;  0.000 
   19     C    1    DOX      C6    6   -0.004  12.0110  
   20     C    1    DOX     C27    6    0.696  12.0110  
   21     O    1    DOX     O11    6   -0.576  15.9994      ;  0.116 
   22    OA    1    DOX      O3    7   -0.556  15.9994  
   23     H    1    DOX     H15    7    0.447   1.0080      ; -0.109 
   24   CH1    1    DOX     C16    8    0.337  13.0190       
   25   CH2    1    DOX     C15    9   -0.197  14.0270       
   26   CH0    1    DOX     C14   10    0.402  12.0110  
   27     C    1    DOX     C23   10    0.171  12.0110  
   28     O    1    DOX      O8   10   -0.576  15.9994       
   29   CH2    1    DOX     C13   11   -0.197  14.0270      ; -0.060 
   30    OA    1    DOX     O10   12   -0.556  15.9994  
   31     H    1    DOX     H30   12    0.447   1.0080      ; -0.109 
   32    OE    1    DOX      O5   13   -0.428  15.9994       
   33   CH1    1    DOX     C17   14    0.430  13.0190       
   34   CH2    1    DOX     C18   15   -0.140  14.0270       
   35   CH1    1    DOX     C19   16    0.316  13.0190       
   36    NL    1    DOX      N1   17   -0.342  14.0067  
   37     H    1    DOX      H4   17    0.244   1.0080  
   38     H    1    DOX      H5   17    0.244   1.0080  
   39     H    1    DOX      H6   17    0.244   1.0080      ;  0.568 
   40    OA    1    DOX      O4   18   -0.687  15.9994  
   41     H    1    DOX     H18   18    0.420   1.0080      ; -0.267 
   42   CH2    1    DOX     C24   19    0.239  14.0270       
   43    OA    1    DOX      O9   20   -0.662  15.9994  
   44     H    1    DOX     H29   20    0.423   1.0080      ;  0.000 
   45    OE    1    DOX      O7   21   -0.443  15.9994       
   46   CH1    1    DOX     C21   22    0.304  13.0190       
   47   CH1    1    DOX     C20   23    0.151  13.0190       
   48    OA    1    DOX      O6   24   -0.574  15.9994  
   49     H    1    DOX     H23   24    0.423   1.0080      ; -0.139 
   50   CH3    1    DOX     C22   25    0.000  15.0350      ;  0.000 
; total charge of the molecule:   1.001 
[ bonds ] 
;  ai   aj  funct   c0         c1 
    1    2    2   0.1430   8.1800e+06 
    2    3    2   0.1360   1.0200e+07 
    3    4    2   0.1390   8.6600e+06 
    3   13    2   0.1390   8.6600e+06 
    4    5    2   0.1520   5.4300e+06 
    4   19    2   0.1390   8.6600e+06 
    5    6    2   0.1230   1.6600e+07 
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    5    7    2   0.1520   5.4300e+06 
    7    8    2   0.1390   8.6600e+06 
    7   12    2   0.1390   8.6600e+06 
    8    9    2   0.1390   8.6600e+06 
    8   22    2   0.1360   1.0200e+07 
    9   10    2   0.1390   8.6600e+06 
    9   24    2   0.1520   5.4300e+06 
   10   11    2   0.1390   8.6600e+06 
   10   29    2   0.1520   5.4300e+06 
   11   12    2   0.1390   8.6600e+06 
   11   30    2   0.1360   1.0200e+07 
   12   20    2   0.1520   5.4300e+06 
   13   14    2   0.1100   1.2100e+07 
   13   15    2   0.1390   8.6600e+06 
   15   16    2   0.1100   1.2100e+07 
   15   17    2   0.1390   8.6600e+06 
   17   18    2   0.1100   1.2100e+07 
   17   19    2   0.1390   8.6600e+06 
   19   20    2   0.1520   5.4300e+06 
   20   21    2   0.1230   1.6600e+07 
   22   23    2   0.1000   1.5700e+07 
   24   25    2   0.1530   7.1500e+06 
   24   32    2   0.1435   6.1000e+06 
   25   26    2   0.1530   7.1500e+06 
   26   27    2   0.1530   7.1500e+06 
   26   29    2   0.1530   7.1500e+06 
   26   40    2   0.1430   8.1800e+06 
   27   28    2   0.1230   1.6600e+07 
   27   42    2   0.1530   7.1500e+06 
   30   31    2   0.1000   1.5700e+07 
   32   33    2   0.1430   8.1800e+06 
   33   34    2   0.1530   7.1500e+06 
   33   45    2   0.1430   8.1800e+06 
   34   35    2   0.1530   7.1500e+06 
   35   36    2   0.1480   5.7300e+06 
   35   47    2   0.1530   7.1500e+06 
   36   37    2   0.1000   1.8700e+07 
   36   38    2   0.1000   1.8700e+07 
   36   39    2   0.1000   1.8700e+07 
   40   41    2   0.1000   1.5700e+07 
   42   43    2   0.1430   8.1800e+06 
   43   44    2   0.1000   1.5700e+07 
   45   46    2   0.1430   8.1800e+06 
   46   47    2   0.1530   7.1500e+06 
   46   50    2   0.1520   5.4300e+06 
   47   48    2   0.1430   8.1800e+06 
   48   49    2   0.1000   1.5700e+07 
[ pairs ] 
;  ai   aj  funct  ;  all 1-4 pairs but the ones excluded in GROMOS itp 
    1    4    1 
    1   13    1 
    3    6    1 
    3    7    1 
    4    8    1 
    4   12    1 
    4   21    1 
    5    9    1 
    5   11    1 
    5   22    1 
    6    8    1 
    6   12    1 
    6   19    1 
    7   10    1 
    7   19    1 
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    7   21    1 
    7   23    1 
    7   24    1 
    7   30    1 
    8   11    1 
    8   20    1 
    8   25    1 
    8   29    1 
    8   32    1 
    9   12    1 
    9   23    1 
    9   26    1 
    9   30    1 
    9   33    1 
   10   20    1 
   10   22    1 
   10   25    1 
   10   27    1 
   10   31    1 
   10   32    1 
   10   40    1 
   11   19    1 
   11   21    1 
   11   24    1 
   11   26    1 
   12   17    1 
   12   22    1 
   12   29    1 
   12   31    1 
   17   21    1 
   20   30    1 
   22   24    1 
   24   27    1 
   24   29    1 
   24   34    1 
   24   40    1 
   24   45    1 
   25   28    1 
   25   33    1 
   25   41    1 
   25   42    1 
   26   32    1 
   26   43    1 
   27   41    1 
   27   44    1 
   28   29    1 
   28   40    1 
   28   43    1 
   29   30    1 
   29   41    1 
   29   42    1 
   32   35    1 
   32   46    1 
   33   36    1 
   33   47    1 
   33   50    1 
   34   37    1 
   34   38    1 
   34   39    1 
   34   46    1 
   34   48    1 
   35   45    1 
   35   49    1 
   35   50    1 
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   36   46    1 
   36   48    1 
   37   47    1 
   38   47    1 
   39   47    1 
   40   42    1 
   45   48    1 
   46   49    1 
   48   50    1 
[ angles ] 
;  ai   aj   ak  funct   angle     fc 
    1    2    3    2    118.00  1080.00 
    2    3    4    2    117.00   635.00 
    2    3   13    2    125.00   750.00 
    4    3   13    2    120.00   560.00 
    3    4    5    2    120.00   560.00 
    3    4   19    2    120.00   560.00 
    5    4   19    2    120.00   560.00 
    4    5    6    2    121.00   685.00 
    4    5    7    2    120.00   560.00 
    6    5    7    2    121.00   685.00 
    5    7    8    2    120.00   560.00 
    5    7   12    2    120.00   560.00 
    8    7   12    2    120.00   560.00 
    7    8    9    2    120.00   560.00 
    7    8   22    2    121.00   685.00 
    9    8   22    2    117.00   635.00 
    8    9   10    2    120.00   560.00 
    8    9   24    2    120.00   560.00 
   10    9   24    2    120.00   560.00 
    9   10   11    2    120.00   560.00 
    9   10   29    2    125.00   750.00 
   11   10   29    2    120.00   560.00 
   10   11   12    2    120.00   560.00 
   10   11   30    2    115.00   610.00 
   12   11   30    2    125.00   750.00 
    7   12   11    2    120.00   560.00 
    7   12   20    2    120.00   560.00 
   11   12   20    2    120.00   560.00 
    3   13   14    2    120.00   505.00 
    3   13   15    2    120.00   560.00 
   14   13   15    2    120.00   505.00 
   13   15   16    2    120.00   505.00 
   13   15   17    2    120.00   560.00 
   16   15   17    2    120.00   505.00 
   15   17   18    2    120.00   505.00 
   15   17   19    2    120.00   560.00 
   18   17   19    2    120.00   505.00 
    4   19   17    2    120.00   560.00 
    4   19   20    2    120.00   560.00 
   17   19   20    2    120.00   560.00 
   12   20   19    2    120.00   560.00 
   12   20   21    2    121.00   685.00 
   19   20   21    2    121.00   685.00 
    8   22   23    2    108.53   443.00 
    9   24   25    2    111.00   530.00 
    9   24   32    2    109.50   320.00 
   25   24   32    2    109.50   320.00 
   24   25   26    2    111.00   530.00 
   25   26   27    2    111.00   530.00 
   25   26   29    2    109.50   285.00 
   25   26   40    2    109.50   320.00 
   27   26   29    2    111.00   530.00 
   27   26   40    2    109.50   320.00 
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   29   26   40    2    110.30   524.00 
   26   27   28    2    121.00   685.00 
   26   27   42    2    120.00   560.00 
   28   27   42    2    121.00   685.00 
   10   29   26    2    111.00   530.00 
   11   30   31    2    109.50   450.00 
   24   32   33    2    118.00  1080.00 
   32   33   34    2    109.50   320.00 
   32   33   45    2    109.50   320.00 
   34   33   45    2    111.00   530.00 
   33   34   35    2    109.50   285.00 
   34   35   36    2    109.50   285.00 
   34   35   47    2    111.00   530.00 
   36   35   47    2    111.00   530.00 
   35   36   37    2    109.50   425.00 
   35   36   38    2    109.50   425.00 
   35   36   39    2    109.50   425.00 
   37   36   38    2    109.50   380.00 
   37   36   39    2    109.50   380.00 
   38   36   39    2    109.50   380.00 
   26   40   41    2    108.53   443.00 
   27   42   43    2    115.00   610.00 
   42   43   44    2    108.53   443.00 
   33   45   46    2    118.00  1080.00 
   45   46   47    2    111.00   530.00 
   45   46   50    2    109.50   320.00 
   47   46   50    2    111.00   530.00 
   35   47   46    2    109.50   285.00 
   35   47   48    2    109.50   320.00 
   46   47   48    2    115.00   610.00 
   47   48   49    2    108.53   443.00 
[ dihedrals ] 
; GROMOS improper dihedrals 
;  ai   aj   ak   al  funct   angle     fc 
    3    4   19   17    2      0.00   167.36 
    4   19   17   15    2      0.00   167.36 
   19   17   15   13    2      0.00   167.36 
   17   15   13    3    2      0.00   167.36 
   15   13    3    4    2      0.00   167.36 
   13    3    4   19    2      0.00   167.36 
    3    2    4   13    2      0.00   167.36 
   13    3   14   15    2      0.00   167.36 
   15   13   16   17    2      0.00   167.36 
   17   15   18   19    2      0.00   167.36 
   19    4   17   20    2      0.00   167.36 
    4    3    5   19    2      0.00   167.36 
    5    4    6    7    2      0.00   167.36 
    7    5    8   12    2      0.00   167.36 
    8    7    9   22    2      0.00   167.36 
    9    8   10   24    2      0.00   167.36 
   10    9   11   29    2      0.00   167.36 
   27   26   28   42    2      0.00   167.36 
   11   10   12   30    2      0.00   167.36 
   12    7   11   20    2      0.00   167.36 
   20   12   19   21    2      0.00   167.36 
   24    9   25   32    2     35.26   334.72 
   33   34   32   45    2     35.26   334.72 
   35   34   36   47    2     35.26   334.72 
   47   35   48   46    2     35.26   334.72 
   46   47   50   45    2     35.26   334.72 
[ dihedrals ] 
;  ai   aj   ak   al  funct    ph0      cp     mult 
    1    2    3   13    1    180.00     7.11    2 
    3    4    5    6    1    180.00     5.86    2 
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    4    5    7    8    1    180.00     1.53    2 
    5    7    8   22    1    180.00     5.86    2 
    5    7   12   11    1    180.00     1.53    2 
    7    8    9   10    1    180.00     1.53    2 
    7    8   22   23    1    180.00     7.11    2 
    8    9   10   29    1    180.00     1.53    2 
    8    9   24   25    1    180.00     1.00    6 
    9   10   11   30    1    180.00     5.86    2 
    9   10   29   26    1      0.00     1.00    6 
   10   11   12    7    1    180.00     1.53    2 
   10   11   30   31    1    180.00     7.11    2 
    7   12   20   19    1    180.00     1.53    2 
   17   19   20   12    1    180.00     1.53    2 
    9   24   25   26    1      0.00     3.77    3 
    9   24   32   33    1    180.00     1.00    3 
   24   25   26   29    1      0.00     3.77    3 
   29   26   27   28    1    180.00     1.00    6 
   40   26   29   10    1      0.00     3.77    3 
   29   26   40   41    1      0.00     1.26    3 
   26   27   42   43    1      0.00     1.00    6 
   24   32   33   34    1    180.00     1.00    3 
   32   33   34   35    1      0.00     3.77    3 
   32   33   45   46    1      0.00     1.26    3 
   33   34   35   36    1      0.00     3.77    3 
   34   35   36   37    1      0.00     1.05    3 
   34   35   47   48    1      0.00     3.77    3 
   27   42   43   44    1      0.00     1.26    3 
   33   45   46   47    1      0.00     1.26    3 
   50   46   47   35    1      0.00     3.77    3 
   35   47   48   49    1    180.00     1.00    3 
[ exclusions ] 
;  ai   aj  funct  ;  GROMOS 1-4 exclusions 
    2    5 
    2   14 
    2   15 
    2   19 
    3   16 
    3   17 
    3   20 
    4   14 
    4   15 
    4   18 
    5   13 
    5   17 
    5   20 
   13   18 
   13   19 
   14   16 
   14   17 
   15   20 
   16   18 
   16   19 
   18   20 
 
 
 
